

    <!DOCTYPE html>
<html class="">

        
<head>
    <title>Inducing death in tumor cells: roles of the... | F1000Research</title>
    <meta charset="utf-8">
    <!--<meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>-->
    <!--<meta lang="$locale">-->
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="google-site-verification" content="9-QVycOO2_ob3Z9QzRmXv2CF08A9oyYXqWyTiVdKPlU" />
    <!-- This is commented out to fix display problems on mobile devices.
    We may use it again once we implement a responsive design that supports native device resolutions.
    <meta name="viewport" content="width=device-width"> -->

    <meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=1">



    <link rel="alternate" title="Recent articles published in F1000Research" href="/rss" type="application/rss+xml">
            <link rel="alternate" type="application/pdf" title="PDF" href="https://f1000research.com/articles/6-587/pdf"/>
        <link rel="canonical" href="https://f1000research.com/articles/6-587" />
    
            <meta name="description" content="Read the original article in full on F1000Research: Inducing death in tumor cells: roles of the inhibitor of apoptosis proteins" />
    
            <meta name="og:title" content="F1000Research Article: Inducing death in tumor cells: roles of the inhibitor of apoptosis proteins.">
            <meta name="og:description" content="Read the latest article version by Darren Finlay, Peter Teriete, Mitchell Vamos, Nicholas D. P. Cosford, Kristiina Vuori, at F1000Research.">
            <meta name="og:image" content="/img/sharing/og_research.png">
            <meta name="version-id" content="11449">
            <meta name="article-id" content="10625">
            <meta name="dc.title" content="Inducing death in tumor cells: roles of the inhibitor of apoptosis proteins">
            <meta name="dc.description" content="The heterogeneous group of diseases collectively termed cancer results not just from aberrant cellular proliferation but also from a lack of accompanying homeostatic cell death. Indeed, cancer cells regularly acquire resistance to programmed cell death, or apoptosis, which not only supports cancer progression but also leads to resistance to therapeutic agents. Thus, various approaches have been undertaken in order to induce apoptosis in tumor cells for therapeutic purposes. Here, we will focus our discussion on agents that directly affect the apoptotic machinery itself rather than on drugs that induce apoptosis in tumor cells indirectly, such as by DNA damage or kinase dependency inhibition. As the roles of the Bcl-2 family have been extensively studied and reviewed recently, we will focus in this review specifically on the inhibitor of apoptosis protein (IAP) family. IAPs are a disparate group of proteins that all contain a baculovirus IAP repeat domain, which is important for the inhibition of apoptosis in some, but not all, family members. We describe each of the family members with respect to their structural and functional similarities and differences and their respective roles in cancer. Finally, we also review the current state of IAPs as targets for anti-cancer therapeutics and discuss the current clinical state of IAP antagonists.">
            <meta name="dc.subject" content="apoptosis, tumours, cancer, IAPs, inhibitor of apoptosis proteins ">
            <meta name="dc.creator" content="Finlay, Darren">
            <meta name="dc.creator" content="Teriete, Peter">
            <meta name="dc.creator" content="Vamos, Mitchell">
            <meta name="dc.creator" content="Cosford, Nicholas D. P.">
            <meta name="dc.creator" content="Vuori, Kristiina">
            <meta name="dc.date" content="2017/04/27">
            <meta name="dc.identifier" content="doi:10.12688/f1000research.10625.1">
            <meta name="dc.source" content="F1000Research 2017 6:587">
            <meta name="dc.format" content="text/html">
            <meta name="dc.language" content="en">
            <meta name="dc.publisher" content="F1000 Research Limited">
            <meta name="dc.rights" content="https://creativecommons.org/licenses/by/3.0/igo/">
            <meta name="dc.type" content="text">
            <meta name="prism.keyword" content="apoptosis">
            <meta name="prism.keyword" content=" tumours">
            <meta name="prism.keyword" content=" cancer">
            <meta name="prism.keyword" content=" IAPs">
            <meta name="prism.keyword" content=" inhibitor of apoptosis proteins ">
            <meta name="prism.publication.Name" content="F1000Research">
            <meta name="prism.publicationDate" content="2017/04/27">
            <meta name="prism.volume" content="6">
            <meta name="prism.number" content="587">
            <meta name="prism.versionIdentifier" content="1">
            <meta name="prism.doi" content="10.12688/f1000research.10625.1">
            <meta name="prism.url" content="https://f1000research.com/articles/6-587">
            <meta name="citation_title" content="Inducing death in tumor cells: roles of the inhibitor of apoptosis proteins">
            <meta name="citation_abstract" content="The heterogeneous group of diseases collectively termed cancer results not just from aberrant cellular proliferation but also from a lack of accompanying homeostatic cell death. Indeed, cancer cells regularly acquire resistance to programmed cell death, or apoptosis, which not only supports cancer progression but also leads to resistance to therapeutic agents. Thus, various approaches have been undertaken in order to induce apoptosis in tumor cells for therapeutic purposes. Here, we will focus our discussion on agents that directly affect the apoptotic machinery itself rather than on drugs that induce apoptosis in tumor cells indirectly, such as by DNA damage or kinase dependency inhibition. As the roles of the Bcl-2 family have been extensively studied and reviewed recently, we will focus in this review specifically on the inhibitor of apoptosis protein (IAP) family. IAPs are a disparate group of proteins that all contain a baculovirus IAP repeat domain, which is important for the inhibition of apoptosis in some, but not all, family members. We describe each of the family members with respect to their structural and functional similarities and differences and their respective roles in cancer. Finally, we also review the current state of IAPs as targets for anti-cancer therapeutics and discuss the current clinical state of IAP antagonists.">
            <meta name="citation_description" content="The heterogeneous group of diseases collectively termed cancer results not just from aberrant cellular proliferation but also from a lack of accompanying homeostatic cell death. Indeed, cancer cells regularly acquire resistance to programmed cell death, or apoptosis, which not only supports cancer progression but also leads to resistance to therapeutic agents. Thus, various approaches have been undertaken in order to induce apoptosis in tumor cells for therapeutic purposes. Here, we will focus our discussion on agents that directly affect the apoptotic machinery itself rather than on drugs that induce apoptosis in tumor cells indirectly, such as by DNA damage or kinase dependency inhibition. As the roles of the Bcl-2 family have been extensively studied and reviewed recently, we will focus in this review specifically on the inhibitor of apoptosis protein (IAP) family. IAPs are a disparate group of proteins that all contain a baculovirus IAP repeat domain, which is important for the inhibition of apoptosis in some, but not all, family members. We describe each of the family members with respect to their structural and functional similarities and differences and their respective roles in cancer. Finally, we also review the current state of IAPs as targets for anti-cancer therapeutics and discuss the current clinical state of IAP antagonists.">
            <meta name="citation_keywords" content="apoptosis, tumours, cancer, IAPs, inhibitor of apoptosis proteins ">
            <meta name="citation_journal_title" content="F1000Research">
            <meta name="citation_author" content="Darren Finlay">
            <meta name="citation_author_institution" content="NCI-Designated Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, 10901 North Torrey Pines Road, La Jolla, CA, 92037, USA">
            <meta name="citation_author" content="Peter Teriete">
            <meta name="citation_author_institution" content="NCI-Designated Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, 10901 North Torrey Pines Road, La Jolla, CA, 92037, USA">
            <meta name="citation_author" content="Mitchell Vamos">
            <meta name="citation_author_institution" content="NCI-Designated Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, 10901 North Torrey Pines Road, La Jolla, CA, 92037, USA">
            <meta name="citation_author" content="Nicholas D. P. Cosford">
            <meta name="citation_author_institution" content="NCI-Designated Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, 10901 North Torrey Pines Road, La Jolla, CA, 92037, USA">
            <meta name="citation_author" content="Kristiina Vuori">
            <meta name="citation_author_institution" content="NCI-Designated Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, 10901 North Torrey Pines Road, La Jolla, CA, 92037, USA">
            <meta name="citation_publication_date" content="2017/04/27">
            <meta name="citation_volume" content="6">
            <meta name="citation_publication_number" content="587">
            <meta name="citation_version_number" content="1">
            <meta name="citation_doi" content="10.12688/f1000research.10625.1">
            <meta name="citation_firstpage" content="587">
            <meta name="citation_pdf_url" content="https://f1000research.com/articles/6-587/v1/pdf">
    

    
    <link href="/img/favicon-research.ico" rel="shortcut icon" type="image/ico">
    <link href="/img/favicon-research.ico" rel="icon" type="image/ico">

        <link rel="stylesheet" href="/1597255280893/css/mdl/material-design-lite.css" type="text/css" media="all" />
    <link href="https://fonts.googleapis.com/icon?family=Material+Icons" rel="stylesheet">
    <link href="https://fonts.googleapis.com/css?family=Roboto:100,100i,300,300i,400,400i,500,500i,700,700i,900,900i" rel="stylesheet">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/MaterialDesign-Webfont/2.2.43/css/materialdesignicons.min.css" />

        
            
    <link rel="stylesheet" href="/1597255280893/css/F1000Research.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/animation.css" type="text/css" media="all" />

        <!--[if IE 7]><link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons-ie7.css" media="all" /><![endif]-->

                    <script>dataLayer = [];</script>
        <!-- Google Tag Manager -->
        <script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
        new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
        j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
        'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
        })(window,document,'script','dataLayer','GTM-54Z2SBK');</script>
        <!-- End Google Tag Manager -->
    
    <script src="https://ajax.googleapis.com/ajax/libs/jquery/1.8.1/jquery.min.js"></script>
    <script>window.jQuery || document.write('<script src="/js/vendor/jquery-1.8.1.min.js"><\/script>')</script>
    <script src="/1597255280893/js/vendor/modernizr-2.6.1-respond-1.1.0.min.js"></script>
    <script src="/1597255280893/js/shared_scripts/sticky.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/shared_scripts/menu.js"></script>
    <script src="/1597255280893/js/shared_scripts/navbar.js"></script>
    <script src="/1597255280893/js/shared_scripts/platforms.js"></script>
    <script src="/1597255280893/js/shared_scripts/object-polyfills.js"></script>
            <script src="/1597255280893/js/vendor/lodash.min.js"></script>
        <script>CKEDITOR_BASEPATH='https://f1000research.com/js/ckeditor/'</script>
    <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/plugins.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/app/research.js"></script>
    <script>window.reactTheme = 'research';</script>
    <script src="/1597255280893/js/public/bundle.js"></script>

    <script src="/1597255280893/js/app/research.ui.js"></script>
    <script src="/1597255280893/js/app/login.js"></script>
    <script src="/1597255280893/js/app/main.js"></script>
    <script src="/1597255280893/js/app/js-date-format.min.js"></script>
    <script src="/1597255280893/js/app/search.js"></script>
    <script src="/1597255280893/js/app/cookies_warning.js"></script>
    <script src="/1597255280893/js/mdl/mdl.min.js"></script>

    <script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.1/MathJax.js?config=TeX-AMS-MML_HTMLorMML"></script>
                <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/ckeditor.js"></script>
            <script src="/js/ckeditor/adapters/jquery.js"></script>
                <script src="/js/article/article_scrolling_module.js"></script>
            <script src="/js/article/article_stats.js"></script>
            <script src="/js/article/article.js"></script>
            <script src="/js/shared_scripts/referee_timeline_pagination.js"></script>
            <script src="/js/app/text_editor_controller.js"></script>
            <script src="//s7.addthis.com/js/250/addthis_widget.js#pubid=ra-503e5e99593dc42c"></script>
            <script src="/js/article/article_metrics.js"></script>
        
                                                                            <script>
            if (window.location.hash == '#_=_'){
                window.location = window.location.href.split('#')[0]
            }
        </script>

                    
        
    <!-- pixelId: 1641728616063202 :: assetPixelId: 6034867600215 :: funderPixelId:  -->

            <!-- Facebook pixel code (merged with EP GTM code) -->
        <script>
            !function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function()

            {n.callMethod? n.callMethod.apply(n,arguments):n.queue.push(arguments)}
            ;if(!f._fbq)f._fbq=n;
            n.push=n;n.loaded=!0;n.version='2.0';n.queue=[];t=b.createElement(e);t.async=!0;
            t.src=v;s=b.getElementsByTagName(e)[0];s.parentNode.insertBefore(t,s)}(window,
            document,'script','https://connect.facebook.net/en_US/fbevents.js');

            fbq('init', '1641728616063202');

            
            fbq('track', "PixelInitialized", {});
        </script>

        <noscript><img height="1" width="1" style="display:none"
            src="https://www.facebook.com/tr?id=1641728616063202&noscript=1&amp;ev=PixelInitialized"
        /></noscript>
        <!-- End Facebook Pixel Code -->
    
                <script>
            (function(h,o,t,j,a,r){
                h.hj=h.hj||function(){(h.hj.q=h.hj.q||[]).push(arguments)};
                h._hjSettings={hjid:917825,hjsv:6};
                a=o.getElementsByTagName('head')[0];
                r=o.createElement('script');r.async=1;
                r.src=t+h._hjSettings.hjid+j+h._hjSettings.hjsv;
                a.appendChild(r);
            })(window,document,'https://static.hotjar.com/c/hotjar-','.js?sv=');
        </script>
    
</head>
<body  class="o-page-container no-js p-article o-layout-reset   ">

    
                            <!-- Google Tag Manager (noscript) -->
        <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-54Z2SBK"
        height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
        <!-- End Google Tag Manager (noscript) -->
    
        
    <div class="o-page">

        <div id="notify-container"></div>
        <div id="pageWarning"></div>
        <div id="pageMessage"></div>
        <div id="pageFooterMessage"></div>

                                <div id="f1r-ga-data" data-name="f1r-ga-data" class="f1r-ga-data"
                data-user-registered="false"
                data-user-module=""
                data-current-path=""
                data-location=""
                data-website="F1000Research"
                data-websiteDisplayName="F1000Research">
            </div>
        
                
        
        <div class="header-wrapper   js-navbar-space ">
                            


    










        
                            
    
            



<nav class="c-navbar js-navbar js-mini-nav js-sticky c-navbar--js-sticky c-navbar--userSite c-navbar__platform-bgcolor  c-navbar--bg-f1000research ">

    <div class="c-navbar__content">

                                <div class="c-navbar__extras">
            <div class="o-wrapper">
                <div class="o-actions o-actions--middle c-navbar__extras-row">
                    <div class="o-actions__primary">
                        
                                            </div>
                                    </div>
            </div>
        </div>

        <div class="o-wrapper t-inverted js-sticky-start">

            <div class="c-navbar__branding-row">
                <div class="c-navbar__row">


                                        
                    <div class="c-navbar__primary u-mr--2">

                                                                                                                                                                                                    <a href="/" class="c-navbar__branding u-ib u-middle"   data-test-id="nav_branding"  >
                                <img class="u-ib u-middle" src="/img/research/F1000Research_white_solid.svg" alt="F1000Research">
                            </a>
                                            </div>

                    <div class="c-navbar__secondary c-navbar__row">


                                                
                                                    <form action="/search" class="-navbar__secondary u-mr--2 c-search-form js-search-form u-hide u-show@navbar">
                                <label for="searchInput" class="c-search-form__label _mdl-layout">
                                    <input name="q" type="search" class="c-search-form__input" id="searchInput" placeholder="Search">
                                    <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                </label>
                            </form>
                        
                                                
                                                    <div class="c-navbar__primary u-hide u-show@navbar">
                                <div class="_mdl-layout c-navbar__cta">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--no-shadow mdl-button--multi-line mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                            </div>
                        

                                                
                        <span class="u-hide@navbar _mdl-layout u-nowrap">

                                                            <button type="button" class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" data-focus="#navbar_mob_search_input" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_search_mob"  ><i class="material-icons">search</i></button>
                            
                                                            <button class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon mdl-button--multi-line c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" type="button" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_toggle_mob"  >
                                    <i class="material-icons c-navbar__toggle-open">menu</i>
                                    <i class="material-icons c-navbar__toggle-close">close</i>
                                </button>
                                                    </span>
                    </div>

                </div>
            </div>

                        
                            <div class="c-navbar__menu-row js-navbar-block is-collapsed" id="navbarMenu">

                                                                                                                                                
                                                                    
                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                            

                                                                
                                                                                                                                                                                                                                
                                            
                    <div class="c-navbar__menu-row-content">

                                                                            <div class="u-hide@navbar c-navbar__menu-bar-spacing">
                                <form action="/search" class="c-search-form js-search-form">
                                    <label for="navbar_mob_search_input" class="c-search-form__label _mdl-layout">
                                        <input id="navbar_mob_search_input" name="q" type="search" class="c-search-form__input" placeholder="Search">
                                        <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                    </label>
                                </form>
                            </div>
                        
                        <div class="o-actions o-actions--middle">

                            <div class="o-actions__primary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="main-menu"   role="menubar" aria-label="Main Navigation"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/browse/articles" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="0"
                              data-test-id="nav_browse"                              >Browse</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/gateways" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_gatewaysViewAndBrowse"                              >Gateways & Collections</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="2"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_for-authors"                              >How to Publish</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="How to Publish">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_submit-manuscript"                      href="/for-authors/publish-your-research"
                    role="menuitem"
                    tabindex="0">Submit your Research</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/for-authors/my-submissions"
                    role="menuitem"
                    tabindex="-1">My Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines"                      href="/for-authors/article-guidelines"
                    role="menuitem"
                    tabindex="-1">Article Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines-new-versions"                      href="/for-authors/article-guidelines-new-versions"
                    role="menuitem"
                    tabindex="-1">Article Guidelines (New Versions)</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_data-guidelines"                      href="/for-authors/data-guidelines"
                    role="menuitem"
                    tabindex="-1">Data Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_asset-guidelines"                      href="/for-authors/posters-and-slides-guidelines"
                    role="menuitem"
                    tabindex="-1">Posters and Slides Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_document-guidelines"                      href="/for-authors/document-guidelines"
                    role="menuitem"
                    tabindex="-1">Document Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-processing-charges"                      href="/for-authors/article-processing-charges"
                    role="menuitem"
                    tabindex="-1">Article Processing Charges</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_finding-referees"                      href="/for-authors/tips-for-finding-referees"
                    role="menuitem"
                    tabindex="-1">Finding Article Reviewers</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="3"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_about-contact"                              >About</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="About">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_about-page"                      href="/about"
                    role="menuitem"
                    tabindex="0">How it Works</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_referee-guidelines"                      href="/for-referees/guidelines"
                    role="menuitem"
                    tabindex="-1">For Reviewers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_advisoryPanel"                      href="/advisors"
                    role="menuitem"
                    tabindex="-1">Our Advisors</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_policy-page"                      href="/about/policies"
                    role="menuitem"
                    tabindex="-1">Policies</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_glossary-page"                      href="/glossary"
                    role="menuitem"
                    tabindex="-1">Glossary</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_faqs-page"                      href="/faqs"
                    role="menuitem"
                    tabindex="-1">FAQs</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              u-hide u-show@navbar"
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      u-hide u-show@navbar"
                                          data-test-id="nav_for-developers"                      href="/developers"
                    role="menuitem"
                    tabindex="-1">For Developers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_newsroom-page"                      href="/newsroom"
                    role="menuitem"
                    tabindex="-1">Newsroom</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_contact-page"                      href="/contact"
                    role="menuitem"
                    tabindex="-1">Contact</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="4"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="https://blog.f1000.com/blogs/f1000research/" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                             target="_blank"                                                         tabindex="-1"
                              data-test-id="nav_blog"                              >Blog</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                            <div class="o-actions__secondary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="secondary-items"   role="menubar" aria-label="My Account"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="0"
                              data-test-id="nav_my-research"                              >My Research</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="My Research">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/login?originalPath=/my/submissions"
                    role="menuitem"
                    tabindex="0">Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-email-alerts"                      href="/login?originalPath=/my/email-alerts"
                    role="menuitem"
                    tabindex="-1">Content and Tracking Alerts</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-user-details"                      href="/login?originalPath=/my/user-details"
                    role="menuitem"
                    tabindex="-1">My Details</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/login?originalPath=/articles/6-587.html" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_sign-in"                              >Sign In</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                                                                                        <div class="_mdl-layout c-navbar__cta u-hide@navbar c-navbar__menu-bar-spacing">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--multi-line mdl-button--no-shadow mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research_mob"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                                                    </div>

                    </div>

                </div>
            
        </div>

    </div>

</nav>
                    </div>

        <div class="content-wrapper o-page__main row ">
            <div id="highlight-area" class="content ">
                





<div id=article-metadata class=hidden> <input type=hidden name=versionId value=11449 /> <input type=hidden id=articleId name=articleId value=10625 /> <input type=hidden id=xmlUrl value="/articles/6-587/v1/xml"/> <input type=hidden id=xmlFileName value="-6-587-v1.xml"> <input type=hidden id=article_uuid value=15b6d791-fba4-4317-b6a1-e57346a94ca1 /> <input type=hidden id=referer value=""/> <input type=hidden id=meta-article-title value="Inducing death in tumor cells: roles of the inhibitor of apoptosis proteins"/> <input type=hidden id=workspace-export-url value="https://sciwheel.com/work/api/import/external?doi=10.12688/f1000research.10625.1"/> <input type=hidden id=versionDoi value="10.12688/f1000research.10625.1"/> <input type=hidden id=usePmcStats value=true /> </div> <main class="o-wrapper p-article__wrapper js-wrapper"> <script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "ScholarlyArticle",
  "mainEntityOfPage": {
    "@type": "WebPage",
    "@id": "https://f1000research.com/articles/6-587"
  },
  "headline": "Inducing death in tumor cells: roles of the inhibitor of apoptosis proteins",
  "datePublished": "2017-04-27T11:50:48",
  "dateModified": "2017-04-27T11:50:48",
  "author": [
    {
      "@type": "Person",
      "name": "Darren Finlay"
    },    {
      "@type": "Person",
      "name": "Peter Teriete"
    },    {
      "@type": "Person",
      "name": "Mitchell Vamos"
    },    {
      "@type": "Person",
      "name": "Nicholas D. P. Cosford"
    },    {
      "@type": "Person",
      "name": "Kristiina Vuori"
    }  ],
  "publisher": {
    "@type": "Organization",
    "name": "F1000Research",
    "logo": {
      "@type": "ImageObject",
      "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
      "height": 480,
      "width": 60
    }
  },
  "image": {
    "@type": "ImageObject",
    "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
    "height": 1200,
    "width": 150
  },
  "description": "The heterogeneous group of diseases collectively termed cancer results not just from aberrant cellular proliferation but also from a lack of accompanying homeostatic cell death. Indeed, cancer cells regularly acquire resistance to programmed cell death, or apoptosis, which not only supports cancer progression but also leads to resistance to therapeutic agents. Thus, various approaches have been undertaken in order to induce apoptosis in tumor cells for therapeutic purposes. Here, we will focus our discussion on agents that directly affect the apoptotic machinery itself rather than on drugs that induce apoptosis in tumor cells indirectly, such as by DNA damage or kinase dependency inhibition. As the roles of the Bcl-2 family have been extensively studied and reviewed recently, we will focus in this review specifically on the inhibitor of apoptosis protein (IAP) family. IAPs are a disparate group of proteins that all contain a baculovirus IAP repeat domain, which is important for the inhibition of apoptosis in some, but not all, family members. We describe each of the family members with respect to their structural and functional similarities and differences and their respective roles in cancer. Finally, we also review the current state of IAPs as targets for anti-cancer therapeutics and discuss the current clinical state of IAP antagonists."
}
</script> <div class="o-layout o-layout--right-gutter"> <div id=article_secondary-column class="p-article__main o-layout__item u-font-size--legal u-2/3@article not-expanded "> <div class=float-left> <script type="application/ld+json">
  {
    "@context": "http://schema.org",
    "@type": "BreadcrumbList",
    "itemListElement": [
              {
          "@type": "ListItem",
          "position": "1",
          "item": {
            "@id": "https://f1000research.com/",
            "name": "Home"
          }
        },              {
          "@type": "ListItem",
          "position": "2",
          "item": {
            "@id": "https://f1000research.com/browse/articles",
            "name": "Browse"
          }
        },              {
          "@type": "ListItem",
          "position": "3",
          "item": {
            "@id": "https://f1000research.com/articles/6-587",
            "name": "Inducing death in tumor cells: roles of the inhibitor of apoptosis..."
          }
        }          ]
  }
  </script> <div class="breadcrumbs js-breadcrumbs"> <a href="/" class=f1r-standard-link>Home</a> <span class=item_separator></span> <a href="/browse/articles" class=f1r-standard-link>Browse</a> <span class=item_separator></span> Inducing death in tumor cells: roles of the inhibitor of apoptosis... </div> </div> <div class="article-badges-container u-mb--2"> <div class=crossmark-new> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js"></script> <a data-target=crossmark><img height=30 width=150 src="https://crossmark-cdn.crossref.org/widget/v2.0/logos/CROSSMARK_Color_horizontal.svg"/></a> </div> <div id=crossmark-dialog style="display: none;" title=""> <iframe id=crossmark-dialog-frame frameborder=0></iframe> </div> <div class=clearfix></div> </div> <div class=article-interaction-container> <div id=main-article-count-box class=article-count-box> <div class="article-metrics-wrapper metrics-icon-wrapper" data-version-id=11449 data-id=10625 data-downloads="" data-views="" data-scholar="10.12688/f1000research.10625.1" data-recommended="" data-doi="10.12688/f1000research.10625.1" data-f1r-ga-helper="Article Page Metrics (Desktop)"> <span class="metrics-on-browse article-metrics-icon f1r-icon icon-89_metrics"></span> <div class="count-title article-metrics-text">ALL Metrics</div> <div class=js-article-metrics-container></div> </div> <div> <div class=count-delimiter></div> <div title="Total views from F1000Research and PubMed Central"> <div class="count-container view-count js-views-count">-</div> <div class=count-title><span class="count-title-icon count-title-views-icon"></span>Views</div> </div> <div class=download-counts hidden> <div class=count-delimiter></div> <div title="Total downloads from F1000Research and PubMed Central"> <div class="count-container js-downloads-count"></div> <div class=count-title><span class="count-title-icon f1r-icon icon-76_download_file"></span>Downloads</div> </div> </div> </div> </div> <div id=main-article-interaction-box class="article-interaction-box has-control-tab"> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-102_download_pdf"></span> <a href="https://f1000research.com/articles/6-587/v1/pdf?article_uuid=15b6d791-fba4-4317-b6a1-e57346a94ca1" title="Download PDF" class="button-link download pdf-download-helper" target=_blank>Get PDF</a> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-103_download_xml"></span> <a id=download-xml href="#" class="button-link download" title="Download XML">Get XML</a> </div> </div> <div class="article-interaction-info article-page"> <div class="cite-article-popup-wrapper article-page-interaction-box"> <div class="article-interaction-button cite-article-button" title="Cite this article" data-windowref=cite-article-popup-10625-1> <span class="f1r-icon icon-82_quote"></span> <a href="#" class="button-link cite-article-popup-link" title="Cite Article">Cite</a> </div> <div id=cite-article-popup-10625-1 class="popup-window-wrapper is-hidden"> <div class=cite-popup-background></div> <div class="popup-window top-popup cite-this-article-box research-layout"> <div class="popup-window-title small cite-title">How to cite this article</div> <span id=cite-article-text-10625-1 data-test-id=copy-citation_text> <span class="article-title-and-info in-popup">Finlay D, Teriete P, Vamos M <em>et al.</em> Inducing death in tumor cells: roles of the inhibitor of apoptosis proteins [version 1; peer review: 3 approved]</span>. <i>F1000Research</i> 2017, <b>6</b>(F1000 Faculty Rev):587 (<a class=new-orange href="https://doi.org/10.12688/f1000research.10625.1" target=_blank>https://doi.org/10.12688/f1000research.10625.1</a>) </span> <div class="popup-window-title small margin-top-20 margin-bottom-20 note"> <strong>NOTE:</strong> it is important to ensure the information in square brackets after the title is included in all citations of this article. </div> <div class=float-right> <button class="secondary no-fill orange-text-and-border margin-right-20 close-cite-popup uppercase">Close</button> <button id=copy-citation-details class="secondary orange copy-cite-article-version uppercase js-clipboard" title="Copy the current citation details to the clipboard." data-clipboard-target="#cite-article-text-10625-1" data-test-id=copy-citation_button>Copy Citation Details</button> </div> </div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-76_download_file"></span> <a id=export-citation href="#" class="button-link download" title="Export Citation">Export</a> </div> <div class="modal-window-wrapper is-hidden"> <div id=export-citation-popup class="modal-window padding-20"> <div class=modal-window-close-button></div> <div class=modal-window-title>Export Citation</div> <div class=modal-window-row> <div> <input type=radio name=export-citation-option value=WORKSPACE /> <span class=radio-label>Sciwheel</span> </div> <div> <input type=radio name=export-citation-option value=ENDNOTE /> <span class=radio-label>EndNote</span> </div> <div> <input type=radio name=export-citation-option value=REF_MANAGER /> <span class=radio-label>Ref. Manager</span> </div> <div> <input type=radio name=export-citation-option value=BIBTEX /> <span class=radio-label>Bibtex</span> </div> <div> <input type=radio name=export-citation-option value=PROCITE /> <span class=radio-label>ProCite</span> </div> <div> <input type=radio name=export-citation-option value=SENTE /> <span class=radio-label>Sente</span> </div> </div> <div class=modal-window-footer> <button class=general-white-orange-button id=export-citation-submit>EXPORT</button> </div> <div class=default-error style="display: none;">Select a format first</div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-90_track"></span> <a class="button-link track-article" data-article-id=10625 id=track-article-signin-10625 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/10625?target=/articles/6-587">Track</a> </div> </div> <div class="article-interaction-info article-page"> <div class="article-interaction-button email-article"> <span class="f1r-icon icon-6_email"></span> <a href="#" class=button-link title="Email this article">Email</a> </div> <div class="email-article-version-container small-tooltip _chrome-fix"> <div class=close-icon><span class="f1r-icon icon-3_close_big"></span></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=11449 /> <input name=articleId type=hidden value=10625 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-34_share"></span> <a href="#" class="button-link last addthis_button share-article" title="Share this article">Share</a> </div> </div> </div> <div id=article-interaction-control-tab class=article-interaction-control-tab> <div id=hide-article-interaction class=article-interaction-control title="Hide Toolbox">&#9644;</div> <div id=show-article-interaction class="article-interaction-control open" title="Show Toolbox">&#10010;</div> </div> </div> <div class="article-header-information article-page"> <div class="f1r-article-mobile article-heading-bar"></div> <div class="article-type article-display">Review </div> <div class="article-title-and-info article-view highlighted-article" id=anchor-title> <h1>Inducing death in tumor cells: roles of the inhibitor of apoptosis proteins</h1><span class=other-info> [version 1; peer review: 3 approved]</span> </div> <div class=article-subtitle></div> <div class=f1r-article-desk> <div class="authors _mdl-layout"><span class=""><a href="mailto:dfinlay@sbpdiscovery.org" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Darren Finlay</span></a><a href="https://orcid.org/0000-0002-8718-9453" target=_blank id=author-orcid-0><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=author-orcid-0><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0002-8718-9453</div><sup>*</sup>,&nbsp;</span><span class="">Peter Teriete<sup>*</sup>,&nbsp;</span><span class="">Mitchell Vamos<sup>*</sup>,&nbsp;</span><span class="">Nicholas D. P. Cosford,&nbsp;</span><span class=""><a href="mailto:kvuori@sbpdiscovery.org" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Kristiina Vuori</span></a></span></div> </div> <div class=f1r-article-mobile> <div class="authors _mdl-layout"><span class=""><a href="mailto:dfinlay@sbpdiscovery.org" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Darren Finlay</span></a><a href="http://orcid.org/0000-0002-8718-9453" target=_blank id=mauthor-orcid-0><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=mauthor-orcid-0><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0002-8718-9453</div><sup>*</sup>,&nbsp;</span><span class="">Peter Teriete<sup>*</sup>,&nbsp;</span><a href="#" class=article-page-expand-authors>[...]&nbsp;</a><span class=article-page-hidden-authors>Mitchell Vamos<sup>*</sup>,&nbsp;</span><span class="">Nicholas D. P. Cosford,&nbsp;</span><span class=""><a href="mailto:kvuori@sbpdiscovery.org" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Kristiina Vuori</span></a></span><span class="author-display-control article-page-expand-authors f1r-icon icon-20_plus_big"></span><span class="author-display-control article-page-hidden-authors f1r-icon icon-12_minus_big"></span></div> </div> <div class="authors extra-info"> <sup>*</sup> Equal contributors </div> <div class=f1r-article-mobile> <div class=article-pubinfo-mobile> PUBLISHED 27 Apr 2017 </div> </div> <span class=Z3988 title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft_id=info:doi/10.12688%2Ff1000research.10625.1"></span> <div class=f1r-article-desk> <div class="contracted-details first"> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> NCI-Designated Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, 10901 North Torrey Pines Road, La Jolla, CA, 92037, USA<br/> <p> </p> </div> </div> </div> <div class=f1r-article-mobile> <div class="article-page-section-box margin-bottom-40 research-layout"> <span class=box-title> <span class="f1r-icon icon-85_peer_review"></span> OPEN PEER REVIEW </span> <button class="tertiary grey float-right" data-scrollto=article-reports>DETAILS</button> <div class="status-row referee-reports-container"> REVIEWER STATUS <span class=status-icons> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=22150-21918></span> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=22153-21919></span> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=22149-21917></span> </span> </div> </div> </div> </div> <h2 class="article-headings article-page-abstract" id=anchor-abstract> <span class="f1r-article-mobile-inline abstract-heading-border"></span> Abstract </h2> <div class="article-abstract article-page-general-text-mobile research-layout"> <div class="abstract-text is-expanded"> The heterogeneous group of diseases collectively termed cancer results not just from aberrant cellular proliferation but also from a lack of accompanying homeostatic cell death. Indeed, cancer cells regularly acquire resistance to programmed cell death, or apoptosis, which not only supports cancer progression but also leads to resistance to therapeutic agents. Thus, various approaches have been undertaken in order to induce apoptosis in tumor cells for therapeutic purposes. Here, we will focus our discussion on agents that directly affect the apoptotic machinery itself rather than on drugs that induce apoptosis in tumor cells indirectly, such as by DNA damage or kinase dependency inhibition. As the roles of the Bcl-2 family have been extensively studied and reviewed recently, we will focus in this review specifically on the inhibitor of apoptosis protein (IAP) family. IAPs are a disparate group of proteins that all contain a baculovirus IAP repeat domain, which is important for the inhibition of apoptosis in some, but not all, family members. We describe each of the family members with respect to their structural and functional similarities and differences and their respective roles in cancer. Finally, we also review the current state of IAPs as targets for anti-cancer therapeutics and discuss the current clinical state of IAP antagonists. </div> <div class=abstract-for-mobile> <div class="margin-top-30 padding-bottom-30 research-layout is-centered"> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border show" style="display: none;"> READ ALL <span class="f1r-icon icon-14_more_small orange vmiddle big"></span> </button> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border hide"> READ LESS <span class="f1r-icon icon-10_less_small orange vmiddle big"></span> </button> </div> </div> </div> <div class=clearfix></div> <div class="article-context no-divider"> <div class="article-abstract article-page-general-text-mobile research-layout generated-article-body"> <h2 class=main-title>Keywords</h2> <p class="u-mb--0 u-pb--2"> apoptosis, tumours, cancer, IAPs, inhibitor of apoptosis proteins </p> </div> </div> <div class=article-information> <span class="info-separation padding-bottom"> <div id=corresponding-author-icon class="email-icon float-left"> <span class="f1r-icon icon-6_email orange"></span> <div id=corresponding-author-window class="margin-top-20 popup-window-wrapper is-hidden"> <div class="popup-window corresponding-authors-popup"> <div class=corresponding-author-container> <div class="popup-window-title small">Corresponding Author(s)</div> <div class=authors> Darren Finlay (<a href="mailto:dfinlay@sbpdiscovery.org">dfinlay@sbpdiscovery.org</a>) <br> Kristiina Vuori (<a href="mailto:kvuori@sbpdiscovery.org">kvuori@sbpdiscovery.org</a>) </div> </div> <div class="margin-top margin-bottom float-left"> <button id=close-popup-window class=general-white-orange-button>Close</button> </div> </div> </div> </div> <span class="icon-text float-left" data-test-id=box-corresponding-author> <b>Corresponding authors:</b> Darren Finlay, Kristiina Vuori </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom competing-interests-display"> <span class=competing-interests-title>Competing interests:</span> No competing interests were disclosed. </span> <div class="info-separation padding-bottom grant-information-display"> <span class=grant-information-title>Grant information:</span> This work was supported by National Institutes of Health grant R01CA195227 to DF and NDPC. <br/> <i>The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</i> </div> <span class="f1r-article-desk info-separation padding-bottom"> <span class="copywrite-icon float-left"> <span class="f1r-icon icon-100_open_access"></span> </span> <span class="icon-text float-left" data-test-id=box-copyright-text> <b>Copyright:</b>&nbsp; © 2017 Finlay D <em>et al</em>. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Data associated with the article are available under the terms of the <a href="http://creativecommons.org/publicdomain/zero/1.0/" target=_blank data-test-id=box-data-licence-link>Creative Commons Zero "No rights reserved" data waiver</a> (CC0 1.0 Public domain dedication). </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom" data-test-id=box-how-to-cite> <b>How to cite:</b> <span class="article-title-and-info in-article-box"> Finlay D, Teriete P, Vamos M <em>et al.</em> Inducing death in tumor cells: roles of the inhibitor of apoptosis proteins [version 1; peer review: 3 approved]</span>. <i>F1000Research</i> 2017, <b>6</b>(F1000 Faculty Rev):587 (<a href="https://doi.org/10.12688/f1000research.10625.1" target=_blank>https://doi.org/10.12688/f1000research.10625.1</a>) </span> <span class=info-separation data-test-id=box-first-published><b>First published:</b> 27 Apr 2017, <b>6</b>(F1000 Faculty Rev):587 (<a href="https://doi.org/10.12688/f1000research.10625.1" target=_blank>https://doi.org/10.12688/f1000research.10625.1</a>)</span> <span class=info-separation data-test-id=box-latest-published><b>Latest published:</b> 27 Apr 2017, <b>6</b>(F1000 Faculty Rev):587 (<a href="https://doi.org/10.12688/f1000research.10625.1" target=_blank>https://doi.org/10.12688/f1000research.10625.1</a>)</span> </div> <div class=clearfix></div> <div id=article-context class=article-context> <div id=article1-body class=generated-article-body><h2 class=main-title id=d2476e241>Introduction to inhibitor of apoptosis family of proteins</h2><p class="" id=d2476e244>The inhibitor of apoptosis protein (IAP) family is a functionally and structurally related group of proteins that serve as endogenous inhibitors of programmed cell death, or apoptosis. In addition, some family members are regulators of another form of programmed cell death termed necroptosis<sup><a href="#ref-1">1</a>,<a href="#ref-2">2</a></sup>. Whilst some of the IAPs have also been shown to be involved in immune regulation<sup><a href="#ref-3">3</a>,<a href="#ref-4">4</a></sup>, chromosome segregation, and cytokinesis<sup><a href="#ref-5">5</a>–<a href="#ref-7">7</a></sup>, this review will focus on their roles in explicitly regulating apoptosis. Although the various IAPs have somewhat differing functions, they are linked by one unique domain: membership of the IAP family is ascribed if the gene/protein in question possesses a baculovirus IAP repeat (BIR) domain. Indeed, as the name suggests, BIR domains were first identified in a baculoviral protein capable of inhibiting cell death in virally infected cells<sup><a href="#ref-8">8</a>–<a href="#ref-10">10</a></sup>. BIR domains are zinc finger domains and invariantly contain three cysteines and one histidine, which co-ordinate the zinc ion<sup><a href="#ref-10">10</a></sup>, and these domains are involved in various protein-protein interactions (PPIs). IAPs were subsequently identified and characterized by various techniques in yeast, worms, insects, and mammalian cells<sup><a href="#ref-5">5</a>,<a href="#ref-11">11</a>–<a href="#ref-15">15</a></sup>. The first human IAP revealed was neuronal apoptosis inhibitory protein (NAIP or BIRC1), which was serendipitously discovered in a search for genes involved in the autosomal recessive condition spinal muscular atrophy (SMA)<sup><a href="#ref-16">16</a></sup>. The next human IAPs to be characterized were the cellular IAPs 1 and 2: cIAP1 (or BIRC2) and cIAP2 (or BIRC3). These proteins were discovered to have a role in tumor necrosis factor receptor (TNFR) signaling through association with the adaptor proteins TRAF1 and TRAF2<sup><a href="#ref-17">17</a>–<a href="#ref-20">20</a></sup>. The fact that several proteins shared the common BIR domain led to the identification of more family members via traditional homology-matching database searches (reviewed in <a href="#ref-21">21</a>). Notably, many of these proteins were further shown to be involved in the regulation of apoptosis<sup><a href="#ref-15">15</a>,<a href="#ref-22">22</a>–<a href="#ref-27">27</a></sup>. Rounding out the group of eight human BIR-containing proteins are XIAP (BIRC4), Survivin (BIRC5), Apollon (BIRC6), Melanoma IAP (ML-IAP or BIRC7), and IAP-like protein 2 (ILP-2 or BIRC8)<sup><a href="#ref-15">15</a>,<a href="#ref-22">22</a>,<a href="#ref-25">25</a>,<a href="#ref-28">28</a>–<a href="#ref-37">37</a></sup>. A schematic of the general IAP family structure is shown in <a href="#f1">Figure 1</a>. <a href="#f2">Figure 2</a> shows the intracellular signaling interplay of IAPs with respect to cell survival and apoptosis.</p><div class="fig panel clearfix"><a name=f1 class=n-a></a><a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/11449/e53bae94-4fb7-4b4b-adba-b48595892aca_figure1.gif"><img alt="e53bae94-4fb7-4b4b-adba-b48595892aca_figure1.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/11449/e53bae94-4fb7-4b4b-adba-b48595892aca_figure1.gif"></a><div class=caption><h3>Figure 1. Domain structures of all known members of the human inhibitor of apoptosis protein (IAP) family, with a focus on the different baculovirus IAP repeat (BIR) domains.</h3><p id=d2476e347>The representation of the homology between the different BIR domains of the IAP family reflects the accepted designation of BIR1, BIR2, and BIR3. The BIR domains of Survivin (BIRC5) and Apollon (BIRC6) can be aligned with either BIR1 or BIR2, depending on the specific alignment criteria, but owing to their uniqueness they are colored and labeled accordingly. CARD, caspase recruitment domain; cIAP1, cellular inhibitor of apoptosis protein 1; cIAP2, cellular inhibitor of apoptosis protein 2; ILP-2, inhibitor of apoptosis protein-like protein 2; LRR, leucine-rich repeat; ML-IAP, melanoma inhibitor of apoptosis protein; NAIP, neuronal apoptosis inhibitory protein; RING, really interesting new gene; UBA, ubiquitin-associated; UBC, ubiquitin-conjugating.</p></div></div><div class="fig panel clearfix"><a name=f2 class=n-a></a><a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/11449/e53bae94-4fb7-4b4b-adba-b48595892aca_figure2.gif"><img alt="e53bae94-4fb7-4b4b-adba-b48595892aca_figure2.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/11449/e53bae94-4fb7-4b4b-adba-b48595892aca_figure2.gif"></a><div class=caption><h3>Figure 2. Schematic of pertinent inhibitor of apoptosis signaling pathways relevant to tumor cell survival and apoptosis.</h3><p id=d2476e364>Dashed lines indicate potential degradative events (blue = ubiquitin-mediated, black = caspase-mediated). cIAP1, cellular inhibitor of apoptosis protein 1; cIAP2, cellular inhibitor of apoptosis protein 2; ML-IAP, melanoma inhibitor of apoptosis protein; NAIP, neuronal apoptosis inhibitory protein; TNF, tumor necrosis factor.</p></div></div><p class="" id=d2476e371>Survivin and ML-IAP are small proteins with only one BIR domain, yet their functions are enigmatic, having been ascribed to various processes, including apoptosis inhibition. As such, their roles, especially with respect to cancer, will be discussed in greater detail later in this review. ML-IAP additionally possesses an E3 ubiquitin ligase domain named RING (really interesting new gene), a domain also present in other IAPs and believed to be important in many signaling events<sup><a href="#ref-38">38</a>–<a href="#ref-41">41</a></sup>. ILP-2, likewise with only one BIR domain, also contains a RING domain and a ubiquitin-associated (UBA) domain. Whilst ILP-2 shows high homology to XIAP, it is a product of a separate gene and its expression in healthy tissues appears to be restricted to the testes<sup><a href="#ref-36">36</a></sup>. Overexpression studies have shown that ILP-2 has no effect on extrinsic death receptor-induced apoptosis but that it can inhibit intrinsic (also known as mitochondrial) apoptosis through a potential interaction with caspase-9, an apical protease involved in mitochondrial apoptosis<sup><a href="#ref-36">36</a></sup>. However, others have shown that its BIR domain is unstable and, as such, it is only a weak binder of caspase-9, at least in the absence of other cellular factors<sup><a href="#ref-42">42</a></sup>.</p><p class="" id=d2476e394>Apollon is an extremely large protein (approximately 528 kDa) containing only one BIR domain that is thought to be membrane-associated as well as a C-terminal ubiquitin-conjugating (UBC) domain<sup><a href="#ref-43">43</a></sup>. It has been shown to attenuate apoptosis<sup><a href="#ref-44">44</a>–<a href="#ref-46">46</a></sup> and to directly engage and interfere with both the second mitochondria-derived activator of caspases (Smac, discussed in greater detail below) and caspase-9<sup><a href="#ref-43">43</a>,<a href="#ref-47">47</a></sup>. Others have confirmed that Apollon is involved in caspase-9-mediated apoptosis but that it can also regulate p53 and is essential in murine embryo development<sup><a href="#ref-48">48</a></sup>.</p><p class="" id=d2476e419>The remaining four IAPs each possess three BIR domains in tandem and are the most studied members of the IAP family. Whilst XIAP and cIAP1 and 2 each contain a UBA and a RING domain, NAIP differs in that it has neither of these features but instead contains a “NACHT” domain and a C-terminal leucine-rich repeat (LRR). The NACHT domain is so named because of its presence in NAIP, C2TA, HET-E, and TEP1, and it is predicted to be a nucleoside-triphosphatase (NTPase) domain<sup><a href="#ref-49">49</a></sup>. Whilst its original discovery as the causative gene in SMA proved erroneous, NAIP has been shown to attenuate apoptosis in multiple models<sup><a href="#ref-15">15</a>,<a href="#ref-50">50</a>,<a href="#ref-51">51</a></sup>. The main role of NAIP, however, appears to be in the regulation of innate immunity. Thus, NAIP, which is also part of the NOD-like receptor (NLR) family, is important for NLRC4 inflammasome activation in response to certain bacterial ligands<sup><a href="#ref-52">52</a>–<a href="#ref-54">54</a></sup>.</p><p class="" id=d2476e443>cIAP1 and 2, whilst showing similar architecture to XIAP, also possess a caspase recruitment domain (CARD). Somewhat confusingly, however, the CARD of the cIAPs does not bind to caspases, but it appears to function in an auto-inhibitory manner to block the cIAP RING domain’s E3 ubiquitin ligase activity<sup><a href="#ref-55">55</a></sup>. The cIAPs are structurally very similar to each other with only a short linker sequence difference, are functionally redundant<sup><a href="#ref-56">56</a>,<a href="#ref-57">57</a></sup>, and are believed to have resulted from a recent evolutionary gene duplication. As with XIAP, they contain three BIR domains, and BIR1 is essential for binding to the TNFR adapter protein TRAF2<sup><a href="#ref-58">58</a>,<a href="#ref-59">59</a></sup>. The third BIR domain (BIR3) in these three proteins, as well as the homologous BIR domain in ML-IAP, all potently bind to Smac, a negative regulator that will be discussed in much greater detail in subsequent sections of this review.</p><p class="" id=d2476e464>The cIAPs have been highly characterized in signaling events associated with a subset of TNFR superfamily members, called the death receptors (DRs), and it appears that their E3 ubiquitin ligase activity is especially pertinent in this regulation. DRs are categorized on the basis of the presence of a so-called death domain (DD). DDs are approximately 80-amino-acid alpha-helical structures that recruit adapter proteins capable of binding multiple other proteins in supramolecular complexes that regulate distinct signaling pathways based on composition (reviewed in <a href="#ref-60">60</a>–<a href="#ref-63">63</a>). cIAPs recruited to these complexes can be involved in both degradative K48- and non-degradative K63-branched ubiquitination. Indeed, cIAP1 has been shown to control the levels of cIAP2 via degradative signaling, as depletion of cIAP1 results in a “rebound” of cIAP2 levels<sup><a href="#ref-64">64</a></sup>. Similarly, levels of nuclear factor-kappa B (NF-κB)-inducing kinase (NIK or <i>MAP3K14</i>) are tightly controlled by cIAPs, and these protein levels are almost undetectable when the E3 ubiquitin ligase activity of the proteins is available<sup><a href="#ref-64">64</a>–<a href="#ref-66">66</a></sup>. Much more significant, however, are the cIAP-mediated non-degradative K63-branched ubiquitination and ensuing signaling. This ubiquitination of receptor-interacting protein 1 (RIP1) results in the formation of a signaling complex that can recruit further ubiquitin ligases and kinases that ultimately result in classical NF-κB activation<sup><a href="#ref-67">67</a>,<a href="#ref-68">68</a></sup> (and reviewed in <a href="#ref-69">69</a>). Indeed, recruitment of RIP1 to these complexes has led to the coining of the term “RIPoptosome” to describe them<sup><a href="#ref-70">70</a>–<a href="#ref-72">72</a></sup>. When cIAPs are absent—owing to genotoxic stress or chemical depletion with Smac mimetics (see below), for example—and the relevant receptor agonist is engaged, RIP1 is not degraded but forms a death signaling RIPoptosome<sup><a href="#ref-72">72</a></sup> with apoptosis effected via the apical caspases-8 or -10 or both. Furthermore, in the absence of these caspases (or upon their inhibition), necroptosis can occur<sup><a href="#ref-1">1</a>,<a href="#ref-2">2</a></sup>. Necroptosis has been demonstrated to be dependent on RIP1 and specifically on its kinase activity (reviewed in <a href="#ref-73">73</a>). RIP1 phosphorylation of RIP3 results in the activation of mixed lineage kinase domain-like protein (MLKL)<sup><a href="#ref-74">74</a>–<a href="#ref-76">76</a></sup>, which induces necroptotic death by rupturing of the plasma membrane<sup><a href="#ref-77">77</a>–<a href="#ref-79">79</a></sup>.</p><p class="" id=d2476e534>In sum, the cIAPs are integral components of multiple signaling complexes emanating from TNFR superfamily members and, as a consequence, can regulate diverse cellular responses such as cell survival, apoptosis, and necroptosis via the RIPoptosome<sup><a href="#ref-80">80</a>,<a href="#ref-81">81</a></sup>.</p><p class="" id=d2476e544>XIAP is by far the most studied and highly characterized member of the IAP family. It is a potent inhibitor of apoptosis as judged by multiple model systems and techniques and has been clearly demonstrated to effect such inhibition due to direct binding of caspases<sup><a href="#ref-24">24</a></sup>. BIR2 and a short linker section between BIR1 and BIR2 are essential for binding and sequestration of the effector caspases -3 and -7<sup><a href="#ref-24">24</a>,<a href="#ref-82">82</a>–<a href="#ref-84">84</a></sup>, whilst BIR3 is crucial for binding to the apical caspase-9<sup><a href="#ref-85">85</a>–<a href="#ref-87">87</a></sup>. As with the cIAPs, the BIR3 of XIAP also binds Smac, and this interaction results in caspase de-repression<sup><a href="#ref-85">85</a>,<a href="#ref-88">88</a>–<a href="#ref-90">90</a></sup>. Thus, XIAP BIR3 binding of Smac has been shown to result in the release of active caspases from the XIAP protein complex and thus BIR3-Smac interaction is permissive for apoptosis induction<sup><a href="#ref-88">88</a>,<a href="#ref-91">91</a></sup>. As such, Smac is not a direct activator of caspases, despite its name, but rather an “inhibitor of the inhibitor”. Smac effects this displacement of factors from the BIR domains because of a four-amino-acid sequence of Ala-Val-Pro-Ile (AVPI) in Smac. Exposure of cells to this peptide motif can therefore sensitize cells to apoptotic stimuli or, in the case of cIAPs, result in their auto-degradation and subsequent switch from inhibitory to pro-apoptotic events from TNFRs. Owing to these effects, the AVPI tetrapeptide sequence has drawn much attention as a potential anti-cancer agent, and multiple Smac mimetics have been developed with a view to promoting apoptosis in tumor cells, where normal apoptotic signaling is perturbed. The current clinical progress of these agents is described in detail later.</p><p class="" id=d2476e586>In summary, the IAP family, whilst small in number, contains a series of diverse members with differing but somewhat overlapping biological roles. The most relevant of these roles in tumors is apoptosis inhibition, and the mechanisms governing how each member is involved are somewhat unique. The next section will discuss the roles of these proteins in cancer, and finally we will discuss the application of IAP inhibitors (Smac mimetics) as potential anti-cancer agents.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d2476e592>Inhibitor of apoptosis and cancer</h2><p class="" id=d2476e595>The evasion of apoptosis is one of the hallmarks of cancer<sup><a href="#ref-92">92</a>–<a href="#ref-95">95</a></sup>, and, as noted above, the IAP family of proteins plays an important role in attenuating programmed cell death pathways, predominantly through modulation of the caspase cascade (extensively reviewed in <a href="#ref-27">27</a>,<a href="#ref-96">96</a>–<a href="#ref-103">103</a>). Furthermore, IAPs are often upregulated in cancers<sup><a href="#ref-104">104</a></sup> and are believed to underlie the resistance of many tumors to chemotherapeutics<sup><a href="#ref-105">105</a>,<a href="#ref-106">106</a></sup>. Ablation or antagonism of IAPs is therefore an attractive strategy to sensitize or re-sensitize tumor cells to apoptosis induced by other agents. The roles that the eight IAPs found in humans play in cancer are discussed below.</p><div class=section><a name=d2476e626 class=n-a></a><h3 class=section-title>NAIP</h3><p class="" id=d2476e631>NAIP (BIRC1) was first identified and named in 1995 by Roy <i>et al</i>.<sup><a href="#ref-16">16</a></sup> as a potential modulator of the neuronal apoptotic pathway. As noted earlier, the main biological role for NAIP appears to be the regulation of innate immunity. Nevertheless, NAIP has been weakly linked to unfavorable prognosis in esophageal cancer<sup><a href="#ref-107">107</a></sup>, breast cancer<sup><a href="#ref-108">108</a></sup>, prostate cancer<sup><a href="#ref-109">109</a></sup>, and neuroblastoma<sup><a href="#ref-110">110</a></sup>. The precise role of NAIP in the dysregulation of apoptosis in cancer and its value as a potential therapeutic target need further study.</p></div><div class=section><a name=d2476e659 class=n-a></a><h3 class=section-title>cIAP1, cIAP2, and XIAP (BIRC2, BIRC3, and BIRC4)</h3><p class="" id=d2476e664>As noted above, XIAP is a very potent binder and inhibitor of caspase-3. Accordingly, research by pharmaceutical companies has primarily focused on antagonizing this protein for oncology applications (reviewed in <a href="#ref-111">111</a>,<a href="#ref-112">112</a>). cIAP1 and cIAP2 have also been implicated in cancer, and their role in the modulation of the NF-κB signaling pathway has been investigated in detail<sup><a href="#ref-113">113</a></sup>. It was also found that cIAP1 can protect cancer cells from the lethal effect of TNF through synergy with the MYC oncogene, thus driving tumorigenesis<sup><a href="#ref-114">114</a>–<a href="#ref-116">116</a></sup>. As cIAPs suppress TNF-induced cell death, it is likely that increased levels of cIAPs support tumor cell survival by modulating cellular responses to TNF. cIAPs and XIAP are additionally thought to contribute to cancer cell invasion and metastasis through their ability to drive NF-κB-mediated expression of genes involved in cell motility, migration, and invasion<sup><a href="#ref-117">117</a>,<a href="#ref-118">118</a></sup>. Similarly, in lymphomas, cIAP2 is often found as a fusion protein with mucosa-associated lymphoid tissue 1 (MALT1), resulting in the activation of NF-κB signaling (reviewed in <a href="#ref-119">119</a>). IAPs have been shown to be overexpressed in many cell lines from the NCI60 panel as compared with the corresponding normal tissue<sup><a href="#ref-120">120</a></sup>. XIAP overexpression in turn has been reported in childhood acute myeloid leukemia (AML)<sup><a href="#ref-121">121</a></sup>, renal carcinoma<sup><a href="#ref-122">122</a>,<a href="#ref-123">123</a></sup>, multiple myeloma (MM)<sup><a href="#ref-124">124</a></sup>, and bladder cancers<sup><a href="#ref-125">125</a></sup>, and AML patients with low levels of expression of XIAP were shown to have a statistically significant survival advantage compared with those patients with higher levels<sup><a href="#ref-120">120</a>,<a href="#ref-126">126</a></sup>. In summary, the role and importance of these members of the IAP family of proteins in cancer have been extensively investigated and reviewed.</p></div><div class=section><a name=d2476e727 class=n-a></a><h3 class=section-title>Survivin</h3><p class="" id=d2476e732>Survivin (BIRC5) was first identified by Altieri <i>et al</i>. as an anti-apoptosis gene expressed in various cancer cells<sup><a href="#ref-25">25</a>,<a href="#ref-127">127</a></sup>. Survivin is an example of one of the earliest IAP proteins strongly implicated in oncogenesis<sup><a href="#ref-128">128</a></sup> and has been well established as a prognostic marker with a negative correlation on outcome in many cancers<sup><a href="#ref-129">129</a>–<a href="#ref-133">133</a></sup> (reviewed in <a href="#ref-134">134</a>–<a href="#ref-138">138</a>). Consistent with this, excessive levels of Survivin inhibit both intrinsic and extrinsic pathways of apoptosis<sup><a href="#ref-25">25</a>,<a href="#ref-139">139</a>–<a href="#ref-141">141</a></sup>. Of note, however, Survivin is only a weak apoptosis inhibitor at physiological concentrations and may in fact exert anti-apoptotic activity through stabilization of XIAP<sup><a href="#ref-142">142</a></sup>. Recent studies have shown Survivin to be an important regulator of cell division, and this appears to be its main biological function<sup><a href="#ref-5">5</a>–<a href="#ref-7">7</a>,<a href="#ref-143">143</a></sup>. The role of Survivin in cancer has recently been reviewed extensively<sup><a href="#ref-144">144</a>–<a href="#ref-147">147</a></sup>. Therapeutic targeting of Survivin has been mostly confined to non-small-molecule strategies<sup><a href="#ref-148">148</a>,<a href="#ref-149">149</a></sup> and repression of protein translation<sup><a href="#ref-150">150</a>–<a href="#ref-152">152</a></sup> (reviewed in <a href="#ref-153">153</a>), and only recently have small-molecule inhibitors been reported<sup><a href="#ref-154">154</a>,<a href="#ref-155">155</a></sup>.</p></div><div class=section><a name=d2476e821 class=n-a></a><h3 class=section-title>Apollon</h3><p class="" id=d2476e826>Apollon (BIRC6, the human homolog of murine BRUCE) was first identified in 1999 by Chen <i>et al</i>.<sup><a href="#ref-32">32</a></sup> as a marker in brain and ovarian cancer cell lines that is linked to resistance to various anti-cancer drugs. A number of subsequent studies have concluded that elevated levels of Apollon are linked to poor prognosis in a range of cancers, such as leukemia<sup><a href="#ref-156">156</a>,<a href="#ref-157">157</a></sup>, breast<sup><a href="#ref-158">158</a></sup>, neuroblastoma<sup><a href="#ref-159">159</a></sup>, prostate<sup><a href="#ref-160">160</a>–<a href="#ref-162">162</a></sup>, lung<sup><a href="#ref-163">163</a></sup>, ovarian<sup><a href="#ref-164">164</a></sup>, colorectal<sup><a href="#ref-165">165</a></sup>, hepatocellular<sup><a href="#ref-166">166</a></sup>, and head and neck<sup><a href="#ref-167">167</a></sup> cancers. It is largely understood that the role of Apollon as an oncogene is centered on its role in modulating Smac and caspase-9 levels, where overexpression of Apollon leads to increased silencing of apoptosis through Smac degradation as well as to attenuation of the caspase cascade by targeting caspase-9 for ubiquitination and subsequent degradation<sup><a href="#ref-43">43</a>,<a href="#ref-45">45</a>,<a href="#ref-47">47</a></sup>. Based on these predictive findings, the role of Apollon as a therapeutic target has been evaluated in a number of studies using functional genomic approaches, since no appropriate small-molecule tool has yet been developed<sup><a href="#ref-158">158</a>,<a href="#ref-159">159</a>,<a href="#ref-166">166</a>,<a href="#ref-168">168</a></sup>. Undoubtedly, the development of potent and selective small-molecule antagonists to Apollon will allow detailed elucidation of its potential as a therapeutic target in oncology.</p></div><div class=section><a name=d2476e904 class=n-a></a><h3 class=section-title>ML-IAP</h3><p class="" id=d2476e909>ML-IAP (BIRC7, also known as Livin or KIAP) was first identified as a member of the IAP family because of its single BIR domain<sup><a href="#ref-33">33</a>,<a href="#ref-35">35</a></sup>. The ML-IAP BIR domain is also responsible for apoptosis inhibition, and small molecules that target this region could potentially re-sensitize cancer cells to chemotherapeutics. In particular, the RING domain of ML-IAP has been shown to function as an E3 ubiquitin ligase facilitating the ubiquitination and subsequent degradation of itself<sup><a href="#ref-169">169</a>,<a href="#ref-170">170</a></sup> and, more importantly, of Smac<sup><a href="#ref-170">170</a></sup>, the natural caspase antagonist that modulates apoptotic signaling. Thus, inhibition of ML-IAP leads to a direct increase of Smac and a re-sensitization of cells to apoptotic stimuli. Both protein and mRNA levels of ML-IAP are low to undetectable in most adult tissues<sup><a href="#ref-171">171</a></sup> but are highly expressed in several cancers<sup><a href="#ref-33">33</a>,<a href="#ref-171">171</a>–<a href="#ref-179">179</a></sup>, including various lung cancers, melanoma, liver cancer, glioblastoma, and oral squamous cell carcinoma. This protein is also highly expressed in renal cell carcinoma<sup><a href="#ref-180">180</a>,<a href="#ref-181">181</a></sup>, and this is why the original name of kidney IAP (KIAP) was coined. ML-IAP maps to chromosome 20q13, a region frequently implicated in the mutagenic etiology of lung cancers<sup><a href="#ref-33">33</a></sup>. ML-IAP levels have been shown to be highly relevant as a prognostic biomarker in lung<sup><a href="#ref-172">172</a>,<a href="#ref-173">173</a>,<a href="#ref-182">182</a>,<a href="#ref-183">183</a></sup> and other<sup><a href="#ref-174">174</a>,<a href="#ref-175">175</a>,<a href="#ref-177">177</a>,<a href="#ref-179">179</a>,<a href="#ref-180">180</a>,<a href="#ref-184">184</a>–<a href="#ref-187">187</a></sup> cancers. These studies have consistently reported that high ML-IAP expression correlates with a poor outcome but that lower levels predict a more favorable prognosis. A number of recent studies have clearly shown the considerable therapeutic potential of ML-IAP inhibition to treat cancer. A wealth of data has been presented in cellular contexts<sup><a href="#ref-188">188</a>–<a href="#ref-195">195</a></sup> as well as in xenograft studies<sup><a href="#ref-196">196</a>,<a href="#ref-197">197</a></sup>. In particular, the mouse xenograft studies by Chen <i>et al.</i><sup><a href="#ref-196">196</a></sup> and the cell-line-based work by Zhuang <i>et al</i>.<sup><a href="#ref-198">198</a></sup> showed a substantial benefit gained from <i>BIRC7</i> gene ablation in models of lung cancer. However, all of these studies inhibited ML-IAP through RNA knockdown approaches because of the unavailability of a selective and potent small-molecule antagonist. Recently, however, potent and uniquely selective ML-IAP inhibitors have been reported, which will help more comprehensive elucidation of the role of ML-IAP in cancers<sup><a href="#ref-199">199</a></sup>.</p></div><div class=section><a name=d2476e1028 class=n-a></a><h3 class=section-title>ILP-2</h3><p class="" id=d2476e1033>ILP-2 (IAP-like protein-2 or BIRC8) was originally detected only in the testis and lymphoblastoid cells<sup><a href="#ref-36">36</a></sup>. However, some recent work has established a tenuous link to breast cancer<sup><a href="#ref-200">200</a></sup>, and it will be of interest to see whether this link gains further support to establish ILP-2 as a novel biomarker in human malignancies as well as a potential target for therapy.</p></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d2476e1048>Inhibitor of apoptosis inhibitor development for cancer therapeutics</h2><p class="" id=d2476e1051>In the mid-1990s, it was shown that the BIR domains were necessary and responsible for the anti-apoptotic and caspase-suppressing activity of the IAP proteins<sup><a href="#ref-10">10</a>,<a href="#ref-14">14</a>,<a href="#ref-84">84</a></sup>. With the subsequent discovery of the endogenous IAP ligand Smac in 2000<sup><a href="#ref-88">88</a>,<a href="#ref-201">201</a></sup>, the path toward the development of small-molecule inhibitors of the IAPs unfolded. Historically, however, the development of small-molecule inhibitors of such PPIs has been quite difficult. Most of these interactions are devoid of the classic druggable binding pockets (about 300–500 Å<sup>2</sup>) with which most drug discovery scientists are familiar<sup><a href="#ref-202">202</a></sup>. Rather, these PPIs typically derive their binding energy from a large number of intermolecular interactions along a relatively flat and large (about 1,000–2,000 Å<sup>2</sup>) surface.</p><p class="" id=d2476e1081>It was a critical observation made by Xiadong Wang <i>et al</i>. regarding the loss of Smac activity upon the addition of a glutathione s-transferase (GST) fusion to its N-terminus that paved the way for the current crop of Smac mimetics<sup><a href="#ref-203">203</a></sup>. Mutation studies further confirmed the importance of the post-translationally processed and flexible N-terminus of mature Smac. Perhaps equally important was the contribution from Fesik <i>et al</i>. that year, generating the first nuclear magnetic resonance structure of truncated Smac bound to one of the IAPs, XIAP BIR3<sup><a href="#ref-89">89</a></sup>. Specifically, four residues, AVPI, that bind to a surface groove on the IAP BIR domains proved indispensable for activity. As shown in <a href="#f3">Figure 3</a>, there exists in the IAP BIR domains a negatively charged cleft of perfect size to accept the alanine. Furthermore, the proline of Smac allows for a crucial reverse turn feature to maintain close contacts with the binding site. These are two key elements represented in nearly all of the reported IAP inhibitors. Early on, several groups showed that synthetic oligopeptides (4–9-mers) exhibit better binding affinity than native Smac for XIAP BIR3 and are notable for their apoptosis-inducing ability<sup><a href="#ref-204">204</a>–<a href="#ref-206">206</a></sup>. These oligopeptides served an important role as a drug discovery proof-of-concept: that mimicking a small portion of Smac is a viable strategy to target the IAPs. Subsequent reports took this concept a step further and focused on developing more drug-like peptidomimetics of the N-terminal AVPI tetrapeptide binding motif to disrupt the IAP-caspase PPI, and thus far this has proven to be the most popular and successful tactic. The first true medicinal chemistry work reported by Fesik <i>et al</i>. in 2004<sup><a href="#ref-207">207</a></sup> laid the groundwork for the advances that would follow in subsequent years, and, also in 2004, seminal work from Wang and Harran showed that a small-molecule Smac mimetic could potentiate TNF-induced and TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis<sup><a href="#ref-208">208</a></sup>. A summary of the collective structure-activity-relationship (SAR) conclusions from Smac mimetic medicinal chemistry work is shown in <a href="#f4">Figure 4</a>.</p><div class="fig panel clearfix"><a name=f3 class=n-a></a><a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/11449/e53bae94-4fb7-4b4b-adba-b48595892aca_figure3.gif"><img alt="e53bae94-4fb7-4b4b-adba-b48595892aca_figure3.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/11449/e53bae94-4fb7-4b4b-adba-b48595892aca_figure3.gif"></a><div class=caption><h3>Figure 3. Crystal structure of Ala-Val-Pro-Ile (AVPI), a Smac core motif, bound to the BIR2 domain of XIAP (Protein Data Bank code = 4J46).</h3><p id=d2476e1133>Binding is strongly driven by hydrogen-bond formation (dashed cyan lines) and non-polar interactions. Hydrophobic surface properties of the BIR2 domain are shown in yellow. Note that the color scheme of the tetrapeptide sequence is maintained for the subsequent figure.</p></div></div><div class="fig panel clearfix"><a name=f4 class=n-a></a><a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/11449/e53bae94-4fb7-4b4b-adba-b48595892aca_figure4.gif"><img alt="e53bae94-4fb7-4b4b-adba-b48595892aca_figure4.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/11449/e53bae94-4fb7-4b4b-adba-b48595892aca_figure4.gif"></a><div class=caption><h3>Figure 4. Structure-activity relationship of Smac mimetics is largely based on the original amino acid positions from the Ala-Val-Pro-Ile (AVPI) peptide.</h3></div></div><p class="" id=d2476e1155>A number of research groups from both academia and industry have initiated programs in the space since these early discoveries, focusing on Smac mimetics<sup><a href="#ref-66">66</a>,<a href="#ref-199">199</a>,<a href="#ref-209">209</a>–<a href="#ref-256">256</a></sup> (also reviewed in <a href="#ref-257">257</a>,<a href="#ref-258">258</a>). Some of these compounds remain in pre-clinical testing, whereas others have entered but are no longer active in clinical trials. Our laboratories are currently testing a series of Smac mimetics developed by us at Sanford Burnham Prebys Medical Discovery Institute. A representative compound with encouraging pre-clinical data in several cancer cell lines is shown in <a href="#f5">Figure 5</a><sup><a href="#ref-199">199</a></sup>. SBI-0636457 has demonstrated potent cell-killing effects in several subtypes of breast, ovarian, and prostate cancer cell lines but only when the DR ligand TRAIL or another such apoptosis inducer is co-administered. Furthermore, SBI-0636457 administered as a single agent exhibited no toxicity to normal human fibroblasts.</p><div class="fig panel clearfix"><a name=f5 class=n-a></a><a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/11449/e53bae94-4fb7-4b4b-adba-b48595892aca_figure5.gif"><img alt="e53bae94-4fb7-4b4b-adba-b48595892aca_figure5.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/11449/e53bae94-4fb7-4b4b-adba-b48595892aca_figure5.gif"></a><div class=caption><h3>Figure 5. Structures of the Smac mimetic SBP-0636457 being developed by Sanford Burnham Prebys Medical Discovery Institute and the bivalent agent JP1201 from Joyant Pharmaceuticals.</h3></div></div><p class="" id=d2476e1197>Bivalent Smac mimetics take advantage of the homodimeric nature of native Smac and are able to bind both the BIR2 and the BIR3 domains. The consequence of this improved binding mode is poorer drug-like properties, as the Smac mimetics must adopt a larger molecular size in order to access both binding sites. Impressive binding data (K<sub>d</sub> = 300 pM for the BIR2–BIR3 construct) were observed for the first reported bivalent IAP inhibitor (JP1201) from the Wang and Harran labs (<a href="#f5">Figure 5</a>)<sup><a href="#ref-208">208</a></sup>.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d2476e1213>Current clinical status of inhibitor of apoptosis inhibitors in oncology</h2><p class="" id=d2476e1216>In the US, several monovalent Smac mimetic compounds and one bivalent compound have entered the clinic and are still active in clinical trials (<a href="#f6">Figure 6</a>). All of the compounds for which clinical data have been reported so far demonstrated generally favorable safety profiles in phase I, and amylase/lipase elevation, alanine and aspartate transaminase (ALT and AST) elevation, cytokine release syndrome (CRS), and Bell’s palsy were the dose-limiting serious adverse events<sup><a href="#ref-112">112</a></sup>. Of note, however, the Bell’s palsy toxicity has been observed only with bivalent and not with monovalent Smac mimetics. It has been suggested that CRS may result from the Smac mimetic-induced degradation of cIAP1 and the consequent activation of the NF-κB pathway and an autocrine/paracrine TNF signaling loop. Other possibilities exist, however, as work from Silke and Vaux suggests that triple knockdown of cIAP1, cIAP2, and XIAP results in a hyperactive inflammatory state through still-undefined mechanisms (reviewed in <a href="#ref-259">259</a>). While TNF release potentially enables the efficacy of Smac mimetics as single agents in cancer therapy, the possibility of inducing a “cytokine storm” may render this approach less desirable compared with a combination approach (TNFR agonists + Smac mimetics), especially for indications outside of cancer<sup><a href="#ref-260">260</a>,<a href="#ref-261">261</a></sup>. Indeed, Smac mimetics have demonstrated synergy with other modes of treatment, including cytotoxic agents (that is, carboplatin<sup><a href="#ref-262">262</a></sup> and paclitaxel<sup><a href="#ref-263">263</a></sup>), radiation therapy<sup><a href="#ref-264">264</a></sup>, and cell DR ligands (TRAIL analogues)<sup><a href="#ref-265">265</a></sup>. These synergies are well defined in pre-clinical models, but, so far, they have been less successful in clinical settings (see below). In general, any treatment that stresses the cells, such as standard chemotherapy or radiation therapy, and induces either intrinsic or extrinsic apoptosis via upstream activation could be combined with the caspase-liberating effect of IAP inhibitors to kill cancer cells. Although a number of Smac mimetics have already entered clinical trials, we shall focus our discussion here on those for which trials are currently active (<a href="#T1">Table 1</a>).</p><div class="fig panel clearfix"><a name=f6 class=n-a></a><a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/11449/e53bae94-4fb7-4b4b-adba-b48595892aca_figure6.gif"><img alt="e53bae94-4fb7-4b4b-adba-b48595892aca_figure6.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/11449/e53bae94-4fb7-4b4b-adba-b48595892aca_figure6.gif"></a><div class=caption><h3>Figure 6. Chemical structures of inhibitor of apoptosis inhibitor compounds in active clinical trials.</h3></div></div><div class="table-wrap panel clearfix"><a name=T1 class=n-a></a><div class=caption><h3>Table 1. Ongoing clinical trials with inhibitor of apoptosis inhibitors.</h3></div><table xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d2476e1281 class=n-a></a><thead><a name=d2476e1283 class=n-a></a><tr><a name=d2476e1285 class=n-a></a><th align=left colspan=1 rowspan=1 valign=top><a name=d2476e1287 class=n-a></a>NCT<br class=br>number</th><th align=left colspan=1 rowspan=1 valign=top><a name=d2476e1292 class=n-a></a>Phase</th><th align=left colspan=1 rowspan=1 valign=top><a name=d2476e1295 class=n-a></a>Title</th><th align=left colspan=1 rowspan=1 valign=top><a name=d2476e1298 class=n-a></a>Interventions</th><th align=left colspan=1 rowspan=1 valign=top><a name=d2476e1301 class=n-a></a>Conditions</th><th align=left colspan=1 rowspan=1 valign=top><a name=d2476e1305 class=n-a></a>Sponsor</th></tr></thead><tbody><a name=d2476e1309 class=n-a></a><tr><a name=d2476e1311 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d2476e1312 class=n-a></a>02587962</td><td colspan=1 rowspan=1 valign=top><a name=d2476e1315 class=n-a></a>I/II</td><td colspan=1 rowspan=1 valign=top><a name=d2476e1318 class=n-a></a>Dose escalation study of birinapant and<br class=br>pembrolizumab in solid tumors</td><td colspan=1 rowspan=1 valign=top><a name=d2476e1323 class=n-a></a>Birinapant,<br class=br>pembrolizumab</td><td colspan=1 rowspan=1 valign=top><a name=d2476e1328 class=n-a></a>Solid tumors</td><td colspan=1 rowspan=1 valign=top><a name=d2476e1331 class=n-a></a>TetraLogic<br class=br>(Medivir)</td></tr><tr><a name=d2476e1336 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d2476e1337 class=n-a></a>02756130</td><td colspan=1 rowspan=1 valign=top><a name=d2476e1340 class=n-a></a>II</td><td colspan=1 rowspan=1 valign=top><a name=d2476e1343 class=n-a></a>Proof-of-concept study of birinapant in combination<br class=br>with platinum-based chemotherapy in subjects with<br class=br>high-grade serous carcinomas</td><td colspan=1 rowspan=1 valign=top><a name=d2476e1350 class=n-a></a>Birinapant, paclitaxel,<br class=br>carboplatin</td><td colspan=1 rowspan=1 valign=top><a name=d2476e1355 class=n-a></a>Advanced newly<br class=br>diagnosed or<br class=br>recurrent high-grade<br class=br>serous carcinomas</td><td colspan=1 rowspan=1 valign=top><a name=d2476e1364 class=n-a></a>TetraLogic<br class=br>(Medivir)</td></tr><tr><a name=d2476e1369 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d2476e1370 class=n-a></a>01486784</td><td colspan=1 rowspan=1 valign=top><a name=d2476e1373 class=n-a></a>I/II</td><td colspan=1 rowspan=1 valign=top><a name=d2476e1376 class=n-a></a>A phase I-II open-label non-randomized study<br class=br>using TL32711 for patients with acute myelogenous<br class=br>leukemia, myelodysplastic syndrome, and acute<br class=br>lymphoblastic leukemia</td><td colspan=1 rowspan=1 valign=top><a name=d2476e1385 class=n-a></a>Birinapant</td><td colspan=1 rowspan=1 valign=top><a name=d2476e1388 class=n-a></a>Acute myelogenous<br class=br>leukemia</td><td colspan=1 rowspan=1 valign=top><a name=d2476e1393 class=n-a></a>Tetralogic<br class=br>(Medivir)</td></tr><tr><a name=d2476e1398 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d2476e1399 class=n-a></a>01934634</td><td colspan=1 rowspan=1 valign=top><a name=d2476e1402 class=n-a></a>I</td><td colspan=1 rowspan=1 valign=top><a name=d2476e1405 class=n-a></a>Phase I trial of LCL161 and gemcitabine plus<br class=br>nab-paclitaxel in metastatic pancreatic cancer</td><td colspan=1 rowspan=1 valign=top><a name=d2476e1410 class=n-a></a>LCL161, gemcitabine,<br class=br>nab-paclitaxel</td><td colspan=1 rowspan=1 valign=top><a name=d2476e1415 class=n-a></a>Metastatic<br class=br>pancreatic cancer</td><td colspan=1 rowspan=1 valign=top><a name=d2476e1420 class=n-a></a>Novartis</td></tr><tr><a name=d2476e1423 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d2476e1424 class=n-a></a>01955434</td><td colspan=1 rowspan=1 valign=top><a name=d2476e1427 class=n-a></a>II</td><td colspan=1 rowspan=1 valign=top><a name=d2476e1430 class=n-a></a>SMAC mimetic LCL161 alone or with<br class=br>cyclophosphamide in treating relapsed or refractory<br class=br>multiple myeloma</td><td colspan=1 rowspan=1 valign=top><a name=d2476e1437 class=n-a></a>LCL161,<br class=br>cyclophosphamide</td><td colspan=1 rowspan=1 valign=top><a name=d2476e1442 class=n-a></a>Recurrent and<br class=br>refractory plasma<br class=br>cell myeloma</td><td colspan=1 rowspan=1 valign=top><a name=d2476e1449 class=n-a></a>Mayo Clinic</td></tr><tr><a name=d2476e1453 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d2476e1454 class=n-a></a>02649673</td><td colspan=1 rowspan=1 valign=top><a name=d2476e1457 class=n-a></a>I/II</td><td colspan=1 rowspan=1 valign=top><a name=d2476e1460 class=n-a></a>LCL161 plus topotecan for patients with relapsed/<br class=br>refractory small cell lung cancer and select<br class=br>gynecologic malignancies</td><td colspan=1 rowspan=1 valign=top><a name=d2476e1467 class=n-a></a>LCL161, topotecan</td><td colspan=1 rowspan=1 valign=top><a name=d2476e1470 class=n-a></a>Small cell lung<br class=br>cancer, ovarian<br class=br>cancer</td><td colspan=1 rowspan=1 valign=top><a name=d2476e1477 class=n-a></a>Novartis</td></tr><tr><a name=d2476e1480 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d2476e1481 class=n-a></a>02098161</td><td colspan=1 rowspan=1 valign=top><a name=d2476e1484 class=n-a></a>II</td><td colspan=1 rowspan=1 valign=top><a name=d2476e1487 class=n-a></a>Phase II LCL-161 in patients with primary<br class=br>myelofibrosis, post-polycythemia vera<br class=br>myelofibrosis, or post-essential thrombocytosis<br class=br>myelofibrosis</td><td colspan=1 rowspan=1 valign=top><a name=d2476e1496 class=n-a></a>LCL-161</td><td colspan=1 rowspan=1 valign=top><a name=d2476e1499 class=n-a></a>Leukemia</td><td colspan=1 rowspan=1 valign=top><a name=d2476e1502 class=n-a></a>Novartis</td></tr><tr><a name=d2476e1505 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d2476e1506 class=n-a></a>02890069</td><td colspan=1 rowspan=1 valign=top><a name=d2476e1509 class=n-a></a>I</td><td colspan=1 rowspan=1 valign=top><a name=d2476e1512 class=n-a></a>A study of PDR001 in combination with LCL161,<br class=br>everolimus, or panobinostat</td><td colspan=1 rowspan=1 valign=top><a name=d2476e1517 class=n-a></a>LCL161, PDR001,<br class=br>everolimus,<br class=br>panobinostat</td><td colspan=1 rowspan=1 valign=top><a name=d2476e1524 class=n-a></a>Colorectal cancer,<br class=br>non-small cell lung<br class=br>carcinoma, triple-<br class=br>negative breast<br class=br>cancer</td><td colspan=1 rowspan=1 valign=top><a name=d2476e1535 class=n-a></a>Novartis</td></tr><tr><a name=d2476e1538 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d2476e1539 class=n-a></a>02022098</td><td colspan=1 rowspan=1 valign=top><a name=d2476e1542 class=n-a></a>I/II</td><td colspan=1 rowspan=1 valign=top><a name=d2476e1545 class=n-a></a>Debio 1143-201 dose-finding and efficacy phase<br class=br>I/II trial</td><td colspan=1 rowspan=1 valign=top><a name=d2476e1550 class=n-a></a>Debio 1143, cisplatin,<br class=br>radiotherapy</td><td colspan=1 rowspan=1 valign=top><a name=d2476e1555 class=n-a></a>Squamous cell<br class=br>carcinoma of the<br class=br>head and neck</td><td colspan=1 rowspan=1 valign=top><a name=d2476e1562 class=n-a></a>Debiopharm</td></tr><tr><a name=d2476e1565 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d2476e1566 class=n-a></a>02503423</td><td colspan=1 rowspan=1 valign=top><a name=d2476e1569 class=n-a></a>I/II</td><td colspan=1 rowspan=1 valign=top><a name=d2476e1572 class=n-a></a>Phase I-II study of ASTX660 in subjects with<br class=br>advanced solid tumors and lymphomas</td><td colspan=1 rowspan=1 valign=top><a name=d2476e1577 class=n-a></a>ASTX660</td><td colspan=1 rowspan=1 valign=top><a name=d2476e1580 class=n-a></a>Solid tumors,<br class=br>lymphoma</td><td colspan=1 rowspan=1 valign=top><a name=d2476e1585 class=n-a></a>Astex</td></tr></tbody></table></div><div class=section><a name=d2476e1591 class=n-a></a><h3 class=section-title>Birinapant</h3><p class="" id=d2476e1596>Birinapant is a bivalent Smac mimetic developed by Tetralogic Pharmaceuticals and currently owned by Medivir. Owing to the size of this molecule, only administration by intravenous line has been reported for birinapant, both as a single agent and in combination with several chemotherapeutics (azacitidine, gemcitabine, irinotecan, and conatumumab)<sup><a href="#ref-266">266</a></sup>. The data released so far have been lackluster, and poor efficacy has been demonstrated in the completed studies. In NCT01681368, no complete nor partial response was observed in solid tumors of 11 patients, and accrual was terminated for lack of detected clinical benefit<sup><a href="#ref-267">267</a></sup>. Good, though muted, news came in the phase I/II trial NCT01188499. In patients with metastatic colorectal cancer who previously failed irinotecan treatment, the combination of irinotecan with birinapant resulted in disease stabilization in 62% of patients, higher than the 41% rate shown by the recently approved kinase inhibitor regorafenib<sup><a href="#ref-268">268</a></sup>. The other silver lining for these results is that the response rate as measured by tumor regression was higher, albeit small, at 8% compared with regorafenib at 1%<sup><a href="#ref-269">269</a></sup> and that the enrolled patients had previously failed all available treatments. When comparing these two sets of trial data, one must bear in mind that the regorafenib data come from an earlier and much larger phase III trial. The failure of birinapant versus placebo in a study (NCT02147873) investigating its capacity to treat myelodysplastic syndrome resulted in the folding of Tetralogic and transfer of assets to Medivir, where trials are ongoing<sup><a href="#ref-270">270</a></sup>. Given the previous failures, it will be critical to see favorable clinical outcomes for the conatumumab (DR5 agonist) combination therapy trial (NCT01940172) as well as the trial with pembrolizumab (PD-1 inhibitor) as co-treatment (NCT02587962). CRS has so far proven to be a relatively minor adverse event in patients who received birinapant, and only 10% of patients reported low-grade symptoms<sup><a href="#ref-266">266</a></sup>.</p></div><div class=section><a name=d2476e1626 class=n-a></a><h3 class=section-title>LCL161</h3><p class="" id=d2476e1631>LCL161 is a monovalent IAP inhibitor developed by Novartis that is currently in active clinical trials and has also shown generally good safety up to a 1,800 mg dose; CRS was the major adverse event<sup><a href="#ref-271">271</a></sup>. Despite the encouraging safety profile, early results in a phase I trial (NCT01098838) indicate no objective response from LCL161 single-agent treatment in patients with solid tumors, and the best response was stable disease observed in 19% of patients. These early trial data indicate that the use of Smac mimetics as a monotherapy may be limited by the amount of CRS elicited by the drug or, more broadly, the class of drugs<sup><a href="#ref-272">272</a></sup>. Results from the phase II study (NCT01617668) testing LCL161 in combination with paclitaxel in triple-negative breast cancer indicate that this approach may circumvent the CRS issues, as it was a serious adverse event for only 0.94% of patients<sup><a href="#ref-273">273</a></sup>. It must be noted that it is not clear why the LCL161 plus paclitaxel treatment did not elicit the same CRS response as observed in the phase I study of LCL161 single-agent treatment at the same 1,800 mg dose. The study also revealed a 38% pathological complete response rate versus 17% for paclitaxel alone in a select patient population (for details of the study design, see <a href="#ref-274">274</a>). Interestingly, the increased pathological response rate is observed in a subgroup of patients who showed an elevated TNF-alpha/RIP1 gene signature prior to treatment. These data are encouraging and also help to further the idea of the need for a combination therapy with Smac mimetics. More recently, LCL161 has been tested in combination with cyclophosphamide in MM (NCT01955434). The combination of cyclophosphamide with LCL161 resulted in progression-free survival of 10 months in patients with relapsed/refractory MM<sup><a href="#ref-275">275</a></sup>. LCL161 was also shown to be effective in a transgenic mouse myeloma model, appearing to act via an immunological mechanism<sup><a href="#ref-275">275</a></sup>. Chesi <i>et al.</i><sup><a href="#ref-275">275</a></sup> demonstrated that the antagonism of IAPs by LCL161 does not result in direct killing of tumor cells, but rather it induces a tumor-cell autonomous type 1 interferon response. This results in a strong inflammatory response that ultimately leads to phagocytosis of the cancer cells. Intriguingly, the authors further show that LCL161 combination with PD-1 blockade was curative of all mice that completed 2 weeks of treatment<sup><a href="#ref-275">275</a></sup>. Expanding on these findings is recent evidence that immune checkpoint blockade combined with Smac mimetics is efficacious in pre-clinical models of glioblastoma<sup><a href="#ref-276">276</a></sup>. As such, the immune regulatory roles of IAPs may also be of much therapeutic relevance.</p></div><div class=section><a name=d2476e1673 class=n-a></a><h3 class=section-title>Debio 1143</h3><p class="" id=d2476e1678>Debio 1143 is another monovalent Smac mimetic in ongoing clinical trials for a number of different malignancies. It was developed in its early stages by the Wang group at the University of Michigan and later at Ascenta Therapeutics, ultimately being licensed to Debiopharm. Phase I safety studies were in line with the previously reported Smac mimetics reported above, when tested as a monotherapy: generally mild adverse events with a highest tested dose of 900 mg<sup><a href="#ref-277">277</a></sup>. On-target pharmacodynamic modulation was achieved at doses above 80 mg, as measured by cIAP1 degradation. Preliminary efficacy data from the trial indicated that 20% of patients exhibited stable disease as the best response. With the encouraging safety data, a phase I/II trial (NCT02022098) with cisplatin and radiotherapy as co-treatment was undertaken for squamous cell carcinoma of the head and neck, and the expected completion date is 2019.</p></div><div class=section><a name=d2476e1686 class=n-a></a><h3 class=section-title>ASTX660</h3><p class="" id=d2476e1691>UK-based Astex Pharmaceuticals recently initiated their own phase I/II trial (NCT02503423) for the small-molecule ASTX660 for solid tumors and lymphomas. Envisioning ASTX660 as part of a two-pronged cell death approach, Astex screened a number of breast, colorectal, ovarian, leukemia, and melanoma cell lines for their response to monotherapy versus co-treatment with TNF-alpha<sup><a href="#ref-278">278</a></sup>. It will be interesting to see how well the pre-clinical data correlate with the clinical data expected in 2018.</p><p class="" id=d2476e1698>While the ability of the reported Smac mimetics to induce cancer cell death in pre-clinical models was exciting and held much promise, so far the first-in-human studies have presented lackluster results. Several compounds that were able to induce cancer cell death and thus partial or complete remission in tissue culture and animal studies have not had similar success in trials as a monotherapy. However, given the promising clinical pharmacodynamics and safety data, further research and development efforts are certainly warranted.</p></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d2476e1705>Conclusions and future work</h2><p class="" id=d2476e1708>As detailed above, the IAPs are at the nexus of cancer cell survival and, conversely, apoptosis. As such, the inhibition of pertinent family members would be expected to afford a valuable therapeutic intervention strategy for cancers, as these diseases are largely conditions of increased proliferation and impaired apoptosis. As often occurs, however, the reality has proven vastly more complicated than first envisioned. As detailed above, although Smac mimetics are safe and well tolerated, they have shown little single-agent activity in clinical trials. Intuitive, yet not extensively pre-clinically verified, combinations of IAP antagonists such as Smac mimetics with standard-of-care chemotherapeutics have likewise proven unfruitful to most degrees, although there have been some responses, as described above. Perhaps most encouraging have been pre-clinical studies showing that IAP antagonists are potent sensitizers to certain TNFR family agonists<sup><a href="#ref-64">64</a>,<a href="#ref-199">199</a>,<a href="#ref-208">208</a>,<a href="#ref-279">279</a>–<a href="#ref-283">283</a></sup>. Additionally, it has been shown that this can be effected not only by the natural ligands themselves but also by agonistic antibodies to TRAIL receptors developed by several pharmaceutical companies<sup><a href="#ref-284">284</a>–<a href="#ref-288">288</a></sup>. Targeting TRAIL receptors with simultaneous IAP inhibition not only is toxic to cancer cells but also leaves non-transformed cells untouched, a “holy grail” of anti-cancer therapy. Expanding on these observations are studies by Beug <i>et al</i>., who show that concomitant induction of an immune response when IAPs are inhibited can produce a profound tumor regression in animal models<sup><a href="#ref-289">289</a></sup>. Indeed, the use of Smac mimetics and attenuated oncolytic viruses as an anti-cancer strategy has shown promising results in some models<sup><a href="#ref-290">290</a></sup>. As such, the notion of targeted activation of certain TNFRs in combination with IAP inhibition is a potential potent intervention point in many cancers. Already, clinical trials of just such a combination are underway (discussed above), and the results should further assist in our progress toward more targeted therapies using these phenomena.</p><p class="" id=d2476e1745>In sum, whilst the clinical application of IAP antagonists has to date not produced the panacea desired, the ongoing development of next-generation agents and pertinent combinations bodes well for the future. “Inhibiting the inhibitors”<sup><a href="#ref-291">291</a></sup> may soon be a viable anti-cancer strategy.</p></div><div id=article1-back class=generated-article-footer><div class=back-section><a name=d2476e1 class=n-a></a><h2 class=main-title id=d3188>Competing interests</h2><p class=metadata-entry><a name=d2476e161 class=n-a></a><p id=d2476e163> No competing interests were disclosed.</p></p></div><div class=back-section><a name=d2476e1 class=n-a></a><h2 class=main-title id=d3190>Grant information</h2><p>This work was supported by National Institutes of Health grant R01CA195227 to DF and NDPC.</p><p> <i>The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</i> </p></div><div class=back-section><a name=d2476e1756 class=n-a></a><span class="research-layout prime-recommended-wrapper reference-heading"><span class="f1r-icon icon-79_faculty_recommended_badge red vmiddle default-cursor"></span><span class="prime-red big">F1000 recommended</span></span><h2 class=main-title id=d4096>References</h2><div class="section ref-list"><a name=d2476e1756 class=n-a></a><ul><li><a name=ref-1 class=n-a></a><span class=label>1. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/1030318"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d2476e1763 class=n-a></a>Degterev A, Huang Z, Boyce M, <i> et al.</i>: Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury. <i>Nat Chem Biol.</i> 2005; <b>1</b>(2): 112–9. <a target=xrefwindow id=d2476e1774 href="http://www.ncbi.nlm.nih.gov/pubmed/16408008">PubMed Abstract </a> | <a target=xrefwindow id=d2476e1777 href="http://dx.doi.org/10.1038/nchembio711">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/1030318">F1000 Recommendation</a></span></li><li><a name=ref-2 class=n-a></a><span class=label>2. </span>&nbsp;<span class=citation><a name=d2476e1790 class=n-a></a>Geserick P, Hupe M, Moulin M, <i> et al.</i>: Cellular IAPs inhibit a cryptic CD95-induced cell death by limiting RIP1 kinase recruitment. <i>J Cell Biol.</i> 2009; <b>187</b>(7): 1037–54. <a target=xrefwindow id=d2476e1801 href="http://www.ncbi.nlm.nih.gov/pubmed/20038679">PubMed Abstract </a> | <a target=xrefwindow id=d2476e1804 href="http://dx.doi.org/10.1083/jcb.200904158">Publisher Full Text </a> | <a target=xrefwindow id=d2476e1808 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2806279">Free Full Text </a></span></li><li><a name=ref-3 class=n-a></a><span class=label>3. </span>&nbsp;<span class=citation><a name=d2476e1817 class=n-a></a>Silke J, Brink R: Regulation of TNFRSF and innate immune signalling complexes by TRAFs and cIAPs. <i>Cell Death Differ.</i> 2010; <b>17</b>(1): 35–45. <a target=xrefwindow id=d2476e1825 href="http://www.ncbi.nlm.nih.gov/pubmed/19680262">PubMed Abstract </a> | <a target=xrefwindow id=d2476e1828 href="http://dx.doi.org/10.1038/cdd.2009.114">Publisher Full Text </a></span></li><li><a name=ref-4 class=n-a></a><span class=label>4. </span>&nbsp;<span class=citation><a name=d2476e1837 class=n-a></a>Gentle IE, Moelter I, Lechler N, <i> et al.</i>: Inhibitors of apoptosis proteins (IAPs) are required for effective T-cell expansion/survival during antiviral immunity in mice. <i>Blood.</i> 2014; <b>123</b>(5): 659–68. <a target=xrefwindow id=d2476e1848 href="http://www.ncbi.nlm.nih.gov/pubmed/24335231">PubMed Abstract </a> | <a target=xrefwindow id=d2476e1851 href="http://dx.doi.org/10.1182/blood-2013-01-479543">Publisher Full Text </a></span></li><li><a name=ref-5 class=n-a></a><span class=label>5. </span>&nbsp;<span class=citation><a name=d2476e1860 class=n-a></a>Uren AG, Beilharz T, O'Connell MJ, <i> et al.</i>: Role for yeast inhibitor of apoptosis (IAP)-like proteins in cell division. <i>Proc Natl Acad Sci U S A.</i> 1999; <b>96</b>(18): 10170–5. <a target=xrefwindow id=d2476e1871 href="http://www.ncbi.nlm.nih.gov/pubmed/10468581">PubMed Abstract </a> | <a target=xrefwindow id=d2476e1874 href="http://dx.doi.org/10.1073/pnas.96.18.10170">Publisher Full Text </a> | <a target=xrefwindow id=d2476e1878 href="http://www.ncbi.nlm.nih.gov/pmc/articles/17861">Free Full Text </a></span></li><li><a name=ref-6 class=n-a></a><span class=label>6. </span>&nbsp;<span class=citation><a name=d2476e1888 class=n-a></a>Uren AG, Wong L, Pakusch M, <i> et al.</i>: Survivin and the inner centromere protein INCENP show similar cell-cycle localization and gene knockout phenotype. <i>Curr Biol.</i> 2000; <b>10</b>(21): 1319–28. <a target=xrefwindow id=d2476e1899 href="http://www.ncbi.nlm.nih.gov/pubmed/11084331">PubMed Abstract </a> | <a target=xrefwindow id=d2476e1902 href="http://dx.doi.org/10.1016/S0960-9822(00)00769-7">Publisher Full Text </a></span></li><li><a name=ref-7 class=n-a></a><span class=label>7. </span>&nbsp;<span class=citation><a name=d2476e1911 class=n-a></a>Silke J, Vaux DL: Two kinds of BIR-containing protein - inhibitors of apoptosis, or required for mitosis. <i>J Cell Sci.</i> 2001; <b>114</b>(Pt 10): 1821–7. <a target=xrefwindow id=d2476e1919 href="http://www.ncbi.nlm.nih.gov/pubmed/11329368">PubMed Abstract </a></span></li><li><a name=ref-8 class=n-a></a><span class=label>8. </span>&nbsp;<span class=citation><a name=d2476e1928 class=n-a></a>Crook NE, Clem RJ, Miller LK: An apoptosis-inhibiting baculovirus gene with a zinc finger-like motif. <i>J Virol.</i> 1993; <b>67</b>(4): 2168–74. <a target=xrefwindow id=d2476e1936 href="http://www.ncbi.nlm.nih.gov/pubmed/8445726">PubMed Abstract </a> | <a target=xrefwindow id=d2476e1939 href="http://www.ncbi.nlm.nih.gov/pmc/articles/240327">Free Full Text </a></span></li><li><a name=ref-9 class=n-a></a><span class=label>9. </span>&nbsp;<span class=citation><a name=d2476e1948 class=n-a></a>Birnbaum MJ, Clem RJ, Miller LK: An apoptosis-inhibiting gene from a nuclear polyhedrosis virus encoding a polypeptide with Cys/His sequence motifs. <i>J Virol.</i> 1994; <b>68</b>(4): 2521–8. <a target=xrefwindow id=d2476e1956 href="http://www.ncbi.nlm.nih.gov/pubmed/8139034">PubMed Abstract </a> | <a target=xrefwindow id=d2476e1959 href="http://www.ncbi.nlm.nih.gov/pmc/articles/236730">Free Full Text </a></span></li><li><a name=ref-10 class=n-a></a><span class=label>10. </span>&nbsp;<span class=citation><a name=d2476e1968 class=n-a></a>Clem RJ, Miller LK: Control of programmed cell death by the baculovirus genes p35 and iap. <i>Mol Cell Biol.</i> 1994; <b>14</b>(8): 5212–22. <a target=xrefwindow id=d2476e1976 href="http://www.ncbi.nlm.nih.gov/pubmed/8035800">PubMed Abstract </a> | <a target=xrefwindow id=d2476e1979 href="http://dx.doi.org/10.1128/MCB.14.8.5212">Publisher Full Text </a> | <a target=xrefwindow id=d2476e1982 href="http://www.ncbi.nlm.nih.gov/pmc/articles/359040">Free Full Text </a></span></li><li><a name=ref-11 class=n-a></a><span class=label>11. </span>&nbsp;<span class=citation><a name=d2476e1991 class=n-a></a>Huang Q, Deveraux QL, Maeda S, <i> et al.</i>: Cloning and characterization of an inhibitor of apoptosis protein (IAP) from <i>Bombyx mori</i>. <i>Biochim Biophys Acta.</i> 2001; <b>1499</b>(3): 191–8. <a target=xrefwindow id=d2476e2005 href="http://www.ncbi.nlm.nih.gov/pubmed/11341966">PubMed Abstract </a> | <a target=xrefwindow id=d2476e2009 href="http://dx.doi.org/10.1016/S0167-4889(00)00105-1">Publisher Full Text </a></span></li><li><a name=ref-12 class=n-a></a><span class=label>12. </span>&nbsp;<span class=citation><a name=d2476e2019 class=n-a></a>Fraser AG, James C, Evan GI, <i> et al.</i>: <i>Caenorhabditis elegans</i> inhibitor of apoptosis protein (IAP) homologue BIR-1 plays a conserved role in cytokinesis. <i>Curr Biol.</i> 1999; <b>9</b>(6): 292–301. <a target=xrefwindow id=d2476e2033 href="http://www.ncbi.nlm.nih.gov/pubmed/10209096">PubMed Abstract </a> | <a target=xrefwindow id=d2476e2037 href="http://dx.doi.org/10.1016/S0960-9822(99)80137-7">Publisher Full Text </a></span></li><li><a name=ref-13 class=n-a></a><span class=label>13. </span>&nbsp;<span class=citation><a name=d2476e2046 class=n-a></a>Yaraghi Z, Korneluk RG, MacKenzie A: Cloning and characterization of the multiple murine homologues of <i>NAIP</i> (neuronal apoptosis inhibitory protein). <i>Genomics.</i> 1998; <b>51</b>(1): 107–13. <a target=xrefwindow id=d2476e2057 href="http://www.ncbi.nlm.nih.gov/pubmed/9693038">PubMed Abstract </a> | <a target=xrefwindow id=d2476e2060 href="http://dx.doi.org/10.1006/geno.1998.5378">Publisher Full Text </a></span></li><li><a name=ref-14 class=n-a></a><span class=label>14. </span>&nbsp;<span class=citation><a name=d2476e2069 class=n-a></a>Hay BA, Wassarman DA, Rubin GM: Drosophila homologs of baculovirus inhibitor of apoptosis proteins function to block cell death. <i>Cell.</i> 1995; <b>83</b>(7): 1253–62. <a target=xrefwindow id=d2476e2077 href="http://www.ncbi.nlm.nih.gov/pubmed/8548811">PubMed Abstract </a> | <a target=xrefwindow id=d2476e2080 href="http://dx.doi.org/10.1016/0092-8674(95)90150-7">Publisher Full Text </a></span></li><li><a name=ref-15 class=n-a></a><span class=label>15. </span>&nbsp;<span class=citation><a name=d2476e2089 class=n-a></a>Liston P, Roy N, Tamai K, <i> et al.</i>: Suppression of apoptosis in mammalian cells by NAIP and a related family of IAP genes. <i>Nature.</i> 1996; <b>379</b>(6563): 349–53. <a target=xrefwindow id=d2476e2100 href="http://www.ncbi.nlm.nih.gov/pubmed/8552191">PubMed Abstract </a> | <a target=xrefwindow id=d2476e2103 href="http://dx.doi.org/10.1038/379349a0">Publisher Full Text </a></span></li><li><a name=ref-16 class=n-a></a><span class=label>16. </span>&nbsp;<span class=citation><a name=d2476e2112 class=n-a></a>Roy N, Mahadevan MS, McLean M, <i> et al.</i>: The gene for neuronal apoptosis inhibitory protein is partially deleted in individuals with spinal muscular atrophy. <i>Cell.</i> 1995; <b>80</b>(1): 167–78. <a target=xrefwindow id=d2476e2123 href="http://www.ncbi.nlm.nih.gov/pubmed/7813013">PubMed Abstract </a> | <a target=xrefwindow id=d2476e2126 href="http://dx.doi.org/10.1016/0092-8674(95)90461-1">Publisher Full Text </a></span></li><li><a name=ref-17 class=n-a></a><span class=label>17. </span>&nbsp;<span class=citation><a name=d2476e2135 class=n-a></a>Rothe M, Wong SC, Henzel WJ, <i> et al.</i>: A novel family of putative signal transducers associated with the cytoplasmic domain of the 75 kDa tumor necrosis factor receptor. <i>Cell.</i> 1994; <b>78</b>(4): 681–92. <a target=xrefwindow id=d2476e2146 href="http://www.ncbi.nlm.nih.gov/pubmed/8069916">PubMed Abstract </a> | <a target=xrefwindow id=d2476e2149 href="http://dx.doi.org/10.1016/0092-8674(94)90532-0">Publisher Full Text </a></span></li><li><a name=ref-18 class=n-a></a><span class=label>18. </span>&nbsp;<span class=citation><a name=d2476e2159 class=n-a></a>Rothe M, Pan MG, Henzel WJ, <i> et al.</i>: The TNFR2-TRAF signaling complex contains two novel proteins related to baculoviral inhibitor of apoptosis proteins. <i>Cell.</i> 1995; <b>83</b>(7): 1243–52. <a target=xrefwindow id=d2476e2170 href="http://www.ncbi.nlm.nih.gov/pubmed/8548810">PubMed Abstract </a> | <a target=xrefwindow id=d2476e2173 href="http://dx.doi.org/10.1016/0092-8674(95)90149-3">Publisher Full Text </a></span></li><li><a name=ref-19 class=n-a></a><span class=label>19. </span>&nbsp;<span class=citation><a name=d2476e2182 class=n-a></a>Shu HB, Takeuchi M, Goeddel DV: The tumor necrosis factor receptor 2 signal transducers TRAF2 and c-IAP1 are components of the tumor necrosis factor receptor 1 signaling complex. <i>Proc Natl Acad Sci U S A.</i> 1996; <b>93</b>(24): 13973–8. <a target=xrefwindow id=d2476e2190 href="http://www.ncbi.nlm.nih.gov/pubmed/8943045">PubMed Abstract </a> | <a target=xrefwindow id=d2476e2193 href="http://dx.doi.org/10.1073/pnas.93.24.13973">Publisher Full Text </a> | <a target=xrefwindow id=d2476e2196 href="http://www.ncbi.nlm.nih.gov/pmc/articles/19479">Free Full Text </a></span></li><li><a name=ref-20 class=n-a></a><span class=label>20. </span>&nbsp;<span class=citation><a name=d2476e2205 class=n-a></a>Wang CY, Mayo MW, Korneluk RG, <i> et al.</i>: NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. <i>Science.</i> 1998; <b>281</b>(5383): 1680–3. <a target=xrefwindow id=d2476e2216 href="http://www.ncbi.nlm.nih.gov/pubmed/9733516">PubMed Abstract </a> | <a target=xrefwindow id=d2476e2219 href="http://dx.doi.org/10.1126/science.281.5383.1680">Publisher Full Text </a></span></li><li><a name=ref-21 class=n-a></a><span class=label>21. </span>&nbsp;<span class=citation><a name=d2476e2228 class=n-a></a>Salvesen GS, Duckett CS: IAP proteins: blocking the road to death's door. <i>Nat Rev Mol Cell Biol.</i> 2002; <b>3</b>(6): 401–10. <a target=xrefwindow id=d2476e2236 href="http://www.ncbi.nlm.nih.gov/pubmed/12042762">PubMed Abstract </a> | <a target=xrefwindow id=d2476e2239 href="http://dx.doi.org/10.1038/nrm830">Publisher Full Text </a></span></li><li><a name=ref-22 class=n-a></a><span class=label>22. </span>&nbsp;<span class=citation><a name=d2476e2248 class=n-a></a>Uren AG, Pakusch M, Hawkins CJ, <i> et al.</i>: Cloning and expression of apoptosis inhibitory protein homologs that function to inhibit apoptosis and/or bind tumor necrosis factor receptor-associated factors. <i>Proc Natl Acad Sci U S A.</i> 1996; <b>93</b>(10): 4974–8. <a target=xrefwindow id=d2476e2259 href="http://www.ncbi.nlm.nih.gov/pubmed/8643514">PubMed Abstract </a> | <a target=xrefwindow id=d2476e2262 href="http://dx.doi.org/10.1073/pnas.93.10.4974">Publisher Full Text </a> | <a target=xrefwindow id=d2476e2266 href="http://www.ncbi.nlm.nih.gov/pmc/articles/39390">Free Full Text </a></span></li><li><a name=ref-23 class=n-a></a><span class=label>23. </span>&nbsp;<span class=citation><a name=d2476e2275 class=n-a></a>Hawkins CJ, Uren AG, Hacker G, <i> et al.</i>: Inhibition of interleukin 1 beta-converting enzyme-mediated apoptosis of mammalian cells by baculovirus IAP. <i>Proc Natl Acad Sci U S A.</i> 1996; <b>93</b>(24): 13786–90. <a target=xrefwindow id=d2476e2286 href="http://www.ncbi.nlm.nih.gov/pubmed/8943013">PubMed Abstract </a> | <a target=xrefwindow id=d2476e2289 href="http://dx.doi.org/10.1073/pnas.93.24.13786">Publisher Full Text </a> | <a target=xrefwindow id=d2476e2293 href="http://www.ncbi.nlm.nih.gov/pmc/articles/19426">Free Full Text </a></span></li><li><a name=ref-24 class=n-a></a><span class=label>24. </span>&nbsp;<span class=citation><a name=d2476e2303 class=n-a></a>Deveraux QL, Takahashi R, Salvesen GS, <i> et al.</i>: X-linked IAP is a direct inhibitor of cell-death proteases. <i>Nature.</i> 1997; <b>388</b>(6639): 300–4. <a target=xrefwindow id=d2476e2314 href="http://www.ncbi.nlm.nih.gov/pubmed/9230442">PubMed Abstract </a> | <a target=xrefwindow id=d2476e2317 href="http://dx.doi.org/10.1038/40901">Publisher Full Text </a></span></li><li><a name=ref-25 class=n-a></a><span class=label>25. </span>&nbsp;<span class=citation><a name=d2476e2326 class=n-a></a>Ambrosini G, Adida C, Altieri DC: A novel anti-apoptosis gene, <i>survivin</i>, expressed in cancer and lymphoma. <i>Nat Med.</i> 1997; <b>3</b>(8): 917–21. <a target=xrefwindow id=d2476e2337 href="http://www.ncbi.nlm.nih.gov/pubmed/9256286">PubMed Abstract </a> | <a target=xrefwindow id=d2476e2340 href="http://dx.doi.org/10.1038/nm0897-917">Publisher Full Text </a></span></li><li><a name=ref-26 class=n-a></a><span class=label>26. </span>&nbsp;<span class=citation><a name=d2476e2349 class=n-a></a>Deveraux QL, Roy N, Stennicke HR, <i> et al.</i>: IAPs block apoptotic events induced by caspase-8 and cytochrome <i>c</i> by direct inhibition of distinct caspases. <i>EMBO J.</i> 1998; <b>17</b>(8): 2215–23. <a target=xrefwindow id=d2476e2363 href="http://www.ncbi.nlm.nih.gov/pubmed/9545235">PubMed Abstract </a> | <a target=xrefwindow id=d2476e2367 href="http://dx.doi.org/10.1093/emboj/17.8.2215">Publisher Full Text </a> | <a target=xrefwindow id=d2476e2370 href="http://www.ncbi.nlm.nih.gov/pmc/articles/1170566">Free Full Text </a></span></li><li><a name=ref-27 class=n-a></a><span class=label>27. </span>&nbsp;<span class=citation><a name=d2476e2379 class=n-a></a>LaCasse EC, Baird S, Korneluk RG, <i> et al.</i>: The inhibitors of apoptosis (IAPs) and their emerging role in cancer. <i>Oncogene.</i> 1998; <b>17</b>(25): 3247–59. <a target=xrefwindow id=d2476e2390 href="http://www.ncbi.nlm.nih.gov/pubmed/9916987">PubMed Abstract </a> | <a target=xrefwindow id=d2476e2393 href="http://dx.doi.org/10.1038/sj.onc.1202569">Publisher Full Text </a></span></li><li><a name=ref-28 class=n-a></a><span class=label>28. </span>&nbsp;<span class=citation><a name=d2476e2402 class=n-a></a>Duckett CS, Nava VE, Gedrich RW, <i> et al.</i>: A conserved family of cellular genes related to the baculovirus iap gene and encoding apoptosis inhibitors. <i>EMBO J.</i> 1996; <b>15</b>(11): 2685–94. <a target=xrefwindow id=d2476e2413 href="http://www.ncbi.nlm.nih.gov/pubmed/8654366">PubMed Abstract </a> | <a target=xrefwindow id=d2476e2416 href="http://www.ncbi.nlm.nih.gov/pmc/articles/450204">Free Full Text </a></span></li><li><a name=ref-29 class=n-a></a><span class=label>29. </span>&nbsp;<span class=citation><a name=d2476e2425 class=n-a></a>Adida C, Crotty PL, McGrath J, <i> et al.</i>: Developmentally regulated expression of the novel cancer anti-apoptosis gene survivin in human and mouse differentiation. <i>Am J Pathol.</i> 1998; <b>152</b>(1): 43–9. <a target=xrefwindow id=d2476e2436 href="http://www.ncbi.nlm.nih.gov/pubmed/9422522">PubMed Abstract </a> | <a target=xrefwindow id=d2476e2439 href="http://www.ncbi.nlm.nih.gov/pmc/articles/1858132">Free Full Text </a></span></li><li><a name=ref-30 class=n-a></a><span class=label>30. </span>&nbsp;<span class=citation><a name=d2476e2449 class=n-a></a>Ambrosini G, Adida C, Sirugo G, <i> et al.</i>: Induction of apoptosis and inhibition of cell proliferation by <i>survivin</i> gene targeting. <i>J Biol Chem.</i> 1998; <b>273</b>(18): 11177–82. <a target=xrefwindow id=d2476e2463 href="http://www.ncbi.nlm.nih.gov/pubmed/9556606">PubMed Abstract </a> | <a target=xrefwindow id=d2476e2467 href="http://dx.doi.org/10.1074/jbc.273.18.11177">Publisher Full Text </a></span></li><li><a name=ref-31 class=n-a></a><span class=label>31. </span>&nbsp;<span class=citation><a name=d2476e2476 class=n-a></a>Hauser HP, Bardroff M, Pyrowolakis G, <i> et al.</i>: A giant ubiquitin-conjugating enzyme related to IAP apoptosis inhibitors. <i>J Cell Biol.</i> 1998; <b>141</b>(6): 1415–22. <a target=xrefwindow id=d2476e2487 href="http://www.ncbi.nlm.nih.gov/pubmed/9628897">PubMed Abstract </a> | <a target=xrefwindow id=d2476e2490 href="http://dx.doi.org/10.1083/jcb.141.6.1415">Publisher Full Text </a> | <a target=xrefwindow id=d2476e2494 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2132795">Free Full Text </a></span></li><li><a name=ref-32 class=n-a></a><span class=label>32. </span>&nbsp;<span class=citation><a name=d2476e2503 class=n-a></a>Chen Z, Naito M, Hori S, <i> et al.</i>: A human IAP-family gene, <i>apollon</i>, expressed in human brain cancer cells. <i>Biochem Biophys Res Commun.</i> 1999; <b>264</b>(3): 847–54. <a target=xrefwindow id=d2476e2517 href="http://www.ncbi.nlm.nih.gov/pubmed/10544019">PubMed Abstract </a> | <a target=xrefwindow id=d2476e2521 href="http://dx.doi.org/10.1006/bbrc.1999.1585">Publisher Full Text </a></span></li><li><a name=ref-33 class=n-a></a><span class=label>33. </span>&nbsp;<span class=citation><a name=d2476e2530 class=n-a></a>Vucic D, Stennicke HR, Pisabarro MT, <i> et al.</i>: ML-IAP, a novel inhibitor of apoptosis that is preferentially expressed in human melanomas. <i>Curr Biol.</i> 2000; <b>10</b>(21): 1359–66. <a target=xrefwindow id=d2476e2541 href="http://www.ncbi.nlm.nih.gov/pubmed/11084335">PubMed Abstract </a> | <a target=xrefwindow id=d2476e2544 href="http://dx.doi.org/10.1016/S0960-9822(00)00781-8">Publisher Full Text </a></span></li><li><a name=ref-34 class=n-a></a><span class=label>34. </span>&nbsp;<span class=citation><a name=d2476e2553 class=n-a></a>Lin JH, Deng G, Huang Q, <i> et al.</i>: KIAP, a novel member of the inhibitor of apoptosis protein family. <i>Biochem Biophys Res Commun.</i> 2000; <b>279</b>(3): 820–31. <a target=xrefwindow id=d2476e2564 href="http://www.ncbi.nlm.nih.gov/pubmed/11162435">PubMed Abstract </a> | <a target=xrefwindow id=d2476e2567 href="http://dx.doi.org/10.1006/bbrc.2000.4027">Publisher Full Text </a></span></li><li><a name=ref-35 class=n-a></a><span class=label>35. </span>&nbsp;<span class=citation><a name=d2476e2576 class=n-a></a>Kasof GM, Gomes BC: Livin, a novel inhibitor of apoptosis protein family member. <i>J Biol Chem.</i> 2001; <b>276</b>(5): 3238–46. <a target=xrefwindow id=d2476e2584 href="http://www.ncbi.nlm.nih.gov/pubmed/11024045">PubMed Abstract </a> | <a target=xrefwindow id=d2476e2587 href="http://dx.doi.org/10.1074/jbc.M003670200">Publisher Full Text </a></span></li><li><a name=ref-36 class=n-a></a><span class=label>36. </span>&nbsp;<span class=citation><a name=d2476e2597 class=n-a></a>Richter BW, Mir SS, Eiben LJ, <i> et al.</i>: Molecular cloning of <i>ILP-2</i>, a novel member of the inhibitor of apoptosis protein family. <i>Mol Cell Biol.</i> 2001; <b>21</b>(13): 4292–301. <a target=xrefwindow id=d2476e2611 href="http://www.ncbi.nlm.nih.gov/pubmed/11390657">PubMed Abstract </a> | <a target=xrefwindow id=d2476e2615 href="http://dx.doi.org/10.1128/MCB.21.13.4292-4301.2001">Publisher Full Text </a> | <a target=xrefwindow id=d2476e2618 href="http://www.ncbi.nlm.nih.gov/pmc/articles/87089">Free Full Text </a></span></li><li><a name=ref-37 class=n-a></a><span class=label>37. </span>&nbsp;<span class=citation><a name=d2476e2627 class=n-a></a>Lagace M, Xuan JY, Young SS, <i> et al.</i>: Genomic organization of the X-linked inhibitor of apoptosis and identification of a novel testis-specific transcript. <i>Genomics.</i> 2001; <b>77</b>(3): 181–8. <a target=xrefwindow id=d2476e2638 href="http://www.ncbi.nlm.nih.gov/pubmed/11597143">PubMed Abstract </a> | <a target=xrefwindow id=d2476e2641 href="http://dx.doi.org/10.1006/geno.2001.6635">Publisher Full Text </a></span></li><li><a name=ref-38 class=n-a></a><span class=label>38. </span>&nbsp;<span class=citation><a name=d2476e2650 class=n-a></a>Chu ZL, McKinsey TA, Liu L, <i> et al.</i>: Suppression of tumor necrosis factor-induced cell death by inhibitor of apoptosis c-IAP2 is under NF-kappaB control. <i>Proc Natl Acad Sci U S A.</i> 1997; <b>94</b>(19): 10057–62. <a target=xrefwindow id=d2476e2661 href="http://www.ncbi.nlm.nih.gov/pubmed/9294162">PubMed Abstract </a> | <a target=xrefwindow id=d2476e2664 href="http://dx.doi.org/10.1073/pnas.94.19.10057">Publisher Full Text </a> | <a target=xrefwindow id=d2476e2668 href="http://www.ncbi.nlm.nih.gov/pmc/articles/23303">Free Full Text </a></span></li><li><a name=ref-39 class=n-a></a><span class=label>39. </span>&nbsp;<span class=citation><a name=d2476e2677 class=n-a></a>Blankenship JW, Varfolomeev E, Goncharov T, <i> et al.</i>: Ubiquitin binding modulates IAP antagonist-stimulated proteasomal degradation of c-IAP1 and c-IAP2(1). <i>Biochem J.</i> 2009; <b>417</b>(1): 149–60. <a target=xrefwindow id=d2476e2688 href="http://www.ncbi.nlm.nih.gov/pubmed/18939944">PubMed Abstract </a> | <a target=xrefwindow id=d2476e2691 href="http://dx.doi.org/10.1042/BJ20081885">Publisher Full Text </a></span></li><li><a name=ref-40 class=n-a></a><span class=label>40. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/1008847"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d2476e2700 class=n-a></a>MacFarlane M, Merrison W, Bratton SB, <i> et al.</i>: Proteasome-mediated degradation of Smac during apoptosis: XIAP promotes Smac ubiquitination <i>in vitro</i>. <i>J Biol Chem.</i> 2002; <b>277</b>(39): 36611–6. <a target=xrefwindow id=d2476e2714 href="http://www.ncbi.nlm.nih.gov/pubmed/12121969">PubMed Abstract </a> | <a target=xrefwindow id=d2476e2718 href="http://dx.doi.org/10.1074/jbc.M200317200">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/1008847">F1000 Recommendation</a></span></li><li><a name=ref-41 class=n-a></a><span class=label>41. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/1000296"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d2476e2731 class=n-a></a>Suzuki Y, Nakabayashi Y, Takahashi R: Ubiquitin-protein ligase activity of X-linked inhibitor of apoptosis protein promotes proteasomal degradation of caspase-3 and enhances its anti-apoptotic effect in Fas-induced cell death. <i>Proc Natl Acad Sci U S A.</i> 2001; <b>98</b>(15): 8662–7. <a target=xrefwindow id=d2476e2739 href="http://www.ncbi.nlm.nih.gov/pubmed/11447297">PubMed Abstract </a> | <a target=xrefwindow id=d2476e2742 href="http://dx.doi.org/10.1073/pnas.161506698">Publisher Full Text </a> | <a target=xrefwindow id=d2476e2745 href="http://www.ncbi.nlm.nih.gov/pmc/articles/37492">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/1000296">F1000 Recommendation</a></span></li><li><a name=ref-42 class=n-a></a><span class=label>42. </span>&nbsp;<span class=citation><a name=d2476e2759 class=n-a></a>Shin H, Renatus M, Eckelman BP, <i> et al.</i>: The BIR domain of IAP-like protein 2 is conformationally unstable: implications for caspase inhibition. <i>Biochem J.</i> 2005; <b>385</b>(Pt 1): 1–10. <a target=xrefwindow id=d2476e2770 href="http://www.ncbi.nlm.nih.gov/pubmed/15485395">PubMed Abstract </a> | <a target=xrefwindow id=d2476e2773 href="http://dx.doi.org/10.1042/BJ20041107">Publisher Full Text </a> | <a target=xrefwindow id=d2476e2777 href="http://www.ncbi.nlm.nih.gov/pmc/articles/1134667">Free Full Text </a></span></li><li><a name=ref-43 class=n-a></a><span class=label>43. </span>&nbsp;<span class=citation><a name=d2476e2786 class=n-a></a>Qiu XB, Goldberg AL: The membrane-associated inhibitor of apoptosis protein, BRUCE/Apollon, antagonizes both the precursor and mature forms of Smac and caspase-9. <i>J Biol Chem.</i> 2005; <b>280</b>(1): 174–82. <a target=xrefwindow id=d2476e2794 href="http://www.ncbi.nlm.nih.gov/pubmed/15507451">PubMed Abstract </a> | <a target=xrefwindow id=d2476e2797 href="http://dx.doi.org/10.1074/jbc.M411430200">Publisher Full Text </a></span></li><li><a name=ref-44 class=n-a></a><span class=label>44. </span>&nbsp;<span class=citation><a name=d2476e2806 class=n-a></a>Qiu XB, Markant SL, Yuan J, <i> et al.</i>: Nrdp1-mediated degradation of the gigantic IAP, BRUCE, is a novel pathway for triggering apoptosis. <i>EMBO J.</i> 2004; <b>23</b>(4): 800–10. <a target=xrefwindow id=d2476e2817 href="http://www.ncbi.nlm.nih.gov/pubmed/14765125">PubMed Abstract </a> | <a target=xrefwindow id=d2476e2820 href="http://dx.doi.org/10.1038/sj.emboj.7600075">Publisher Full Text </a> | <a target=xrefwindow id=d2476e2824 href="http://www.ncbi.nlm.nih.gov/pmc/articles/380992">Free Full Text </a></span></li><li><a name=ref-45 class=n-a></a><span class=label>45. </span>&nbsp;<span class=citation><a name=d2476e2833 class=n-a></a>Martin SJ: An Apollon vista of death and destruction. <i>Nat Cell Biol.</i> 2004; <b>6</b>(9): 804–6. <a target=xrefwindow id=d2476e2841 href="http://www.ncbi.nlm.nih.gov/pubmed/15340445">PubMed Abstract </a> | <a target=xrefwindow id=d2476e2844 href="http://dx.doi.org/10.1038/ncb0904-804">Publisher Full Text </a></span></li><li><a name=ref-46 class=n-a></a><span class=label>46. </span>&nbsp;<span class=citation><a name=d2476e2853 class=n-a></a>Sokka A, Mudo G, Aaltonen J, <i> et al.</i>: Bruce/apollon promotes hippocampal neuron survival and is downregulated by kainic acid. <i>Biochem Biophys Res Commun.</i> 2005; <b>338</b>(2): 729–35. <a target=xrefwindow id=d2476e2864 href="http://www.ncbi.nlm.nih.gov/pubmed/16236253">PubMed Abstract </a> | <a target=xrefwindow id=d2476e2867 href="http://dx.doi.org/10.1016/j.bbrc.2005.09.197">Publisher Full Text </a></span></li><li><a name=ref-47 class=n-a></a><span class=label>47. </span>&nbsp;<span class=citation><a name=d2476e2876 class=n-a></a>Hao Y, Sekine K, Kawabata A, <i> et al.</i>: Apollon ubiquitinates SMAC and caspase-9, and has an essential cytoprotection function. <i>Nat Cell Biol.</i> 2004; <b>6</b>(9): 849–60. <a target=xrefwindow id=d2476e2887 href="http://www.ncbi.nlm.nih.gov/pubmed/15300255">PubMed Abstract </a> | <a target=xrefwindow id=d2476e2890 href="http://dx.doi.org/10.1038/ncb1159">Publisher Full Text </a></span></li><li><a name=ref-48 class=n-a></a><span class=label>48. </span>&nbsp;<span class=citation><a name=d2476e2900 class=n-a></a>Ren J, Shi M, Liu R, <i> et al.</i>: The Birc6 (Bruce) gene regulates p53 and the mitochondrial pathway of apoptosis and is essential for mouse embryonic development. <i>Proc Natl Acad Sci U S A.</i> 2005; <b>102</b>(3): 565–70. <a target=xrefwindow id=d2476e2911 href="http://www.ncbi.nlm.nih.gov/pubmed/15640352">PubMed Abstract </a> | <a target=xrefwindow id=d2476e2914 href="http://dx.doi.org/10.1073/pnas.0408744102">Publisher Full Text </a> | <a target=xrefwindow id=d2476e2918 href="http://www.ncbi.nlm.nih.gov/pmc/articles/543482">Free Full Text </a></span></li><li><a name=ref-49 class=n-a></a><span class=label>49. </span>&nbsp;<span class=citation><a name=d2476e2927 class=n-a></a>Koonin EV, Aravind L: The NACHT family - a new group of predicted NTPases implicated in apoptosis and MHC transcription activation. <i>Trends Biochem Sci.</i> 2000; <b>25</b>(5): 223–4. <a target=xrefwindow id=d2476e2935 href="http://www.ncbi.nlm.nih.gov/pubmed/10782090">PubMed Abstract </a> | <a target=xrefwindow id=d2476e2938 href="http://dx.doi.org/10.1016/S0968-0004(00)01577-2">Publisher Full Text </a></span></li><li><a name=ref-50 class=n-a></a><span class=label>50. </span>&nbsp;<span class=citation><a name=d2476e2947 class=n-a></a>Mercer EA, Korhonen L, Skoglösa Y, <i> et al.</i>: NAIP interacts with hippocalcin and protects neurons against calcium-induced cell death through caspase-3-dependent and -independent pathways. <i>EMBO J.</i> 2000; <b>19</b>(14): 3597–607. <a target=xrefwindow id=d2476e2958 href="http://www.ncbi.nlm.nih.gov/pubmed/10899114">PubMed Abstract </a> | <a target=xrefwindow id=d2476e2961 href="http://dx.doi.org/10.1093/emboj/19.14.3597">Publisher Full Text </a> | <a target=xrefwindow id=d2476e2965 href="http://www.ncbi.nlm.nih.gov/pmc/articles/313967">Free Full Text </a></span></li><li><a name=ref-51 class=n-a></a><span class=label>51. </span>&nbsp;<span class=citation><a name=d2476e2974 class=n-a></a>Gotz R, Karch C, Digby MR, <i> et al.</i>: The neuronal apoptosis inhibitory protein suppresses neuronal differentiation and apoptosis in PC12 cells. <i>Hum Mol Genet.</i> 2000; <b>9</b>(17): 2479–89. <a target=xrefwindow id=d2476e2985 href="http://www.ncbi.nlm.nih.gov/pubmed/11030753">PubMed Abstract </a> | <a target=xrefwindow id=d2476e2988 href="http://dx.doi.org/10.1093/hmg/9.17.2479">Publisher Full Text </a></span></li><li><a name=ref-52 class=n-a></a><span class=label>52. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/13125956"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d2476e2997 class=n-a></a>Kofoed EM, Vance RE: Innate immune recognition of bacterial ligands by NAIPs determines inflammasome specificity. <i>Nature.</i> 2011; <b>477</b>(7366): 592–5. <a target=xrefwindow id=d2476e3005 href="http://www.ncbi.nlm.nih.gov/pubmed/21874021">PubMed Abstract </a> | <a target=xrefwindow id=d2476e3008 href="http://dx.doi.org/10.1038/nature10394">Publisher Full Text </a> | <a target=xrefwindow id=d2476e3011 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3184209">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/13125956">F1000 Recommendation</a></span></li><li><a name=ref-53 class=n-a></a><span class=label>53. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/718321447"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d2476e3024 class=n-a></a>Tenthorey JL, Kofoed EM, Daugherty MD, <i> et al.</i>: Molecular basis for specific recognition of bacterial ligands by NAIP/NLRC4 inflammasomes. <i>Mol Cell.</i> 2014; <b>54</b>(1): 17–29. <a target=xrefwindow id=d2476e3035 href="http://www.ncbi.nlm.nih.gov/pubmed/24657167">PubMed Abstract </a> | <a target=xrefwindow id=d2476e3038 href="http://dx.doi.org/10.1016/j.molcel.2014.02.018">Publisher Full Text </a> | <a target=xrefwindow id=d2476e3042 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3988258">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/718321447">F1000 Recommendation</a></span></li><li><a name=ref-54 class=n-a></a><span class=label>54. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/726265731"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d2476e3056 class=n-a></a>Rauch I, Tenthorey JL, Nichols RD, <i> et al.</i>: NAIP proteins are required for cytosolic detection of specific bacterial ligands <i>in vivo</i>. <i>J Exp Med.</i> 2016; <b>213</b>(5): 657–65. <a target=xrefwindow id=d2476e3070 href="http://www.ncbi.nlm.nih.gov/pubmed/27045008">PubMed Abstract </a> | <a target=xrefwindow id=d2476e3074 href="http://dx.doi.org/10.1084/jem.20151809">Publisher Full Text </a> | <a target=xrefwindow id=d2476e3077 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4854734">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/726265731">F1000 Recommendation</a></span></li><li><a name=ref-55 class=n-a></a><span class=label>55. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/11140956"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d2476e3090 class=n-a></a>Lopez J, John SW, Tenev T, <i> et al.</i>: CARD-mediated autoinhibition of cIAP1's E3 ligase activity suppresses cell proliferation and migration. <i>Mol Cell.</i> 2011; <b>42</b>(5): 569–83. <a target=xrefwindow id=d2476e3101 href="http://www.ncbi.nlm.nih.gov/pubmed/21549626">PubMed Abstract </a> | <a target=xrefwindow id=d2476e3104 href="http://dx.doi.org/10.1016/j.molcel.2011.04.008">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/11140956">F1000 Recommendation</a></span></li><li><a name=ref-56 class=n-a></a><span class=label>56. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/1123836"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d2476e3117 class=n-a></a>Mahoney DJ, Cheung HH, Mrad RL, <i> et al.</i>: Both cIAP1 and cIAP2 regulate TNFalpha-mediated NF-kappaB activation. <i>Proc Natl Acad Sci U S A.</i> 2008; <b>105</b>(33): 11778–83. <a target=xrefwindow id=d2476e3128 href="http://www.ncbi.nlm.nih.gov/pubmed/18697935">PubMed Abstract </a> | <a target=xrefwindow id=d2476e3131 href="http://dx.doi.org/10.1073/pnas.0711122105">Publisher Full Text </a> | <a target=xrefwindow id=d2476e3135 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2575330">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/1123836">F1000 Recommendation</a></span></li><li><a name=ref-57 class=n-a></a><span class=label>57. </span>&nbsp;<span class=citation><a name=d2476e3148 class=n-a></a>Varfolomeev E, Goncharov T, Fedorova AV, <i> et al.</i>: c-IAP1 and c-IAP2 are critical mediators of tumor necrosis factor alpha (TNFalpha)-induced NF-kappaB activation. <i>J Biol Chem.</i> 2008; <b>283</b>(36): 24295–9. <a target=xrefwindow id=d2476e3159 href="http://www.ncbi.nlm.nih.gov/pubmed/18621737">PubMed Abstract </a> | <a target=xrefwindow id=d2476e3162 href="http://dx.doi.org/10.1074/jbc.C800128200">Publisher Full Text </a> | <a target=xrefwindow id=d2476e3166 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3259840">Free Full Text </a></span></li><li><a name=ref-58 class=n-a></a><span class=label>58. </span>&nbsp;<span class=citation><a name=d2476e3175 class=n-a></a>Mace PD, Smits C, Vaux DL, <i> et al.</i>: Asymmetric recruitment of cIAPs by TRAF2. <i>J Mol Biol.</i> 2010; <b>400</b>(1): 8–15. <a target=xrefwindow id=d2476e3186 href="http://www.ncbi.nlm.nih.gov/pubmed/20447407">PubMed Abstract </a> | <a target=xrefwindow id=d2476e3189 href="http://dx.doi.org/10.1016/j.jmb.2010.04.055">Publisher Full Text </a></span></li><li><a name=ref-59 class=n-a></a><span class=label>59. </span>&nbsp;<span class=citation><a name=d2476e3198 class=n-a></a>Samuel T, Welsh K, Lober T, <i> et al.</i>: Distinct BIR domains of cIAP1 mediate binding to and ubiquitination of tumor necrosis factor receptor-associated factor 2 and second mitochondrial activator of caspases. <i>J Biol Chem.</i> 2006; <b>281</b>(2): 1080–90. <a target=xrefwindow id=d2476e3209 href="http://www.ncbi.nlm.nih.gov/pubmed/16282325">PubMed Abstract </a> | <a target=xrefwindow id=d2476e3212 href="http://dx.doi.org/10.1074/jbc.M509381200">Publisher Full Text </a></span></li><li><a name=ref-60 class=n-a></a><span class=label>60. </span>&nbsp;<span class=citation><a name=d2476e3222 class=n-a></a>Ashkenazi A, Dixit VM: Death receptors: signaling and modulation. <i>Science.</i> 1998; <b>281</b>(5381): 1305–8. <a target=xrefwindow id=d2476e3230 href="http://www.ncbi.nlm.nih.gov/pubmed/9721089">PubMed Abstract </a> | <a target=xrefwindow id=d2476e3233 href="http://dx.doi.org/10.1126/science.281.5381.1305">Publisher Full Text </a></span></li><li><a name=ref-61 class=n-a></a><span class=label>61. </span>&nbsp;<span class=citation><a name=d2476e3242 class=n-a></a>Locksley RM, Killeen N, Lenardo MJ: The TNF and TNF receptor superfamilies: integrating mammalian biology. <i>Cell.</i> 2001; <b>104</b>(4): 487–501. <a target=xrefwindow id=d2476e3250 href="http://www.ncbi.nlm.nih.gov/pubmed/11239407">PubMed Abstract </a> | <a target=xrefwindow id=d2476e3253 href="http://dx.doi.org/10.1016/S0092-8674(01)00237-9">Publisher Full Text </a></span></li><li><a name=ref-62 class=n-a></a><span class=label>62. </span>&nbsp;<span class=citation><a name=d2476e3262 class=n-a></a>Nagata S: Apoptosis by death factor. <i>Cell.</i> 1997; <b>88</b>(3): 355–65. <a target=xrefwindow id=d2476e3270 href="http://www.ncbi.nlm.nih.gov/pubmed/9039262">PubMed Abstract </a> | <a target=xrefwindow id=d2476e3273 href="http://dx.doi.org/10.1016/S0092-8674(00)81874-7">Publisher Full Text </a></span></li><li><a name=ref-63 class=n-a></a><span class=label>63. </span>&nbsp;<span class=citation><a name=d2476e3282 class=n-a></a>Sessler T, Healy S, Samali A, <i> et al.</i>: Structural determinants of DISC function: new insights into death receptor-mediated apoptosis signalling. <i>Pharmacol Ther.</i> 2013; <b>140</b>(2): 186–99. <a target=xrefwindow id=d2476e3293 href="http://www.ncbi.nlm.nih.gov/pubmed/23845861">PubMed Abstract </a> | <a target=xrefwindow id=d2476e3296 href="http://dx.doi.org/10.1016/j.pharmthera.2013.06.009">Publisher Full Text </a></span></li><li><a name=ref-64 class=n-a></a><span class=label>64. </span>&nbsp;<span class=citation><a name=d2476e3305 class=n-a></a>Finlay D, Vamos M, González-López M, <i> et al.</i>: Small-molecule IAP antagonists sensitize cancer cells to TRAIL-induced apoptosis: roles of XIAP and cIAPs. <i>Mol Cancer Ther.</i> 2014; <b>13</b>(1): 5–15. <a target=xrefwindow id=d2476e3316 href="http://www.ncbi.nlm.nih.gov/pubmed/24194568">PubMed Abstract </a> | <a target=xrefwindow id=d2476e3319 href="http://dx.doi.org/10.1158/1535-7163.MCT-13-0153">Publisher Full Text </a> | <a target=xrefwindow id=d2476e3323 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3947130">Free Full Text </a></span></li><li><a name=ref-65 class=n-a></a><span class=label>65. </span>&nbsp;<span class=citation><a name=d2476e3332 class=n-a></a>Lee S, Challa-Malladi M, Bratton SB, <i> et al.</i>: Nuclear factor-κB-inducing kinase (NIK) contains an amino-terminal inhibitor of apoptosis (IAP)-binding motif (IBM) that potentiates NIK degradation by cellular IAP1 (c-IAP1). <i>J Biol Chem.</i> 2014; <b>289</b>(44): 30680–9. <a target=xrefwindow id=d2476e3343 href="http://www.ncbi.nlm.nih.gov/pubmed/25246529">PubMed Abstract </a> | <a target=xrefwindow id=d2476e3346 href="http://dx.doi.org/10.1074/jbc.M114.587808">Publisher Full Text </a> | <a target=xrefwindow id=d2476e3350 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4215246">Free Full Text </a></span></li><li><a name=ref-66 class=n-a></a><span class=label>66. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/1098507"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d2476e3360 class=n-a></a>Varfolomeev E, Blankenship JW, Wayson SM, <i> et al.</i>: IAP antagonists induce autoubiquitination of c-IAPs, NF-kappaB activation, and TNFalpha-dependent apoptosis. <i>Cell.</i> 2007; <b>131</b>(4): 669–81. <a target=xrefwindow id=d2476e3371 href="http://www.ncbi.nlm.nih.gov/pubmed/18022362">PubMed Abstract </a> | <a target=xrefwindow id=d2476e3374 href="http://dx.doi.org/10.1016/j.cell.2007.10.030">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/1098507">F1000 Recommendation</a></span></li><li><a name=ref-67 class=n-a></a><span class=label>67. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/1014267"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d2476e3387 class=n-a></a>Harper N, Hughes M, MacFarlane M, <i> et al.</i>: Fas-associated death domain protein and caspase-8 are not recruited to the tumor necrosis factor receptor 1 signaling complex during tumor necrosis factor-induced apoptosis. <i>J Biol Chem.</i> 2003; <b>278</b>(28): 25534–41. <a target=xrefwindow id=d2476e3398 href="http://www.ncbi.nlm.nih.gov/pubmed/12721308">PubMed Abstract </a> | <a target=xrefwindow id=d2476e3401 href="http://dx.doi.org/10.1074/jbc.M303399200">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/1014267">F1000 Recommendation</a></span></li><li><a name=ref-68 class=n-a></a><span class=label>68. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/1014699"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d2476e3414 class=n-a></a>Micheau O, Tschopp J: Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes. <i>Cell.</i> 2003; <b>114</b>(2): 181–90. <a target=xrefwindow id=d2476e3422 href="http://www.ncbi.nlm.nih.gov/pubmed/12887920">PubMed Abstract </a> | <a target=xrefwindow id=d2476e3425 href="http://dx.doi.org/10.1016/S0092-8674(03)00521-X">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/1014699">F1000 Recommendation</a></span></li><li><a name=ref-69 class=n-a></a><span class=label>69. </span>&nbsp;<span class=citation><a name=d2476e3438 class=n-a></a>Vucic D, Dixit VM, Wertz IE: Ubiquitylation in apoptosis: a post-translational modification at the edge of life and death. <i>Nat Rev Mol Cell Biol.</i> 2011; <b>12</b>(7): 439–52. <a target=xrefwindow id=d2476e3446 href="http://www.ncbi.nlm.nih.gov/pubmed/21697901">PubMed Abstract </a> | <a target=xrefwindow id=d2476e3449 href="http://dx.doi.org/10.1038/nrm3143">Publisher Full Text </a></span></li><li><a name=ref-70 class=n-a></a><span class=label>70. </span>&nbsp;<span class=citation><a name=d2476e3458 class=n-a></a>Bertrand MJ, Vandenabeele P: The Ripoptosome: death decision in the cytosol. <i>Mol Cell.</i> 2011; <b>43</b>(3): 323–5. <a target=xrefwindow id=d2476e3466 href="http://www.ncbi.nlm.nih.gov/pubmed/21816342">PubMed Abstract </a> | <a target=xrefwindow id=d2476e3469 href="http://dx.doi.org/10.1016/j.molcel.2011.07.007">Publisher Full Text </a></span></li><li><a name=ref-71 class=n-a></a><span class=label>71. </span>&nbsp;<span class=citation><a name=d2476e3478 class=n-a></a>Imre G, Larisch S, Rajalingam K: Ripoptosome: a novel IAP-regulated cell death-signalling platform. <i>J Mol Cell Biol.</i> 2011; <b>3</b>(6): 324–6. <a target=xrefwindow id=d2476e3486 href="http://www.ncbi.nlm.nih.gov/pubmed/22114055">PubMed Abstract </a> | <a target=xrefwindow id=d2476e3489 href="http://dx.doi.org/10.1093/jmcb/mjr034">Publisher Full Text </a></span></li><li><a name=ref-72 class=n-a></a><span class=label>72. </span>&nbsp;<span class=citation><a name=d2476e3499 class=n-a></a>Tenev T, Bianchi K, Darding M, <i> et al.</i>: The Ripoptosome, a signaling platform that assembles in response to genotoxic stress and loss of IAPs. <i>Mol Cell.</i> 2011; <b>43</b>(3): 432–48. <a target=xrefwindow id=d2476e3510 href="http://www.ncbi.nlm.nih.gov/pubmed/21737329">PubMed Abstract </a> | <a target=xrefwindow id=d2476e3513 href="http://dx.doi.org/10.1016/j.molcel.2011.06.006">Publisher Full Text </a></span></li><li><a name=ref-73 class=n-a></a><span class=label>73. </span>&nbsp;<span class=citation><a name=d2476e3522 class=n-a></a>Zhou Z, Han V, Han J: New components of the necroptotic pathway. <i>Protein Cell.</i> 2012; <b>3</b>(11): 811–7. <a target=xrefwindow id=d2476e3530 href="http://www.ncbi.nlm.nih.gov/pubmed/23073834">PubMed Abstract </a> | <a target=xrefwindow id=d2476e3533 href="http://dx.doi.org/10.1007/s13238-012-2083-9">Publisher Full Text </a> | <a target=xrefwindow id=d2476e3536 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4875459">Free Full Text </a></span></li><li><a name=ref-74 class=n-a></a><span class=label>74. </span>&nbsp;<span class=citation><a name=d2476e3545 class=n-a></a>Chen W, Zhou Z, Li L, <i> et al.</i>: Diverse sequence determinants control human and mouse receptor interacting protein 3 (RIP3) and mixed lineage kinase domain-like (MLKL) interaction in necroptotic signaling. <i>J Biol Chem.</i> 2013; <b>288</b>(23): 16247–61. <a target=xrefwindow id=d2476e3556 href="http://www.ncbi.nlm.nih.gov/pubmed/23612963">PubMed Abstract </a> | <a target=xrefwindow id=d2476e3559 href="http://dx.doi.org/10.1074/jbc.M112.435545">Publisher Full Text </a> | <a target=xrefwindow id=d2476e3563 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3675564">Free Full Text </a></span></li><li><a name=ref-75 class=n-a></a><span class=label>75. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/725524639"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d2476e3572 class=n-a></a>Rodriguez DA, Weinlich R, Brown S, <i> et al.</i>: Characterization of RIPK3-mediated phosphorylation of the activation loop of MLKL during necroptosis. <i>Cell Death Differ.</i> 2016; <b>23</b>(1): 76–88. <a target=xrefwindow id=d2476e3583 href="http://www.ncbi.nlm.nih.gov/pubmed/26024392">PubMed Abstract </a> | <a target=xrefwindow id=d2476e3586 href="http://dx.doi.org/10.1038/cdd.2015.70">Publisher Full Text </a> | <a target=xrefwindow id=d2476e3590 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4815980">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/725524639">F1000 Recommendation</a></span></li><li><a name=ref-76 class=n-a></a><span class=label>76. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/14267354"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d2476e3603 class=n-a></a>Sun L, Wang H, Wang Z, <i> et al.</i>: Mixed lineage kinase domain-like protein mediates necrosis signaling downstream of RIP3 kinase. <i>Cell.</i> 2012; <b>148</b>(1–2): 213–27. <a target=xrefwindow id=d2476e3614 href="http://www.ncbi.nlm.nih.gov/pubmed/22265413">PubMed Abstract </a> | <a target=xrefwindow id=d2476e3617 href="http://dx.doi.org/10.1016/j.cell.2011.11.031">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/14267354">F1000 Recommendation</a></span></li><li><a name=ref-77 class=n-a></a><span class=label>77. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/718201342"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d2476e3630 class=n-a></a>Cai Z, Jitkaew S, Zhao J, <i> et al.</i>: Plasma membrane translocation of trimerized MLKL protein is required for TNF-induced necroptosis. <i>Nat Cell Biol.</i> 2014; <b>16</b>(1): 55–65. <a target=xrefwindow id=d2476e3641 href="http://www.ncbi.nlm.nih.gov/pubmed/24316671">PubMed Abstract </a> | <a target=xrefwindow id=d2476e3644 href="http://dx.doi.org/10.1038/ncb2883">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/718201342">F1000 Recommendation</a></span></li><li><a name=ref-78 class=n-a></a><span class=label>78. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/718217885"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d2476e3658 class=n-a></a>Chen X, Li W, Ren J, <i> et al.</i>: Translocation of mixed lineage kinase domain-like protein to plasma membrane leads to necrotic cell death. <i>Cell Res.</i> 2014; <b>24</b>(1): 105–21. <a target=xrefwindow id=d2476e3669 href="http://www.ncbi.nlm.nih.gov/pubmed/24366341">PubMed Abstract </a> | <a target=xrefwindow id=d2476e3672 href="http://dx.doi.org/10.1038/cr.2013.171">Publisher Full Text </a> | <a target=xrefwindow id=d2476e3676 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3879712">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/718217885">F1000 Recommendation</a></span></li><li><a name=ref-79 class=n-a></a><span class=label>79. </span>&nbsp;<span class=citation><a name=d2476e3689 class=n-a></a>Linkermann A, Kunzendorf U, Krautwald S: Phosphorylated MLKL causes plasma membrane rupture. <i>Mol Cell Oncol.</i> 2014; <b>1</b>(1): e29915. <a target=xrefwindow id=d2476e3697 href="http://www.ncbi.nlm.nih.gov/pubmed/27308322">PubMed Abstract </a> | <a target=xrefwindow id=d2476e3700 href="http://dx.doi.org/10.4161/mco.29915">Publisher Full Text </a> | <a target=xrefwindow id=d2476e3703 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4905185">Free Full Text </a></span></li><li><a name=ref-80 class=n-a></a><span class=label>80. </span>&nbsp;<span class=citation><a name=d2476e3712 class=n-a></a>Dickens LS, Powley IR, Hughes MA, <i> et al.</i>: The 'complexities' of life and death: death receptor signalling platforms. <i>Exp Cell Res.</i> 2012; <b>318</b>(11): 1269–77. <a target=xrefwindow id=d2476e3723 href="http://www.ncbi.nlm.nih.gov/pubmed/22542855">PubMed Abstract </a> | <a target=xrefwindow id=d2476e3726 href="http://dx.doi.org/10.1016/j.yexcr.2012.04.005">Publisher Full Text </a></span></li><li><a name=ref-81 class=n-a></a><span class=label>81. </span>&nbsp;<span class=citation><a name=d2476e3735 class=n-a></a>Feoktistova M, Geserick P, Panayotova-Dimitrova D, <i> et al.</i>: Pick your poison: the Ripoptosome, a cell death platform regulating apoptosis and necroptosis. <i>Cell Cycle.</i> 2012; <b>11</b>(3): 460–7. <a target=xrefwindow id=d2476e3746 href="http://www.ncbi.nlm.nih.gov/pubmed/22274400">PubMed Abstract </a> | <a target=xrefwindow id=d2476e3749 href="http://dx.doi.org/10.4161/cc.11.3.19060">Publisher Full Text </a></span></li><li><a name=ref-82 class=n-a></a><span class=label>82. </span>&nbsp;<span class=citation><a name=d2476e3758 class=n-a></a>Riedl SJ, Renatus M, Schwarzenbacher R, <i> et al.</i>: Structural basis for the inhibition of caspase-3 by XIAP. <i>Cell.</i> 2001; <b>104</b>(5): 791–800. <a target=xrefwindow id=d2476e3769 href="http://www.ncbi.nlm.nih.gov/pubmed/11257232">PubMed Abstract </a> | <a target=xrefwindow id=d2476e3772 href="http://dx.doi.org/10.1016/S0092-8674(01)00274-4">Publisher Full Text </a></span></li><li><a name=ref-83 class=n-a></a><span class=label>83. </span>&nbsp;<span class=citation><a name=d2476e3781 class=n-a></a>Huang Y, Park YC, Rich RL, <i> et al.</i>: Structural basis of caspase inhibition by XIAP: differential roles of the linker versus the BIR domain. <i>Cell.</i> 2001; <b>104</b>(5): 781–90. <a target=xrefwindow id=d2476e3792 href="http://www.ncbi.nlm.nih.gov/pubmed/11257231">PubMed Abstract </a> | <a target=xrefwindow id=d2476e3795 href="http://dx.doi.org/10.1016/S0092-8674(01)00273-2">Publisher Full Text </a></span></li><li><a name=ref-84 class=n-a></a><span class=label>84. </span>&nbsp;<span class=citation><a name=d2476e3805 class=n-a></a>Takahashi R, Deveraux Q, Tamm I, <i> et al.</i>: A single BIR domain of XIAP sufficient for inhibiting caspases. <i>J Biol Chem.</i> 1998; <b>273</b>(14): 7787–90. <a target=xrefwindow id=d2476e3816 href="http://www.ncbi.nlm.nih.gov/pubmed/9525868">PubMed Abstract </a></span></li><li><a name=ref-85 class=n-a></a><span class=label>85. </span>&nbsp;<span class=citation><a name=d2476e3825 class=n-a></a>Srinivasula SM, Hegde R, Saleh A, <i> et al.</i>: A conserved XIAP-interaction motif in caspase-9 and Smac/DIABLO regulates caspase activity and apoptosis. <i>Nature.</i> 2001; <b>410</b>(6824): 112–6. <a target=xrefwindow id=d2476e3836 href="http://www.ncbi.nlm.nih.gov/pubmed/11242052">PubMed Abstract </a> | <a target=xrefwindow id=d2476e3839 href="http://dx.doi.org/10.1038/35065125">Publisher Full Text </a></span></li><li><a name=ref-86 class=n-a></a><span class=label>86. </span>&nbsp;<span class=citation><a name=d2476e3848 class=n-a></a>Bratton SB, Walker G, Srinivasula SM, <i> et al.</i>: Recruitment, activation and retention of caspases-9 and -3 by Apaf-1 apoptosome and associated XIAP complexes. <i>EMBO J.</i> 2001; <b>20</b>(5): 998–1009. <a target=xrefwindow id=d2476e3859 href="http://www.ncbi.nlm.nih.gov/pubmed/11230124">PubMed Abstract </a> | <a target=xrefwindow id=d2476e3862 href="http://dx.doi.org/10.1093/emboj/20.5.998">Publisher Full Text </a> | <a target=xrefwindow id=d2476e3866 href="http://www.ncbi.nlm.nih.gov/pmc/articles/145489">Free Full Text </a></span></li><li><a name=ref-87 class=n-a></a><span class=label>87. </span>&nbsp;<span class=citation><a name=d2476e3875 class=n-a></a>Datta R, Oki E, Endo K, <i> et al.</i>: XIAP regulates DNA damage-induced apoptosis downstream of caspase-9 cleavage. <i>J Biol Chem.</i> 2000; <b>275</b>(41): 31733–8. <a target=xrefwindow id=d2476e3886 href="http://www.ncbi.nlm.nih.gov/pubmed/10930419">PubMed Abstract </a> | <a target=xrefwindow id=d2476e3889 href="http://dx.doi.org/10.1074/jbc.M910231199">Publisher Full Text </a></span></li><li><a name=ref-88 class=n-a></a><span class=label>88. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/1002201"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d2476e3898 class=n-a></a>Du C, Fang M, Li Y, <i> et al.</i>: Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. <i>Cell.</i> 2000; <b>102</b>(1): 33–42. <a target=xrefwindow id=d2476e3909 href="http://www.ncbi.nlm.nih.gov/pubmed/10929711">PubMed Abstract </a> | <a target=xrefwindow id=d2476e3912 href="http://dx.doi.org/10.1016/S0092-8674(00)00008-8">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/1002201">F1000 Recommendation</a></span></li><li><a name=ref-89 class=n-a></a><span class=label>89. </span>&nbsp;<span class=citation><a name=d2476e3925 class=n-a></a>Liu Z, Sun C, Olejniczak ET, <i> et al.</i>: Structural basis for binding of Smac/DIABLO to the XIAP BIR3 domain. <i>Nature.</i> 2000; <b>408</b>(6815): 1004–8. <a target=xrefwindow id=d2476e3936 href="http://www.ncbi.nlm.nih.gov/pubmed/11140637">PubMed Abstract </a> | <a target=xrefwindow id=d2476e3939 href="http://dx.doi.org/10.1038/35050006">Publisher Full Text </a></span></li><li><a name=ref-90 class=n-a></a><span class=label>90. </span>&nbsp;<span class=citation><a name=d2476e3949 class=n-a></a>Wu G, Chai J, Suber TL, <i> et al.</i>: Structural basis of IAP recognition by Smac/DIABLO. <i>Nature.</i> 2000; <b>408</b>(6815): 1008–12. <a target=xrefwindow id=d2476e3960 href="http://www.ncbi.nlm.nih.gov/pubmed/11140638">PubMed Abstract </a> | <a target=xrefwindow id=d2476e3963 href="http://dx.doi.org/10.1038/35050012">Publisher Full Text </a></span></li><li><a name=ref-91 class=n-a></a><span class=label>91. </span>&nbsp;<span class=citation><a name=d2476e3972 class=n-a></a>Ekert PG, Silke J, Hawkins CJ, <i> et al.</i>: DIABLO promotes apoptosis by removing MIHA/XIAP from processed caspase 9. <i>J Cell Biol.</i> 2001; <b>152</b>(3): 483–90. <a target=xrefwindow id=d2476e3983 href="http://www.ncbi.nlm.nih.gov/pubmed/11157976">PubMed Abstract </a> | <a target=xrefwindow id=d2476e3986 href="http://dx.doi.org/10.1083/jcb.152.3.483">Publisher Full Text </a> | <a target=xrefwindow id=d2476e3990 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2195997">Free Full Text </a></span></li><li><a name=ref-92 class=n-a></a><span class=label>92. </span>&nbsp;<span class=citation><a name=d2476e3999 class=n-a></a>Hanahan D, Weinberg RA: The hallmarks of cancer. <i>Cell.</i> 2000; <b>100</b>(1): 57–70. <a target=xrefwindow id=d2476e4007 href="http://www.ncbi.nlm.nih.gov/pubmed/10647931">PubMed Abstract </a> | <a target=xrefwindow id=d2476e4010 href="http://dx.doi.org/10.1016/S0092-8674(00)81683-9">Publisher Full Text </a></span></li><li><a name=ref-93 class=n-a></a><span class=label>93. </span>&nbsp;<span class=citation><a name=d2476e4019 class=n-a></a>Levine B, Kroemer G: Autophagy in the pathogenesis of disease. <i>Cell.</i> 2008; <b>132</b>(1): 27–42. <a target=xrefwindow id=d2476e4027 href="http://www.ncbi.nlm.nih.gov/pubmed/18191218">PubMed Abstract </a> | <a target=xrefwindow id=d2476e4030 href="http://dx.doi.org/10.1016/j.cell.2007.12.018">Publisher Full Text </a> | <a target=xrefwindow id=d2476e4033 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2696814">Free Full Text </a></span></li><li><a name=ref-94 class=n-a></a><span class=label>94. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/9499956"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d2476e4042 class=n-a></a>Hanahan D, Weinberg RA: Hallmarks of cancer: the next generation. <i>Cell.</i> 2011; <b>144</b>(5): 646–74. <a target=xrefwindow id=d2476e4050 href="http://www.ncbi.nlm.nih.gov/pubmed/21376230">PubMed Abstract </a> | <a target=xrefwindow id=d2476e4053 href="http://dx.doi.org/10.1016/j.cell.2011.02.013">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/9499956">F1000 Recommendation</a></span></li><li><a name=ref-95 class=n-a></a><span class=label>95. </span>&nbsp;<span class=citation><a name=d2476e4066 class=n-a></a>Ouyang L, Shi Z, Zhao S, <i> et al.</i>: Programmed cell death pathways in cancer: a review of apoptosis, autophagy and programmed necrosis. <i>Cell Prolif.</i> 2012; <b>45</b>(6): 487–98. <a target=xrefwindow id=d2476e4077 href="http://www.ncbi.nlm.nih.gov/pubmed/23030059">PubMed Abstract </a> | <a target=xrefwindow id=d2476e4080 href="http://dx.doi.org/10.1111/j.1365-2184.2012.00845.x">Publisher Full Text </a></span></li><li><a name=ref-96 class=n-a></a><span class=label>96. </span>&nbsp;<span class=citation><a name=d2476e4090 class=n-a></a>Reed JC: Dysregulation of apoptosis in cancer. <i>J Clin Oncol.</i> 1999; <b>17</b>(9): 2941–53. <a target=xrefwindow id=d2476e4098 href="http://www.ncbi.nlm.nih.gov/pubmed/10561374">PubMed Abstract </a> | <a target=xrefwindow id=d2476e4101 href="http://dx.doi.org/10.1200/JCO.1999.17.9.2941">Publisher Full Text </a></span></li><li><a name=ref-97 class=n-a></a><span class=label>97. </span>&nbsp;<span class=citation><a name=d2476e4110 class=n-a></a>Reed JC: Mechanisms of apoptosis avoidance in cancer. <i>Curr Opin Oncol.</i> 1999; <b>11</b>(1): 68–75. <a target=xrefwindow id=d2476e4118 href="http://www.ncbi.nlm.nih.gov/pubmed/9914881">PubMed Abstract </a> | <a target=xrefwindow id=d2476e4121 href="http://dx.doi.org/ 10.1097/00001622-199901000-00014">Publisher Full Text </a></span></li><li><a name=ref-98 class=n-a></a><span class=label>98. </span>&nbsp;<span class=citation><a name=d2476e4130 class=n-a></a>Liston P, Fong WG, Korneluk RG: The inhibitors of apoptosis: there is more to life than Bcl2. <i>Oncogene.</i> 2003; <b>22</b>(53): 8568–80. <a target=xrefwindow id=d2476e4138 href="http://www.ncbi.nlm.nih.gov/pubmed/14634619">PubMed Abstract </a> | <a target=xrefwindow id=d2476e4141 href="http://dx.doi.org/10.1038/sj.onc.1207101">Publisher Full Text </a></span></li><li><a name=ref-99 class=n-a></a><span class=label>99. </span>&nbsp;<span class=citation><a name=d2476e4150 class=n-a></a>Schimmer AD: Inhibitor of apoptosis proteins: translating basic knowledge into clinical practice. <i>Cancer Res.</i> 2004; <b>64</b>(20): 7183–90. <a target=xrefwindow id=d2476e4158 href="http://www.ncbi.nlm.nih.gov/pubmed/15492230">PubMed Abstract </a> | <a target=xrefwindow id=d2476e4161 href="http://dx.doi.org/10.1158/0008-5472.CAN-04-1918">Publisher Full Text </a></span></li><li><a name=ref-100 class=n-a></a><span class=label>100. </span>&nbsp;<span class=citation><a name=d2476e4170 class=n-a></a>Nachmias B, Ashhab Y, Ben-Yehuda D: The inhibitor of apoptosis protein family (IAPs): an emerging therapeutic target in cancer. <i>Semin Cancer Biol.</i> 2004; <b>14</b>(4): 231–43. <a target=xrefwindow id=d2476e4178 href="http://www.ncbi.nlm.nih.gov/pubmed/15219616">PubMed Abstract </a> | <a target=xrefwindow id=d2476e4181 href="http://dx.doi.org/10.1016/j.semcancer.2004.04.002">Publisher Full Text </a></span></li><li><a name=ref-101 class=n-a></a><span class=label>101. </span>&nbsp;<span class=citation><a name=d2476e4190 class=n-a></a>Fan TJ, Han LH, Cong RS, <i> et al.</i>: Caspase family proteases and apoptosis. <i>Acta Biochim Biophys Sin (Shanghai).</i> 2005; <b>37</b>(11): 719–27. <a target=xrefwindow id=d2476e4201 href="http://www.ncbi.nlm.nih.gov/pubmed/16270150">PubMed Abstract </a> | <a target=xrefwindow id=d2476e4204 href="http://dx.doi.org/10.1111/j.1745-7270.2005.00108.x">Publisher Full Text </a></span></li><li><a name=ref-102 class=n-a></a><span class=label>102. </span>&nbsp;<span class=citation><a name=d2476e4214 class=n-a></a>Hunter AM, LaCasse EC, Korneluk RG: The inhibitors of apoptosis (IAPs) as cancer targets. <i>Apoptosis.</i> 2007; <b>12</b>(9): 1543–68. <a target=xrefwindow id=d2476e4222 href="http://www.ncbi.nlm.nih.gov/pubmed/17573556">PubMed Abstract </a> | <a target=xrefwindow id=d2476e4225 href="http://dx.doi.org/10.1007/s10495-007-0087-3">Publisher Full Text </a></span></li><li><a name=ref-103 class=n-a></a><span class=label>103. </span>&nbsp;<span class=citation><a name=d2476e4234 class=n-a></a>Reubold TF, Eschenburg S: A molecular view on signal transduction by the apoptosome. <i>Cell Signal.</i> 2012; <b>24</b>(7): 1420–5. <a target=xrefwindow id=d2476e4242 href="http://www.ncbi.nlm.nih.gov/pubmed/22446004">PubMed Abstract </a> | <a target=xrefwindow id=d2476e4245 href="http://dx.doi.org/10.1016/j.cellsig.2012.03.007">Publisher Full Text </a></span></li><li><a name=ref-104 class=n-a></a><span class=label>104. </span>&nbsp;<span class=citation><a name=d2476e4254 class=n-a></a>Deveraux QL, Reed JC: IAP family proteins--suppressors of apoptosis. <i>Genes Dev.</i> 1999; <b>13</b>(3): 239–52. <a target=xrefwindow id=d2476e4262 href="http://www.ncbi.nlm.nih.gov/pubmed/9990849">PubMed Abstract </a></span></li><li><a name=ref-105 class=n-a></a><span class=label>105. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/1013969"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d2476e4271 class=n-a></a>Hong X, Lei L, Glas R: Tumors acquire inhibitor of apoptosis protein (IAP)-mediated apoptosis resistance through altered specificity of cytosolic proteolysis. <i>J Exp Med.</i> 2003; <b>197</b>(12): 1731–43. <a target=xrefwindow id=d2476e4279 href="http://www.ncbi.nlm.nih.gov/pubmed/12810691">PubMed Abstract </a> | <a target=xrefwindow id=d2476e4282 href="http://dx.doi.org/10.1084/jem.20020801">Publisher Full Text </a> | <a target=xrefwindow id=d2476e4285 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2193958">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/1013969">F1000 Recommendation</a></span></li><li><a name=ref-106 class=n-a></a><span class=label>106. </span>&nbsp;<span class=citation><a name=d2476e4298 class=n-a></a>Holcik M, Yeh C, Korneluk RG, <i> et al.</i>: Translational upregulation of X-linked inhibitor of apoptosis (XIAP) increases resistance to radiation induced cell death. <i>Oncogene.</i> 2000; <b>19</b>(36): 4174–7. <a target=xrefwindow id=d2476e4309 href="http://www.ncbi.nlm.nih.gov/pubmed/10962579">PubMed Abstract </a> | <a target=xrefwindow id=d2476e4312 href="http://dx.doi.org/10.1038/sj.onc.1203765">Publisher Full Text </a></span></li><li><a name=ref-107 class=n-a></a><span class=label>107. </span>&nbsp;<span class=citation><a name=d2476e4321 class=n-a></a>Nemoto T, Kitagawa M, Hasegawa M, <i> et al.</i>: Expression of IAP family proteins in esophageal cancer. <i>Exp Mol Pathol.</i> 2004; <b>76</b>(3): 253–9. <a target=xrefwindow id=d2476e4332 href="http://www.ncbi.nlm.nih.gov/pubmed/15126108">PubMed Abstract </a> | <a target=xrefwindow id=d2476e4335 href="http://dx.doi.org/10.1016/j.yexmp.2004.01.001">Publisher Full Text </a></span></li><li><a name=ref-108 class=n-a></a><span class=label>108. </span>&nbsp;<span class=citation><a name=d2476e4345 class=n-a></a>Choi J, Hwang YK, Choi YJ, <i> et al.</i>: Neuronal apoptosis inhibitory protein is overexpressed in patients with unfavorable prognostic factors in breast cancer. <i>J Korean Med Sci.</i> 2007; <b>22 Suppl</b>: S17–23. <a target=xrefwindow id=d2476e4356 href="http://www.ncbi.nlm.nih.gov/pubmed/17923748">PubMed Abstract </a> | <a target=xrefwindow id=d2476e4359 href="http://dx.doi.org/10.3346/jkms.2007.22.S.S17">Publisher Full Text </a> | <a target=xrefwindow id=d2476e4363 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2694398">Free Full Text </a></span></li><li><a name=ref-109 class=n-a></a><span class=label>109. </span>&nbsp;<span class=citation><a name=d2476e4372 class=n-a></a>Chiu HH, Yong TM, Wang J, <i> et al.</i>: Induction of neuronal apoptosis inhibitory protein expression in response to androgen deprivation in prostate cancer. <i>Cancer Lett.</i> 2010; <b>292</b>(2): 176–85. <a target=xrefwindow id=d2476e4383 href="http://www.ncbi.nlm.nih.gov/pubmed/20044205">PubMed Abstract </a> | <a target=xrefwindow id=d2476e4386 href="http://dx.doi.org/10.1016/j.canlet.2009.11.023">Publisher Full Text </a> | <a target=xrefwindow id=d2476e4390 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3433396">Free Full Text </a></span></li><li><a name=ref-110 class=n-a></a><span class=label>110. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/718537699"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d2476e4399 class=n-a></a>Harvey H, Piskareva O, Creevey L, <i> et al.</i>: Modulation of chemotherapeutic drug resistance in neuroblastoma SK-N-AS cells by the neural apoptosis inhibitory protein and miR-520f. <i>Int J Cancer.</i> 2015; <b>136</b>(7): 1579–88. <a target=xrefwindow id=d2476e4410 href="http://www.ncbi.nlm.nih.gov/pubmed/25137037">PubMed Abstract </a> | <a target=xrefwindow id=d2476e4413 href="http://dx.doi.org/10.1002/ijc.29144">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/718537699">F1000 Recommendation</a></span></li><li><a name=ref-111 class=n-a></a><span class=label>111. </span>&nbsp;<span class=citation><a name=d2476e4426 class=n-a></a>Fulda S, Vucic D: Targeting IAP proteins for therapeutic intervention in cancer. <i>Nat Rev Drug Discov.</i> 2012; <b>11</b>(2): 109–24. <a target=xrefwindow id=d2476e4434 href="http://www.ncbi.nlm.nih.gov/pubmed/22293567">PubMed Abstract </a> | <a target=xrefwindow id=d2476e4437 href="http://dx.doi.org/10.1038/nrd3627">Publisher Full Text </a></span></li><li><a name=ref-112 class=n-a></a><span class=label>112. </span>&nbsp;<span class=citation><a name=d2476e4446 class=n-a></a>Fulda S: Promises and Challenges of Smac Mimetics as Cancer Therapeutics. <i>Clin Cancer Res.</i> 2015; <b>21</b>(22): 5030–6. <a target=xrefwindow id=d2476e4454 href="http://www.ncbi.nlm.nih.gov/pubmed/26567362">PubMed Abstract </a> | <a target=xrefwindow id=d2476e4457 href="http://dx.doi.org/10.1158/1078-0432.CCR-15-0365">Publisher Full Text </a></span></li><li><a name=ref-113 class=n-a></a><span class=label>113. </span>&nbsp;<span class=citation><a name=d2476e4466 class=n-a></a>Zarnegar BJ, Wang Y, Mahoney DJ, <i> et al.</i>: Noncanonical NF-kappaB activation requires coordinated assembly of a regulatory complex of the adaptors cIAP1, cIAP2, TRAF2 and TRAF3 and the kinase NIK. <i>Nat Immunol.</i> 2008; <b>9</b>(12): 1371–8. <a target=xrefwindow id=d2476e4477 href="http://www.ncbi.nlm.nih.gov/pubmed/18997794">PubMed Abstract </a> | <a target=xrefwindow id=d2476e4480 href="http://dx.doi.org/10.1038/ni.1676">Publisher Full Text </a> | <a target=xrefwindow id=d2476e4484 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2676931">Free Full Text </a></span></li><li><a name=ref-114 class=n-a></a><span class=label>114. </span>&nbsp;<span class=citation><a name=d2476e4494 class=n-a></a>Ma O, Cai W, Zender L, <i> et al.</i>: MMP13, Birc2 (cIAP1), and Birc3 (cIAP2), amplified on chromosome 9, collaborate with p53 deficiency in mouse osteosarcoma progression. <i>Cancer Res.</i> 2009; <b>69</b>(6): 2559–67. <a target=xrefwindow id=d2476e4505 href="http://www.ncbi.nlm.nih.gov/pubmed/19276372">PubMed Abstract </a> | <a target=xrefwindow id=d2476e4508 href="http://dx.doi.org/10.1158/0008-5472.CAN-08-2929">Publisher Full Text </a> | <a target=xrefwindow id=d2476e4512 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2663905">Free Full Text </a></span></li><li><a name=ref-115 class=n-a></a><span class=label>115. </span>&nbsp;<span class=citation><a name=d2476e4521 class=n-a></a>Zender L, Spector MS, Xue W, <i> et al.</i>: Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. <i>Cell.</i> 2006; <b>125</b>(7): 1253–67. <a target=xrefwindow id=d2476e4532 href="http://www.ncbi.nlm.nih.gov/pubmed/16814713">PubMed Abstract </a> | <a target=xrefwindow id=d2476e4535 href="http://dx.doi.org/10.1016/j.cell.2006.05.030">Publisher Full Text </a> | <a target=xrefwindow id=d2476e4539 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3026384">Free Full Text </a></span></li><li><a name=ref-116 class=n-a></a><span class=label>116. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/1123956"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d2476e4548 class=n-a></a>Bertrand MJ, Milutinovic S, Dickson KM, <i> et al.</i>: cIAP1 and cIAP2 facilitate cancer cell survival by functioning as E3 ligases that promote RIP1 ubiquitination. <i>Mol Cell.</i> 2008; <b>30</b>(6): 689–700. <a target=xrefwindow id=d2476e4559 href="http://www.ncbi.nlm.nih.gov/pubmed/18570872">PubMed Abstract </a> | <a target=xrefwindow id=d2476e4562 href="http://dx.doi.org/10.1016/j.molcel.2008.05.014">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/1123956">F1000 Recommendation</a></span></li><li><a name=ref-117 class=n-a></a><span class=label>117. </span>&nbsp;<span class=citation><a name=d2476e4575 class=n-a></a>Kenneth NS, Duckett CS: IAP proteins: regulators of cell migration and development. <i>Curr Opin Cell Biol.</i> 2012; <b>24</b>(6): 871–5. <a target=xrefwindow id=d2476e4583 href="http://www.ncbi.nlm.nih.gov/pubmed/23219152">PubMed Abstract </a> | <a target=xrefwindow id=d2476e4586 href="http://dx.doi.org/10.1016/j.ceb.2012.11.004">Publisher Full Text </a></span></li><li><a name=ref-118 class=n-a></a><span class=label>118. </span>&nbsp;<span class=citation><a name=d2476e4595 class=n-a></a>Oberoi-Khanuja TK, Murali A, Rajalingam K: IAPs on the move: role of inhibitors of apoptosis proteins in cell migration. <i>Cell Death Dis.</i> 2013; <b>4</b>: e784. <a target=xrefwindow id=d2476e4603 href="http://www.ncbi.nlm.nih.gov/pubmed/24008728">PubMed Abstract </a> | <a target=xrefwindow id=d2476e4606 href="http://dx.doi.org/10.1038/cddis.2013.311">Publisher Full Text </a> | <a target=xrefwindow id=d2476e4609 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3789170">Free Full Text </a></span></li><li><a name=ref-119 class=n-a></a><span class=label>119. </span>&nbsp;<span class=citation><a name=d2476e4618 class=n-a></a>Kingeter LM, Schaefer BC: Malt1 and cIAP2-Malt1 as effectors of NF-kappaB activation: kissing cousins or distant relatives? <i>Cell Signal.</i> 2010; <b>22</b>(1): 9–22. <a target=xrefwindow id=d2476e4626 href="http://www.ncbi.nlm.nih.gov/pubmed/19772915">PubMed Abstract </a> | <a target=xrefwindow id=d2476e4629 href="http://dx.doi.org/10.1016/j.cellsig.2009.09.033">Publisher Full Text </a> | <a target=xrefwindow id=d2476e4632 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2766428">Free Full Text </a></span></li><li><a name=ref-120 class=n-a></a><span class=label>120. </span>&nbsp;<span class=citation><a name=d2476e4642 class=n-a></a>Tamm I, Kornblau SM, Segall H, <i> et al.</i>: Expression and prognostic significance of IAP-family genes in human cancers and myeloid leukemias. <i>Clin Cancer Res.</i> 2000; <b>6</b>(5): 1796–803. <a target=xrefwindow id=d2476e4653 href="http://www.ncbi.nlm.nih.gov/pubmed/10815900">PubMed Abstract </a></span></li><li><a name=ref-121 class=n-a></a><span class=label>121. </span>&nbsp;<span class=citation><a name=d2476e4662 class=n-a></a>Tamm I, Richter S, Oltersdorf D, <i> et al.</i>: High expression levels of x-linked inhibitor of apoptosis protein and survivin correlate with poor overall survival in childhood <i>de novo</i> acute myeloid leukemia. <i>Clin Cancer Res.</i> 2004; <b>10</b>(11): 3737–44. <a target=xrefwindow id=d2476e4676 href="http://www.ncbi.nlm.nih.gov/pubmed/15173080">PubMed Abstract </a> | <a target=xrefwindow id=d2476e4680 href="http://dx.doi.org/10.1158/1078-0432.CCR-03-0642">Publisher Full Text </a></span></li><li><a name=ref-122 class=n-a></a><span class=label>122. </span>&nbsp;<span class=citation><a name=d2476e4689 class=n-a></a>Mizutani Y, Nakanishi H, Li YN, <i> et al.</i>: Overexpression of XIAP expression in renal cell carcinoma predicts a worse prognosis. <i>Int J Oncol.</i> 2007; <b>30</b>(4): 919–25. <a target=xrefwindow id=d2476e4700 href="http://www.ncbi.nlm.nih.gov/pubmed/17332931">PubMed Abstract </a> | <a target=xrefwindow id=d2476e4703 href="http://dx.doi.org/10.3892/ijo.30.4.919">Publisher Full Text </a></span></li><li><a name=ref-123 class=n-a></a><span class=label>123. </span>&nbsp;<span class=citation><a name=d2476e4712 class=n-a></a>Ramp U, Krieg T, Caliskan E, <i> et al.</i>: XIAP expression is an independent prognostic marker in clear-cell renal carcinomas. <i>Hum Pathol.</i> 2004; <b>35</b>(8): 1022–8. <a target=xrefwindow id=d2476e4723 href="http://www.ncbi.nlm.nih.gov/pubmed/15297970">PubMed Abstract </a> | <a target=xrefwindow id=d2476e4726 href="http://dx.doi.org/10.1016/j.humpath.2004.03.011">Publisher Full Text </a></span></li><li><a name=ref-124 class=n-a></a><span class=label>124. </span>&nbsp;<span class=citation><a name=d2476e4735 class=n-a></a>Nakagawa Y, Abe S, Kurata M, <i> et al.</i>: IAP family protein expression correlates with poor outcome of multiple myeloma patients in association with chemotherapy-induced overexpression of multidrug resistance genes. <i>Am J Hematol.</i> 2006; <b>81</b>(11): 824–31. <a target=xrefwindow id=d2476e4746 href="http://www.ncbi.nlm.nih.gov/pubmed/16929535">PubMed Abstract </a> | <a target=xrefwindow id=d2476e4749 href="http://dx.doi.org/10.1002/ajh.20656">Publisher Full Text </a></span></li><li><a name=ref-125 class=n-a></a><span class=label>125. </span>&nbsp;<span class=citation><a name=d2476e4758 class=n-a></a>Li M, Song T, Yin ZF, <i> et al.</i>: XIAP as a prognostic marker of early recurrence of nonmuscular invasive bladder cancer. <i>Chin Med J (Engl).</i> 2007; <b>120</b>(6): 469–73. <a target=xrefwindow id=d2476e4769 href="http://www.ncbi.nlm.nih.gov/pubmed/17439739">PubMed Abstract </a></span></li><li><a name=ref-126 class=n-a></a><span class=label>126. </span>&nbsp;<span class=citation><a name=d2476e4779 class=n-a></a>Dean EJ, Ranson M, Blackhall F, <i> et al.</i>: X-linked inhibitor of apoptosis protein as a therapeutic target. <i>Expert Opin Ther Targets.</i> 2007; <b>11</b>(11): 1459–71. <a target=xrefwindow id=d2476e4790 href="http://www.ncbi.nlm.nih.gov/pubmed/18028010">PubMed Abstract </a> | <a target=xrefwindow id=d2476e4793 href="http://dx.doi.org/10.1517/14728222.11.11.1459">Publisher Full Text </a></span></li><li><a name=ref-127 class=n-a></a><span class=label>127. </span>&nbsp;<span class=citation><a name=d2476e4802 class=n-a></a>Altieri DC, Edgington TS: Identification of effector cell protease receptor-1. A leukocyte-distributed receptor for the serine protease factor Xa. <i>J Immunol.</i> 1990; <b>145</b>(1): 246–53. <a target=xrefwindow id=d2476e4810 href="http://www.ncbi.nlm.nih.gov/pubmed/2162887">PubMed Abstract </a></span></li><li><a name=ref-128 class=n-a></a><span class=label>128. </span>&nbsp;<span class=citation><a name=d2476e4819 class=n-a></a>Altieri DC: Survivin, cancer networks and pathway-directed drug discovery. <i>Nat Rev Cancer.</i> 2008; <b>8</b>(1): 61–70. <a target=xrefwindow id=d2476e4827 href="http://www.ncbi.nlm.nih.gov/pubmed/18075512">PubMed Abstract </a> | <a target=xrefwindow id=d2476e4830 href="http://dx.doi.org/10.1038/nrc2293">Publisher Full Text </a></span></li><li><a name=ref-129 class=n-a></a><span class=label>129. </span>&nbsp;<span class=citation><a name=d2476e4839 class=n-a></a>Kami K, Doi R, Koizumi M, <i> et al.</i>: Survivin expression is a prognostic marker in pancreatic cancer patients. <i>Surgery.</i> 2004; <b>136</b>(2): 443–8. <a target=xrefwindow id=d2476e4850 href="http://www.ncbi.nlm.nih.gov/pubmed/15300213">PubMed Abstract </a> | <a target=xrefwindow id=d2476e4853 href="http://dx.doi.org/10.1016/j.surg.2004.05.023">Publisher Full Text </a></span></li><li><a name=ref-130 class=n-a></a><span class=label>130. </span>&nbsp;<span class=citation><a name=d2476e4862 class=n-a></a>Sugahara K, Uemura A, Harasawa H, <i> et al.</i>: Clinical relevance of survivin as a biomarker in neoplasms, especially in adult T-cell leukemias and acute leukemias. <i>Int J Hematol.</i> 2004; <b>80</b>(1): 52–8. <a target=xrefwindow id=d2476e4873 href="http://www.ncbi.nlm.nih.gov/pubmed/15293568">PubMed Abstract </a> | <a target=xrefwindow id=d2476e4876 href="http://dx.doi.org/10.1532/IJH97.04031">Publisher Full Text </a></span></li><li><a name=ref-131 class=n-a></a><span class=label>131. </span>&nbsp;<span class=citation><a name=d2476e4885 class=n-a></a>Mega S, Miyamoto M, Li L, <i> et al.</i>: Immunohistochemical analysis of nuclear survivin expression in esophageal squamous cell carcinoma. <i>Dis Esophagus.</i> 2006; <b>19</b>(5): 355–9. <a target=xrefwindow id=d2476e4896 href="http://www.ncbi.nlm.nih.gov/pubmed/16984532">PubMed Abstract </a> | <a target=xrefwindow id=d2476e4899 href="http://dx.doi.org/10.1111/j.1442-2050.2006.00604.x">Publisher Full Text </a></span></li><li><a name=ref-132 class=n-a></a><span class=label>132. </span>&nbsp;<span class=citation><a name=d2476e4909 class=n-a></a>Gritsko T, Williams A, Turkson J, <i> et al.</i>: Persistent activation of stat3 signaling induces survivin gene expression and confers resistance to apoptosis in human breast cancer cells. <i>Clin Cancer Res.</i> 2006; <b>12</b>(1): 11–9. <a target=xrefwindow id=d2476e4920 href="http://www.ncbi.nlm.nih.gov/pubmed/16397018">PubMed Abstract </a> | <a target=xrefwindow id=d2476e4923 href="http://dx.doi.org/10.1158/1078-0432.CCR-04-1752">Publisher Full Text </a></span></li><li><a name=ref-133 class=n-a></a><span class=label>133. </span>&nbsp;<span class=citation><a name=d2476e4932 class=n-a></a>Kaneko R, Tsuji N, Asanuma K, <i> et al.</i>: Survivin down-regulation plays a crucial role in 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor-induced apoptosis in cancer. <i>J Biol Chem.</i> 2007; <b>282</b>(27): 19273–81. <a target=xrefwindow id=d2476e4943 href="http://www.ncbi.nlm.nih.gov/pubmed/17472962">PubMed Abstract </a> | <a target=xrefwindow id=d2476e4946 href="http://dx.doi.org/10.1074/jbc.M610350200">Publisher Full Text </a></span></li><li><a name=ref-134 class=n-a></a><span class=label>134. </span>&nbsp;<span class=citation><a name=d2476e4955 class=n-a></a>Stauber RH, Mann W, Knauer SK: Nuclear and cytoplasmic survivin: molecular mechanism, prognostic, and therapeutic potential. <i>Cancer Res.</i> 2007; <b>67</b>(13): 5999–6002. <a target=xrefwindow id=d2476e4963 href="http://www.ncbi.nlm.nih.gov/pubmed/17616652">PubMed Abstract </a> | <a target=xrefwindow id=d2476e4966 href="http://dx.doi.org/10.1158/0008-5472.CAN-07-0494">Publisher Full Text </a></span></li><li><a name=ref-135 class=n-a></a><span class=label>135. </span>&nbsp;<span class=citation><a name=d2476e4975 class=n-a></a>Waligórska-Stachura J, Jankowska A, Wasko R, <i> et al.</i>: Survivin--prognostic tumor biomarker in human neoplasms--review. <i>Ginekol Pol.</i> 2012; <b>83</b>(7): 537–40. <a target=xrefwindow id=d2476e4986 href="http://www.ncbi.nlm.nih.gov/pubmed/22880480">PubMed Abstract </a></span></li><li><a name=ref-136 class=n-a></a><span class=label>136. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/725621336"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d2476e4995 class=n-a></a>Jaiswal PK, Goel A, Mittal RD: Survivin: A molecular biomarker in cancer. <i>Indian J Med Res.</i> 2015; <b>141</b>(4): 389–97. <a target=xrefwindow id=d2476e5003 href="http://www.ncbi.nlm.nih.gov/pubmed/26112839">PubMed Abstract </a> | <a target=xrefwindow id=d2476e5006 href="http://dx.doi.org/10.4103/0971-5916.159250">Publisher Full Text </a> | <a target=xrefwindow id=d2476e5009 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4510718">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/725621336">F1000 Recommendation</a></span></li><li><a name=ref-137 class=n-a></a><span class=label>137. </span>&nbsp;<span class=citation><a name=d2476e5022 class=n-a></a>Altieri DC: Survivin - The inconvenient IAP. <i>Semin Cell Dev Biol.</i> 2015; <b>39</b>: 91–6. <a target=xrefwindow id=d2476e5030 href="http://www.ncbi.nlm.nih.gov/pubmed/25591986">PubMed Abstract </a> | <a target=xrefwindow id=d2476e5033 href="http://dx.doi.org/10.1016/j.semcdb.2014.12.007">Publisher Full Text </a> | <a target=xrefwindow id=d2476e5036 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4410054">Free Full Text </a></span></li><li><a name=ref-138 class=n-a></a><span class=label>138. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/725832809"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d2476e5046 class=n-a></a>Soleimanpour E, Babaei E: Survivin as a Potential Target for Cancer Therapy. <i>Asian Pac J Cancer Prev.</i> 2015; <b>16</b>(15): 6187–91. <a target=xrefwindow id=d2476e5054 href="http://www.ncbi.nlm.nih.gov/pubmed/26434815">PubMed Abstract </a> | <a target=xrefwindow id=d2476e5057 href="http://dx.doi.org/10.7314/APJCP.2015.16.15.6187">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/725832809">F1000 Recommendation</a></span></li><li><a name=ref-139 class=n-a></a><span class=label>139. </span>&nbsp;<span class=citation><a name=d2476e5070 class=n-a></a>Tamm I, Wang Y, Sausville E, <i> et al.</i>: IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. <i>Cancer Res.</i> 1998; <b>58</b>(23): 5315–20. <a target=xrefwindow id=d2476e5081 href="http://www.ncbi.nlm.nih.gov/pubmed/9850056">PubMed Abstract </a></span></li><li><a name=ref-140 class=n-a></a><span class=label>140. </span>&nbsp;<span class=citation><a name=d2476e5090 class=n-a></a>Kobayashi K, Hatano M, Otaki M, <i> et al.</i>: Expression of a murine homologue of the inhibitor of apoptosis protein is related to cell proliferation. <i>Proc Natl Acad Sci U S A.</i> 1999; <b>96</b>(4): 1457–62. <a target=xrefwindow id=d2476e5101 href="http://www.ncbi.nlm.nih.gov/pubmed/9990045">PubMed Abstract </a> | <a target=xrefwindow id=d2476e5104 href="http://dx.doi.org/10.1073/pnas.96.4.1457">Publisher Full Text </a> | <a target=xrefwindow id=d2476e5108 href="http://www.ncbi.nlm.nih.gov/pmc/articles/15484">Free Full Text </a></span></li><li><a name=ref-141 class=n-a></a><span class=label>141. </span>&nbsp;<span class=citation><a name=d2476e5117 class=n-a></a>Mahotka C, Wenzel M, Springer E, <i> et al.</i>: Survivin-deltaEx3 and survivin-2B: two novel splice variants of the apoptosis inhibitor survivin with different antiapoptotic properties. <i>Cancer Res.</i> 1999; <b>59</b>(24): 6097–102. <a target=xrefwindow id=d2476e5128 href="http://www.ncbi.nlm.nih.gov/pubmed/10626797">PubMed Abstract </a></span></li><li><a name=ref-142 class=n-a></a><span class=label>142. </span>&nbsp;<span class=citation><a name=d2476e5137 class=n-a></a>Dohi T, Okada K, Xia F, <i> et al.</i>: An IAP-IAP complex inhibits apoptosis. <i>J Biol Chem.</i> 2004; <b>279</b>(33): 34087–90. <a target=xrefwindow id=d2476e5148 href="http://www.ncbi.nlm.nih.gov/pubmed/15218035">PubMed Abstract </a> | <a target=xrefwindow id=d2476e5151 href="http://dx.doi.org/10.1074/jbc.C400236200">Publisher Full Text </a></span></li><li><a name=ref-143 class=n-a></a><span class=label>143. </span>&nbsp;<span class=citation><a name=d2476e5160 class=n-a></a>Speliotes EK, Uren A, Vaux D, <i> et al.</i>: The survivin-like <i>C. elegans</i> BIR-1 protein acts with the Aurora-like kinase AIR-2 to affect chromosomes and the spindle midzone. <i>Mol Cell.</i> 2000; <b>6</b>(2): 211–23. <a target=xrefwindow id=d2476e5174 href="http://www.ncbi.nlm.nih.gov/pubmed/10983970">PubMed Abstract </a> | <a target=xrefwindow id=d2476e5178 href="http://dx.doi.org/10.1016/S1097-2765(00)00023-X">Publisher Full Text </a></span></li><li><a name=ref-144 class=n-a></a><span class=label>144. </span>&nbsp;<span class=citation><a name=d2476e5188 class=n-a></a>Cheung CH, Huang CC, Tsai FY, <i> et al.</i>: Survivin - biology and potential as a therapeutic target in oncology. <i>Onco Targets Ther.</i> 2013; <b>6</b>: 1453–62. <a target=xrefwindow id=d2476e5199 href="http://www.ncbi.nlm.nih.gov/pubmed/24204160">PubMed Abstract </a> | <a target=xrefwindow id=d2476e5202 href="http://dx.doi.org/10.2147/OTT.S33374">Publisher Full Text </a> | <a target=xrefwindow id=d2476e5206 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3804542">Free Full Text </a></span></li><li><a name=ref-145 class=n-a></a><span class=label>145. </span>&nbsp;<span class=citation><a name=d2476e5215 class=n-a></a>Coumar MS, Tsai FY, Kanwar JR, <i> et al.</i>: Treat cancers by targeting survivin: just a dream or future reality? <i>Cancer Treat Rev.</i> 2013; <b>39</b>(7): 802–11. <a target=xrefwindow id=d2476e5226 href="http://www.ncbi.nlm.nih.gov/pubmed/23453862">PubMed Abstract </a> | <a target=xrefwindow id=d2476e5229 href="http://dx.doi.org/10.1016/j.ctrv.2013.02.002">Publisher Full Text </a></span></li><li><a name=ref-146 class=n-a></a><span class=label>146. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/727512871"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d2476e5238 class=n-a></a>Garg H, Suri P, Gupta JC, <i> et al.</i>: Survivin: a unique target for tumor therapy. <i>Cancer Cell Int.</i> 2016; <b>16</b>: 49. <a target=xrefwindow id=d2476e5249 href="http://www.ncbi.nlm.nih.gov/pubmed/27340370">PubMed Abstract </a> | <a target=xrefwindow id=d2476e5252 href="http://dx.doi.org/10.1186/s12935-016-0326-1">Publisher Full Text </a> | <a target=xrefwindow id=d2476e5256 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4917988">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/727512871">F1000 Recommendation</a></span></li><li><a name=ref-147 class=n-a></a><span class=label>147. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/727512872"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d2476e5269 class=n-a></a>Chen X, Duan N, Zhang C, <i> et al.</i>: Survivin and Tumorigenesis: Molecular Mechanisms and Therapeutic Strategies. <i>J Cancer.</i> 2016; <b>7</b>(3): 314–23. <a target=xrefwindow id=d2476e5280 href="http://www.ncbi.nlm.nih.gov/pubmed/26918045">PubMed Abstract </a> | <a target=xrefwindow id=d2476e5283 href="http://dx.doi.org/10.7150/jca.13332">Publisher Full Text </a> | <a target=xrefwindow id=d2476e5287 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4747886">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/727512872">F1000 Recommendation</a></span></li><li><a name=ref-148 class=n-a></a><span class=label>148. </span>&nbsp;<span class=citation><a name=d2476e5300 class=n-a></a>Han Z, Lee S, Je S, <i> et al.</i>: Survivin silencing and TRAIL expression using oncolytic adenovirus increase anti-tumorigenic activity in gemcitabine-resistant pancreatic cancer cells. <i>Apoptosis.</i> 2016; <b>21</b>(3): 351–64. <a target=xrefwindow id=d2476e5311 href="http://www.ncbi.nlm.nih.gov/pubmed/26677013">PubMed Abstract </a> | <a target=xrefwindow id=d2476e5314 href="http://dx.doi.org/10.1007/s10495-015-1208-z">Publisher Full Text </a></span></li><li><a name=ref-149 class=n-a></a><span class=label>149. </span>&nbsp;<span class=citation><a name=d2476e5323 class=n-a></a>Bi Y, Zhang Y, Cui C, <i> et al.</i>: Gene-silencing effects of anti-survivin siRNA delivered by RGDV-functionalized nanodiamond carrier in the breast carcinoma cell line MCF-7. <i>Int J Nanomedicine.</i> 2016; <b>11</b>: 5771–87. <a target=xrefwindow id=d2476e5334 href="http://www.ncbi.nlm.nih.gov/pubmed/27853365">PubMed Abstract </a> | <a target=xrefwindow id=d2476e5337 href="http://dx.doi.org/10.2147/IJN.S117611">Publisher Full Text </a> | <a target=xrefwindow id=d2476e5341 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5104303">Free Full Text </a></span></li><li><a name=ref-150 class=n-a></a><span class=label>150. </span>&nbsp;<span class=citation><a name=d2476e5351 class=n-a></a>Ling X, Cao S, Cheng Q, <i> et al.</i>: A novel small molecule FL118 that selectively inhibits survivin, Mcl-1, XIAP and cIAP2 in a p53-independent manner, shows superior antitumor activity. <i>PLoS One.</i> 2012; <b>7</b>(9): e45571. <a target=xrefwindow id=d2476e5362 href="http://www.ncbi.nlm.nih.gov/pubmed/23029106">PubMed Abstract </a> | <a target=xrefwindow id=d2476e5365 href="http://dx.doi.org/10.1371/journal.pone.0045571">Publisher Full Text </a> | <a target=xrefwindow id=d2476e5369 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3446924">Free Full Text </a></span></li><li><a name=ref-151 class=n-a></a><span class=label>151. </span>&nbsp;<span class=citation><a name=d2476e5378 class=n-a></a>Falkenhorst J, Grunewald S, Mühlenberg T, <i> et al.</i>: Inhibitor of Apoptosis Proteins (IAPs) are commonly dysregulated in GIST and can be pharmacologically targeted to enhance the pro-apoptotic activity of imatinib. <i>Oncotarget.</i> 2016; <b>7</b>(27): 41390–403. <a target=xrefwindow id=d2476e5389 href="http://www.ncbi.nlm.nih.gov/pubmed/27167336">PubMed Abstract </a> | <a target=xrefwindow id=d2476e5392 href="http://dx.doi.org/10.18632/oncotarget.9159">Publisher Full Text </a> | <a target=xrefwindow id=d2476e5396 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5173067">Free Full Text </a></span></li><li><a name=ref-152 class=n-a></a><span class=label>152. </span>&nbsp;<span class=citation><a name=d2476e5405 class=n-a></a>Gyurászová K, Mikeš J, Halaburková A, <i> et al.</i>: YM155, a small molecule inhibitor of survivin expression, sensitizes cancer cells to hypericin-mediated photodynamic therapy. <i>Photochem Photobiol Sci.</i> 2016; <b>15</b>(6): 812–21. <a target=xrefwindow id=d2476e5416 href="http://www.ncbi.nlm.nih.gov/pubmed/27241169">PubMed Abstract </a> | <a target=xrefwindow id=d2476e5419 href="http://dx.doi.org/10.1039/c5pp00438a">Publisher Full Text </a></span></li><li><a name=ref-153 class=n-a></a><span class=label>153. </span>&nbsp;<span class=citation><a name=d2476e5428 class=n-a></a>Groner B, Weiss A: Targeting survivin in cancer: novel drug development approaches. <i>BioDrugs.</i> 2014; <b>28</b>(1): 27–39. <a target=xrefwindow id=d2476e5436 href="http://www.ncbi.nlm.nih.gov/pubmed/23955284">PubMed Abstract </a> | <a target=xrefwindow id=d2476e5439 href="http://dx.doi.org/10.1007/s40259-013-0058-x">Publisher Full Text </a> | <a target=xrefwindow id=d2476e5442 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3929033">Free Full Text </a></span></li><li><a name=ref-154 class=n-a></a><span class=label>154. </span>&nbsp;<span class=citation><a name=d2476e5451 class=n-a></a>Xiao M, Li W: Recent Advances on Small-Molecule Survivin Inhibitors. <i>Curr Med Chem.</i> 2015; <b>22</b>(9): 1136–1146. <a target=xrefwindow id=d2476e5459 href="http://www.ncbi.nlm.nih.gov/pubmed/25613234">PubMed Abstract </a> | <a target=xrefwindow id=d2476e5462 href="http://dx.doi.org/10.2174/0929867322666150114102146">Publisher Full Text </a> | <a target=xrefwindow id=d2476e5465 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5342940">Free Full Text </a></span></li><li><a name=ref-155 class=n-a></a><span class=label>155. </span>&nbsp;<span class=citation><a name=d2476e5474 class=n-a></a>Qi J, Dong Z, Liu J, <i> et al.</i>: Effective Targeting of the Survivin Dimerization Interface with Small-Molecule Inhibitors. <i>Cancer Res.</i> 2016; <b>76</b>(2): 453–62. <a target=xrefwindow id=d2476e5485 href="http://www.ncbi.nlm.nih.gov/pubmed/26744521">PubMed Abstract </a> | <a target=xrefwindow id=d2476e5488 href="http://dx.doi.org/10.1158/0008-5472.CAN-15-1874">Publisher Full Text </a></span></li><li><a name=ref-156 class=n-a></a><span class=label>156. </span>&nbsp;<span class=citation><a name=d2476e5498 class=n-a></a>Sung KW, Choi J, Hwang YK, <i> et al.</i>: Overexpression of Apollon, an antiapoptotic protein, is associated with poor prognosis in childhood <i>de novo</i> acute myeloid leukemia. <i>Clin Cancer Res.</i> 2007; <b>13</b>(17): 5109–14. <a target=xrefwindow id=d2476e5512 href="http://www.ncbi.nlm.nih.gov/pubmed/17785565">PubMed Abstract </a> | <a target=xrefwindow id=d2476e5516 href="http://dx.doi.org/10.1158/1078-0432.CCR-07-0693">Publisher Full Text </a></span></li><li><a name=ref-157 class=n-a></a><span class=label>157. </span>&nbsp;<span class=citation><a name=d2476e5525 class=n-a></a>Ismail EA, Mahmoud HM, Tawfik LM, <i> et al.</i>: <i>BIRC6</i>/Apollon gene expression in childhood acute leukemia: impact on therapeutic response and prognosis. <i>Eur J Haematol.</i> 2012; <b>88</b>(2): 118–27. <a target=xrefwindow id=d2476e5539 href="http://www.ncbi.nlm.nih.gov/pubmed/22085301">PubMed Abstract </a> | <a target=xrefwindow id=d2476e5543 href="http://dx.doi.org/10.1111/j.1600-0609.2011.01734.x">Publisher Full Text </a></span></li><li><a name=ref-158 class=n-a></a><span class=label>158. </span>&nbsp;<span class=citation><a name=d2476e5552 class=n-a></a>Lopergolo A, Pennati M, Gandellini P, <i> et al.</i>: Apollon gene silencing induces apoptosis in breast cancer cells through p53 stabilisation and caspase-3 activation. <i>Br J Cancer.</i> 2009; <b>100</b>(5): 739–46. <a target=xrefwindow id=d2476e5563 href="http://www.ncbi.nlm.nih.gov/pubmed/19223905">PubMed Abstract </a> | <a target=xrefwindow id=d2476e5566 href="http://dx.doi.org/10.1038/sj.bjc.6604927">Publisher Full Text </a> | <a target=xrefwindow id=d2476e5570 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2653776">Free Full Text </a></span></li><li><a name=ref-159 class=n-a></a><span class=label>159. </span>&nbsp;<span class=citation><a name=d2476e5579 class=n-a></a>Lamers F, Schild L, Koster J, <i> et al.</i>: Identification of BIRC6 as a novel intervention target for neuroblastoma therapy. <i>BMC Cancer.</i> 2012; <b>12</b>: 285. <a target=xrefwindow id=d2476e5590 href="http://www.ncbi.nlm.nih.gov/pubmed/22788920">PubMed Abstract </a> | <a target=xrefwindow id=d2476e5593 href="http://dx.doi.org/10.1186/1471-2407-12-285">Publisher Full Text </a> | <a target=xrefwindow id=d2476e5597 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3495678">Free Full Text </a></span></li><li><a name=ref-160 class=n-a></a><span class=label>160. </span>&nbsp;<span class=citation><a name=d2476e5606 class=n-a></a>Low CG, Luk IS, Lin D, <i> et al.</i>: BIRC6 protein, an inhibitor of apoptosis: role in survival of human prostate cancer cells. <i>PLoS One.</i> 2013; <b>8</b>(2): e55837. <a target=xrefwindow id=d2476e5617 href="http://www.ncbi.nlm.nih.gov/pubmed/23409057">PubMed Abstract </a> | <a target=xrefwindow id=d2476e5620 href="http://dx.doi.org/10.1371/journal.pone.0055837">Publisher Full Text </a> | <a target=xrefwindow id=d2476e5624 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3568134">Free Full Text </a></span></li><li><a name=ref-161 class=n-a></a><span class=label>161. </span>&nbsp;<span class=citation><a name=d2476e5633 class=n-a></a>Luk SU, Xue H, Cheng H, <i> et al.</i>: The <i>BIRC6</i> gene as a novel target for therapy of prostate cancer: dual targeting of inhibitors of apoptosis. <i>Oncotarget.</i> 2014; <b>5</b>(16): 6896–908. <a target=xrefwindow id=d2476e5647 href="http://www.ncbi.nlm.nih.gov/pubmed/25071009">PubMed Abstract </a> | <a target=xrefwindow id=d2476e5651 href="http://dx.doi.org/10.18632/oncotarget.2229">Publisher Full Text </a> | <a target=xrefwindow id=d2476e5654 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4196171">Free Full Text </a></span></li><li><a name=ref-162 class=n-a></a><span class=label>162. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/726770134"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d2476e5664 class=n-a></a>Luk IS, Shrestha R, Xue H, <i> et al.</i>: <i>BIRC6</i> Targeting as Potential Therapy for Advanced, Enzalutamide-Resistant Prostate Cancer. <i>Clin Cancer Res.</i> 2017; <b>23</b>(6): 1542–1551. <a target=xrefwindow id=d2476e5678 href="http://www.ncbi.nlm.nih.gov/pubmed/27663589">PubMed Abstract </a> | <a target=xrefwindow id=d2476e5682 href="http://dx.doi.org/10.1158/1078-0432.CCR-16-0718">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/726770134">F1000 Recommendation</a></span></li><li><a name=ref-163 class=n-a></a><span class=label>163. </span>&nbsp;<span class=citation><a name=d2476e5695 class=n-a></a>Dong X, Lin D, Low C, <i> et al.</i>: Elevated expression of BIRC6 protein in non-small-cell lung cancers is associated with cancer recurrence and chemoresistance. <i>J Thorac Oncol.</i> 2013; <b>8</b>(2): 161–70. <a target=xrefwindow id=d2476e5706 href="http://www.ncbi.nlm.nih.gov/pubmed/23287853">PubMed Abstract </a> | <a target=xrefwindow id=d2476e5709 href="http://dx.doi.org/10.1097/JTO.0b013e31827d5237">Publisher Full Text </a></span></li><li><a name=ref-164 class=n-a></a><span class=label>164. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/718249183"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d2476e5718 class=n-a></a>Wang L, Chen YJ, Hou J, <i> et al.</i>: Expression and clinical significance of BIRC6 in human epithelial ovarian cancer. <i>Tumour Biol.</i> 2014; <b>35</b>(5): 4891–6. <a target=xrefwindow id=d2476e5729 href="http://www.ncbi.nlm.nih.gov/pubmed/24453032">PubMed Abstract </a> | <a target=xrefwindow id=d2476e5732 href="http://dx.doi.org/10.1007/s13277-014-1641-6">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/718249183">F1000 Recommendation</a></span></li><li><a name=ref-165 class=n-a></a><span class=label>165. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/725457373"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d2476e5745 class=n-a></a>Hu T, Weng S, Tang W, <i> et al.</i>: Overexpression of BIRC6 Is a Predictor of Prognosis for Colorectal Cancer. <i>PLoS One.</i> 2015; <b>10</b>(5): e0125281. <a target=xrefwindow id=d2476e5756 href="http://www.ncbi.nlm.nih.gov/pubmed/25933218">PubMed Abstract </a> | <a target=xrefwindow id=d2476e5759 href="http://dx.doi.org/10.1371/journal.pone.0125281">Publisher Full Text </a> | <a target=xrefwindow id=d2476e5763 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4416929">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/725457373">F1000 Recommendation</a></span></li><li><a name=ref-166 class=n-a></a><span class=label>166. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/718765994"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d2476e5776 class=n-a></a>Tang W, Xue R, Weng S, <i> et al.</i>: BIRC6 promotes hepatocellular carcinogenesis: interaction of BIRC6 with p53 facilitating p53 degradation. <i>Int J Cancer.</i> 2015; <b>136</b>(6): E475–87. <a target=xrefwindow id=d2476e5787 href="http://www.ncbi.nlm.nih.gov/pubmed/25196217">PubMed Abstract </a> | <a target=xrefwindow id=d2476e5790 href="http://dx.doi.org/10.1002/ijc.29194">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/718765994">F1000 Recommendation</a></span></li><li><a name=ref-167 class=n-a></a><span class=label>167. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/727512875"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d2476e5803 class=n-a></a>Li R, Chen BL, Zhou YW, <i> et al.</i>: Expression and clinical significance of Apollon in esophageal squamous cell carcinoma. <i>Mol Med Rep.</i> 2016; <b>14</b>(3): 1933–40. <a target=xrefwindow id=d2476e5814 href="http://www.ncbi.nlm.nih.gov/pubmed/27432467">PubMed Abstract </a> | <a target=xrefwindow id=d2476e5817 href="http://dx.doi.org/10.3892/mmr.2016.5473">Publisher Full Text </a> | <a target=xrefwindow id=d2476e5821 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4991688">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/727512875">F1000 Recommendation</a></span></li><li><a name=ref-168 class=n-a></a><span class=label>168. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/726065900"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d2476e5835 class=n-a></a>Milani S, Bandehpour M, Sharifi Z, <i> et al.</i>: Suppressive Effect of Constructed shRNAs against Apollon Induces Apoptosis and Growth Inhibition in the HeLa Cell Line. <i>Iran Biomed J.</i> 2016; <b>20</b>(3): 145–51. <a target=xrefwindow id=d2476e5846 href="http://www.ncbi.nlm.nih.gov/pubmed/26748613">PubMed Abstract </a> | <a target=xrefwindow id=d2476e5849 href="http://dx.doi.org/10.7508/ibj.2016.03.003">Publisher Full Text </a> | <a target=xrefwindow id=d2476e5853 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4949978">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/726065900">F1000 Recommendation</a></span></li><li><a name=ref-169 class=n-a></a><span class=label>169. </span>&nbsp;<span class=citation><a name=d2476e5866 class=n-a></a>Varfolomeev E, Moradi E, Dynek JN, <i> et al.</i>: Characterization of ML-IAP protein stability and physiological role <i>in vivo</i>. <i>Biochem J.</i> 2012; <b>447</b>(3): 427–36. <a target=xrefwindow id=d2476e5880 href="http://www.ncbi.nlm.nih.gov/pubmed/22853455">PubMed Abstract </a> | <a target=xrefwindow id=d2476e5884 href="http://dx.doi.org/10.1042/BJ20121103">Publisher Full Text </a></span></li><li><a name=ref-170 class=n-a></a><span class=label>170. </span>&nbsp;<span class=citation><a name=d2476e5893 class=n-a></a>Ma L, Huang Y, Song Z, <i> et al.</i>: Livin promotes Smac/DIABLO degradation by ubiquitin-proteasome pathway. <i>Cell Death Differ.</i> 2006; <b>13</b>(12): 2079–88. <a target=xrefwindow id=d2476e5904 href="http://www.ncbi.nlm.nih.gov/pubmed/16729033">PubMed Abstract </a> | <a target=xrefwindow id=d2476e5907 href="http://dx.doi.org/10.1038/sj.cdd.4401959">Publisher Full Text </a></span></li><li><a name=ref-171 class=n-a></a><span class=label>171. </span>&nbsp;<span class=citation><a name=d2476e5916 class=n-a></a>Hariu H, Hirohashi Y, Torigoe T, <i> et al.</i>: Aberrant expression and potency as a cancer immunotherapy target of inhibitor of apoptosis protein family, Livin/ML-IAP in lung cancer. <i>Clin Cancer Res.</i> 2005; <b>11</b>(3): 1000–9. <a target=xrefwindow id=d2476e5927 href="http://www.ncbi.nlm.nih.gov/pubmed/15709165">PubMed Abstract </a></span></li><li><a name=ref-172 class=n-a></a><span class=label>172. </span>&nbsp;<span class=citation><a name=d2476e5936 class=n-a></a>Tanabe H, Yagihashi A, Tsuji N, <i> et al.</i>: Expression of survivin mRNA and livin mRNA in non-small-cell lung cancer. <i>Lung Cancer.</i> 2004; <b>46</b>(3): 299–304. <a target=xrefwindow id=d2476e5947 href="http://www.ncbi.nlm.nih.gov/pubmed/15541814">PubMed Abstract </a> | <a target=xrefwindow id=d2476e5950 href="http://dx.doi.org/10.1016/j.lungcan.2004.05.002">Publisher Full Text </a></span></li><li><a name=ref-173 class=n-a></a><span class=label>173. </span>&nbsp;<span class=citation><a name=d2476e5959 class=n-a></a>Crnković-Mertens I, Muley T, Meister M, <i> et al.</i>: The anti-apoptotic <i>livin</i> gene is an important determinant for the apoptotic resistance of non-small cell lung cancer cells. <i>Lung Cancer.</i> 2006; <b>54</b>(2): 135–42. <a target=xrefwindow id=d2476e5973 href="http://www.ncbi.nlm.nih.gov/pubmed/16965834">PubMed Abstract </a> | <a target=xrefwindow id=d2476e5977 href="http://dx.doi.org/10.1016/j.lungcan.2006.07.018">Publisher Full Text </a></span></li><li><a name=ref-174 class=n-a></a><span class=label>174. </span>&nbsp;<span class=citation><a name=d2476e5987 class=n-a></a>Dasgupta A, Alvarado CS, Xu Z, <i> et al.</i>: Expression and functional role of inhibitor-of-apoptosis protein livin (BIRC7) in neuroblastoma. <i>Biochem Biophys Res Commun.</i> 2010; <b>400</b>(1): 53–9. <a target=xrefwindow id=d2476e5998 href="http://www.ncbi.nlm.nih.gov/pubmed/20691667">PubMed Abstract </a> | <a target=xrefwindow id=d2476e6001 href="http://dx.doi.org/10.1016/j.bbrc.2010.08.001">Publisher Full Text </a></span></li><li><a name=ref-175 class=n-a></a><span class=label>175. </span>&nbsp;<span class=citation><a name=d2476e6010 class=n-a></a>El-Mesallamy HO, Hegab HM, Kamal AM: Expression of inhibitor of apoptosis protein (IAP) livin/BIRC7 in acute leukemia in adults: correlation with prognostic factors and outcome. <i>Leuk Res.</i> 2011; <b>35</b>(12): 1616–22. <a target=xrefwindow id=d2476e6018 href="http://www.ncbi.nlm.nih.gov/pubmed/21700335">PubMed Abstract </a> | <a target=xrefwindow id=d2476e6021 href="http://dx.doi.org/10.1016/j.leukres.2011.05.026">Publisher Full Text </a></span></li><li><a name=ref-176 class=n-a></a><span class=label>176. </span>&nbsp;<span class=citation><a name=d2476e6030 class=n-a></a>Grzybowska-Izydorczyk O, Cebula B, Robak T, <i> et al.</i>: Expression and prognostic significance of the inhibitor of apoptosis protein (IAP) family and its antagonists in chronic lymphocytic leukaemia. <i>Eur J Cancer.</i> 2010; <b>46</b>(4): 800–10. <a target=xrefwindow id=d2476e6041 href="http://www.ncbi.nlm.nih.gov/pubmed/20045309">PubMed Abstract </a> | <a target=xrefwindow id=d2476e6044 href="http://dx.doi.org/10.1016/j.ejca.2009.11.023">Publisher Full Text </a></span></li><li><a name=ref-177 class=n-a></a><span class=label>177. </span>&nbsp;<span class=citation><a name=d2476e6053 class=n-a></a>Kim DK, Alvarado CS, Abramowsky CR, <i> et al.</i>: Expression of inhibitor-of-apoptosis protein (IAP) livin by neuroblastoma cells: correlation with prognostic factors and outcome. <i>Pediatr Dev Pathol.</i> 2005; <b>8</b>(4): 621–9. <a target=xrefwindow id=d2476e6064 href="http://www.ncbi.nlm.nih.gov/pubmed/16328668">PubMed Abstract </a> | <a target=xrefwindow id=d2476e6067 href="http://dx.doi.org/10.1007/s10024-005-4108-3">Publisher Full Text </a></span></li><li><a name=ref-178 class=n-a></a><span class=label>178. </span>&nbsp;<span class=citation><a name=d2476e6076 class=n-a></a>Xi RC, Biao WS, Gang ZZ: Significant elevation of survivin and livin expression in human colorectal cancer: inverse correlation between expression and overall survival. <i>Onkologie.</i> 2011; <b>34</b>(8–9): 428–32. <a target=xrefwindow id=d2476e6084 href="http://www.ncbi.nlm.nih.gov/pubmed/21934342">PubMed Abstract </a> | <a target=xrefwindow id=d2476e6087 href="http://dx.doi.org/10.1159/000331132">Publisher Full Text </a></span></li><li><a name=ref-179 class=n-a></a><span class=label>179. </span>&nbsp;<span class=citation><a name=d2476e6096 class=n-a></a>Zhou J, Yuen NK, Zhan Q, <i> et al.</i>: Immunity to the melanoma inhibitor of apoptosis protein (ML-IAP; livin) in patients with malignant melanoma. <i>Cancer Immunol Immunother.</i> 2012; <b>61</b>(5): 655–65. <a target=xrefwindow id=d2476e6107 href="http://www.ncbi.nlm.nih.gov/pubmed/22033581">PubMed Abstract </a> | <a target=xrefwindow id=d2476e6110 href="http://dx.doi.org/10.1007/s00262-011-1124-1">Publisher Full Text </a> | <a target=xrefwindow id=d2476e6114 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3337996">Free Full Text </a></span></li><li><a name=ref-180 class=n-a></a><span class=label>180. </span>&nbsp;<span class=citation><a name=d2476e6124 class=n-a></a>Wagener N, Crnković-Mertens I, Vetter C, <i> et al.</i>: Expression of inhibitor of apoptosis protein Livin in renal cell carcinoma and non-tumorous adult kidney. <i>Br J Cancer.</i> 2007; <b>97</b>(9): 1271–6. <a target=xrefwindow id=d2476e6135 href="http://www.ncbi.nlm.nih.gov/pubmed/17968430">PubMed Abstract </a> | <a target=xrefwindow id=d2476e6138 href="http://dx.doi.org/10.1038/sj.bjc.6604028">Publisher Full Text </a> | <a target=xrefwindow id=d2476e6142 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2360474">Free Full Text </a></span></li><li><a name=ref-181 class=n-a></a><span class=label>181. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/727512876"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d2476e6151 class=n-a></a>Wang Z, Liu S, Ding K, <i> et al.</i>: Silencing Livin induces apoptotic and autophagic cell death, increasing chemotherapeutic sensitivity to cisplatin of renal carcinoma cells. <i>Tumour Biol.</i> 2016; <b>37</b>(11): 15133–43. <a target=xrefwindow id=d2476e6162 href="http://www.ncbi.nlm.nih.gov/pubmed/27677286">PubMed Abstract </a> | <a target=xrefwindow id=d2476e6165 href="http://dx.doi.org/10.1007/s13277-016-5395-1">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/727512876">F1000 Recommendation</a></span></li><li><a name=ref-182 class=n-a></a><span class=label>182. </span>&nbsp;<span class=citation><a name=d2476e6178 class=n-a></a>Li J, Chen P, Li XQ, <i> et al.</i>: Elevated levels of survivin and livin mRNA in bronchial aspirates as markers to support the diagnosis of lung cancer. <i>Int J Cancer.</i> 2013; <b>132</b>(5): 1098–104. <a target=xrefwindow id=d2476e6189 href="http://www.ncbi.nlm.nih.gov/pubmed/22930255">PubMed Abstract </a> | <a target=xrefwindow id=d2476e6192 href="http://dx.doi.org/10.1002/ijc.27757">Publisher Full Text </a></span></li><li><a name=ref-183 class=n-a></a><span class=label>183. </span>&nbsp;<span class=citation><a name=d2476e6201 class=n-a></a>Yagihashi A, Asanuma K, Kobayashi D, <i> et al.</i>: Detection of autoantibodies to livin and survivin in Sera from lung cancer patients. <i>Lung Cancer.</i> 2005; <b>48</b>(2): 217–21.. <a target=xrefwindow id=d2476e6212 href="http://www.ncbi.nlm.nih.gov/pubmed/15829321">PubMed Abstract </a> | <a target=xrefwindow id=d2476e6215 href="http://dx.doi.org/10.1016/j.lungcan.2004.11.002">Publisher Full Text </a></span></li><li><a name=ref-184 class=n-a></a><span class=label>184. </span>&nbsp;<span class=citation><a name=d2476e6224 class=n-a></a>Gazzaniga P, Gradilone A, Giuliani L, <i> et al.</i>: Expression and prognostic significance of <i>LIVIN, SURVIVIN</i> and other apoptosis-related genes in the progression of superficial bladder cancer. <i>Ann Oncol.</i> 2003; <b>14</b>(1): 85–90. <a target=xrefwindow id=d2476e6238 href="http://www.ncbi.nlm.nih.gov/pubmed/12488298">PubMed Abstract </a> | <a target=xrefwindow id=d2476e6242 href="http://dx.doi.org/10.1093/annonc/mdg002">Publisher Full Text </a></span></li><li><a name=ref-185 class=n-a></a><span class=label>185. </span>&nbsp;<span class=citation><a name=d2476e6251 class=n-a></a>Lazar I, Perlman R, Lotem M, <i> et al.</i>: The clinical effect of the inhibitor of apopotosis protein livin in melanoma. <i>Oncology.</i> 2012; <b>82</b>(4): 197–204. <a target=xrefwindow id=d2476e6262 href="http://www.ncbi.nlm.nih.gov/pubmed/22441029">PubMed Abstract </a> | <a target=xrefwindow id=d2476e6265 href="http://dx.doi.org/10.1159/000334234">Publisher Full Text </a></span></li><li><a name=ref-186 class=n-a></a><span class=label>186. </span>&nbsp;<span class=citation><a name=d2476e6275 class=n-a></a>Xi RC, Sheng YR, Chen WH, <i> et al.</i>: Expression of survivin and livin predicts early recurrence in non-muscle invasive bladder cancer. <i>J Surg Oncol.</i> 2013; <b>107</b>(5): 550–4. <a target=xrefwindow id=d2476e6286 href="http://www.ncbi.nlm.nih.gov/pubmed/23090902">PubMed Abstract </a> | <a target=xrefwindow id=d2476e6289 href="http://dx.doi.org/10.1002/jso.23272">Publisher Full Text </a></span></li><li><a name=ref-187 class=n-a></a><span class=label>187. </span>&nbsp;<span class=citation><a name=d2476e6298 class=n-a></a>Yagihashi A, Ohmura T, Asanuma K, <i> et al.</i>: Detection of autoantibodies to survivin and livin in sera from patients with breast cancer. <i>Clin Chim Acta.</i> 2005; <b>362</b>(1–2): 125–30. <a target=xrefwindow id=d2476e6309 href="http://www.ncbi.nlm.nih.gov/pubmed/16026775">PubMed Abstract </a> | <a target=xrefwindow id=d2476e6312 href="http://dx.doi.org/10.1016/j.cccn.2005.06.009">Publisher Full Text </a></span></li><li><a name=ref-188 class=n-a></a><span class=label>188. </span>&nbsp;<span class=citation><a name=d2476e6321 class=n-a></a>Li G, Chang H, Zhai YP, <i> et al.</i>: Targeted silencing of inhibitors of apoptosis proteins with siRNAs: a potential anti-cancer strategy for hepatocellular carcinoma. <i>Asian Pac J Cancer Prev.</i> 2013; <b>14</b>(9): 4943–52. <a target=xrefwindow id=d2476e6332 href="http://www.ncbi.nlm.nih.gov/pubmed/24175757">PubMed Abstract </a> | <a target=xrefwindow id=d2476e6335 href="http://dx.doi.org/10.7314/APJCP.2013.14.9.4943">Publisher Full Text </a></span></li><li><a name=ref-189 class=n-a></a><span class=label>189. </span>&nbsp;<span class=citation><a name=d2476e6344 class=n-a></a>Liu H, Wang S, Sun H, <i> et al.</i>: Inhibition of tumorigenesis and invasion of hepatocellular carcinoma by siRNA-mediated silencing of the livin gene. <i>Mol Med Rep.</i> 2010; <b>3</b>(6): 903–7. <a target=xrefwindow id=d2476e6355 href="http://www.ncbi.nlm.nih.gov/pubmed/21472331">PubMed Abstract </a> | <a target=xrefwindow id=d2476e6358 href="http://dx.doi.org/10.3892/mmr.2010.355">Publisher Full Text </a></span></li><li><a name=ref-190 class=n-a></a><span class=label>190. </span>&nbsp;<span class=citation><a name=d2476e6367 class=n-a></a>Liu X, Wang A, Gao H, <i> et al.</i>: Expression and role of the inhibitor of apoptosis protein livin in chemotherapy sensitivity of ovarian carcinoma. <i>Int J Oncol.</i> 2012; <b>41</b>(3): 1021–8. <a target=xrefwindow id=d2476e6378 href="http://www.ncbi.nlm.nih.gov/pubmed/22766624">PubMed Abstract </a> | <a target=xrefwindow id=d2476e6381 href="http://dx.doi.org/10.3892/ijo.2012.1540">Publisher Full Text </a></span></li><li><a name=ref-191 class=n-a></a><span class=label>191. </span>&nbsp;<span class=citation><a name=d2476e6390 class=n-a></a>Sun JG, Liao RX, Zhang SX, <i> et al.</i>: Role of inhibitor of apoptosis protein Livin in radiation resistance in nonsmall cell lung cancer. <i>Cancer Biother Radiopharm.</i> 2011; <b>26</b>(5): 585–92. <a target=xrefwindow id=d2476e6401 href="http://www.ncbi.nlm.nih.gov/pubmed/21883015">PubMed Abstract </a> | <a target=xrefwindow id=d2476e6404 href="http://dx.doi.org/10.1089/cbr.2011.0962">Publisher Full Text </a></span></li><li><a name=ref-192 class=n-a></a><span class=label>192. </span>&nbsp;<span class=citation><a name=d2476e6414 class=n-a></a>Yuan B, Ran B, Wang S, <i> et al.</i>: siRNA directed against Livin inhibits tumor growth and induces apoptosis in human glioma cells. <i>J Neurooncol.</i> 2012; <b>107</b>(1): 81–7. <a target=xrefwindow id=d2476e6425 href="http://www.ncbi.nlm.nih.gov/pubmed/22086237">PubMed Abstract </a> | <a target=xrefwindow id=d2476e6428 href="http://dx.doi.org/10.1007/s11060-011-0728-9">Publisher Full Text </a></span></li><li><a name=ref-193 class=n-a></a><span class=label>193. </span>&nbsp;<span class=citation><a name=d2476e6437 class=n-a></a>Yang D, Song X, Zhang J, <i> et al.</i>: Therapeutic potential of siRNA-mediated combined knockdown of the IAP genes (<i>Livin</i>, <i>XIAP</i>, and <i>Survivin</i>) on human bladder cancer T24 cells. <i>Acta Biochim Biophys Sin (Shanghai).</i> 2010; <b>42</b>(2): 137–44. <a target=xrefwindow id=d2476e6458 href="http://www.ncbi.nlm.nih.gov/pubmed/20119625">PubMed Abstract </a> | <a target=xrefwindow id=d2476e6461 href="http://dx.doi.org/10.1093/abbs/gmp118">Publisher Full Text </a></span></li><li><a name=ref-194 class=n-a></a><span class=label>194. </span>&nbsp;<span class=citation><a name=d2476e6470 class=n-a></a>Yu L, Wang Z: Effects of Livin gene RNA interference on apoptosis of cervical cancer HeLa cells and enhanced sensitivity to cisplatin. <i>J Huazhong Univ Sci Technolog Med Sci.</i> 2009; <b>29</b>(5): 625–30. <a target=xrefwindow id=d2476e6478 href="http://www.ncbi.nlm.nih.gov/pubmed/19821098">PubMed Abstract </a> | <a target=xrefwindow id=d2476e6481 href="http://dx.doi.org/10.1007/s11596-009-0518-1">Publisher Full Text </a></span></li><li><a name=ref-195 class=n-a></a><span class=label>195. </span>&nbsp;<span class=citation><a name=d2476e6490 class=n-a></a>Wang R, Lin F, Wang X, <i> et al.</i>: Silencing Livin gene expression to inhibit proliferation and enhance chemosensitivity in tumor cells. <i>Cancer Gene Ther.</i> 2008; <b>15</b>(6): 402–12. <a target=xrefwindow id=d2476e6501 href="http://www.ncbi.nlm.nih.gov/pubmed/18340356">PubMed Abstract </a> | <a target=xrefwindow id=d2476e6504 href="http://dx.doi.org/10.1038/cgt.2008.16">Publisher Full Text </a></span></li><li><a name=ref-196 class=n-a></a><span class=label>196. </span>&nbsp;<span class=citation><a name=d2476e6513 class=n-a></a>Chen YS, Li HR, Miao Y, <i> et al.</i>: Local injection of lentivirus-delivered livinshRNA suppresses lung adenocarcinoma growth by inducing a G0/G1 phase cell cycle arrest. <i>Int J Clin Exp Pathol.</i> 2012; <b>5</b>(8): 796–805. <a target=xrefwindow id=d2476e6524 href="http://www.ncbi.nlm.nih.gov/pubmed/23071862">PubMed Abstract </a> | <a target=xrefwindow id=d2476e6527 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3466986">Free Full Text </a></span></li><li><a name=ref-197 class=n-a></a><span class=label>197. </span>&nbsp;<span class=citation><a name=d2476e6536 class=n-a></a>Oh BY, Lee RA, Kim KH: siRNA targeting Livin decreases tumor in a xenograft model for colon cancer. <i>World J Gastroenterol.</i> 2011; <b>17</b>(20): 2563–71. <a target=xrefwindow id=d2476e6544 href="http://www.ncbi.nlm.nih.gov/pubmed/21633662">PubMed Abstract </a> | <a target=xrefwindow id=d2476e6547 href="http://dx.doi.org/10.3748/wjg.v17.i20.2563">Publisher Full Text </a> | <a target=xrefwindow id=d2476e6550 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3103815">Free Full Text </a></span></li><li><a name=ref-198 class=n-a></a><span class=label>198. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/727512877"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d2476e6560 class=n-a></a>Zhuang L, Shen LD, Li K, <i> et al.</i>: Inhibition of livin expression suppresses cell proliferation and enhances chemosensitivity to cisplatin in human lung adenocarcinoma cells. <i>Mol Med Rep.</i> 2015; <b>12</b>(1): 547–52. <a target=xrefwindow id=d2476e6571 href="http://www.ncbi.nlm.nih.gov/pubmed/25695324">PubMed Abstract </a> | <a target=xrefwindow id=d2476e6574 href="http://dx.doi.org/10.3892/mmr.2015.3372">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/727512877">F1000 Recommendation</a></span></li><li><a name=ref-199 class=n-a></a><span class=label>199. </span>&nbsp;<span class=citation><a name=d2476e6587 class=n-a></a>Vamos M, Welsh K, Finlay D, <i> et al.</i>: Expedient synthesis of highly potent antagonists of inhibitor of apoptosis proteins (IAPs) with unique selectivity for ML-IAP. <i>ACS Chem Biol.</i> 2013; <b>8</b>(4): 725–32. <a target=xrefwindow id=d2476e6598 href="http://www.ncbi.nlm.nih.gov/pubmed/23323685">PubMed Abstract </a> | <a target=xrefwindow id=d2476e6601 href="http://dx.doi.org/10.1021/cb3005512">Publisher Full Text </a> | <a target=xrefwindow id=d2476e6605 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3953502">Free Full Text </a></span></li><li><a name=ref-200 class=n-a></a><span class=label>200. </span>&nbsp;<span class=citation><a name=d2476e6614 class=n-a></a>Xiang M, Zhou W, Gao D, <i> et al.</i>: Inhibitor of apoptosis protein-like protein-2 as a novel serological biomarker for breast cancer. <i>Int J Mol Sci.</i> 2012; <b>13</b>(12): 16737–50. <a target=xrefwindow id=d2476e6625 href="http://www.ncbi.nlm.nih.gov/pubmed/23222679">PubMed Abstract </a> | <a target=xrefwindow id=d2476e6628 href="http://dx.doi.org/10.3390/ijms131216737">Publisher Full Text </a> | <a target=xrefwindow id=d2476e6632 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3546717">Free Full Text </a></span></li><li><a name=ref-201 class=n-a></a><span class=label>201. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/1002202"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d2476e6641 class=n-a></a>Verhagen AM, Ekert PG, Pakusch M, <i> et al.</i>: Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins. <i>Cell.</i> 2000; <b>102</b>(1): 43–53. <a target=xrefwindow id=d2476e6652 href="http://www.ncbi.nlm.nih.gov/pubmed/10929712">PubMed Abstract </a> | <a target=xrefwindow id=d2476e6655 href="http://dx.doi.org/10.1016/S0092-8674(00)00009-X">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/1002202">F1000 Recommendation</a></span></li><li><a name=ref-202 class=n-a></a><span class=label>202. </span>&nbsp;<span class=citation><a name=d2476e6668 class=n-a></a>Arkin MR, Tang Y, Wells JA: Small-molecule inhibitors of protein-protein interactions: progressing toward the reality. <i>Chem Biol.</i> 2014; <b>21</b>(9): 1102–14. <a target=xrefwindow id=d2476e6676 href="http://www.ncbi.nlm.nih.gov/pubmed/25237857">PubMed Abstract </a> | <a target=xrefwindow id=d2476e6679 href="http://dx.doi.org/10.1016/j.chembiol.2014.09.001">Publisher Full Text </a> | <a target=xrefwindow id=d2476e6682 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4179228">Free Full Text </a></span></li><li><a name=ref-203 class=n-a></a><span class=label>203. </span>&nbsp;<span class=citation><a name=d2476e6691 class=n-a></a>Chai J, Du C, Wu JW, <i> et al.</i>: Structural and biochemical basis of apoptotic activation by Smac/DIABLO. <i>Nature.</i> 2000; <b>406</b>(6798): 855–62. <a target=xrefwindow id=d2476e6702 href="http://www.ncbi.nlm.nih.gov/pubmed/10972280">PubMed Abstract </a> | <a target=xrefwindow id=d2476e6705 href="http://dx.doi.org/10.1038/35022514">Publisher Full Text </a></span></li><li><a name=ref-204 class=n-a></a><span class=label>204. </span>&nbsp;<span class=citation><a name=d2476e6715 class=n-a></a>Guo F, Nimmanapalli R, Paranawithana S, <i> et al.</i>: Ectopic overexpression of second mitochondria-derived activator of caspases (Smac/DIABLO) or cotreatment with N-terminus of Smac/DIABLO peptide potentiates epothilone B derivative-(BMS 247550) and Apo-2L/TRAIL-induced apoptosis. <i>Blood.</i> 2002; <b>99</b>(9): 3419–26. <a target=xrefwindow id=d2476e6726 href="http://www.ncbi.nlm.nih.gov/pubmed/11964312">PubMed Abstract </a> | <a target=xrefwindow id=d2476e6729 href="http://dx.doi.org/10.1182/blood.V99.9.3419">Publisher Full Text </a></span></li><li><a name=ref-205 class=n-a></a><span class=label>205. </span>&nbsp;<span class=citation><a name=d2476e6738 class=n-a></a>Arnt CR, Chiorean MV, Heldebrant MP, <i> et al.</i>: Synthetic Smac/DIABLO peptides enhance the effects of chemotherapeutic agents by binding XIAP and cIAP1 <i>in situ</i>. <i>J Biol Chem.</i> 2002; <b>277</b>(46): 44236–43. <a target=xrefwindow id=d2476e6752 href="http://www.ncbi.nlm.nih.gov/pubmed/12218061">PubMed Abstract </a> | <a target=xrefwindow id=d2476e6756 href="http://dx.doi.org/10.1074/jbc.M207578200">Publisher Full Text </a></span></li><li><a name=ref-206 class=n-a></a><span class=label>206. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/1012699"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d2476e6765 class=n-a></a>Yang L, Mashima T, Sato S, <i> et al.</i>: Predominant suppression of apoptosome by inhibitor of apoptosis protein in non-small cell lung cancer H460 cells: therapeutic effect of a novel polyarginine-conjugated Smac peptide. <i>Cancer Res.</i> 2003; <b>63</b>(4): 831–7. <a target=xrefwindow id=d2476e6776 href="http://www.ncbi.nlm.nih.gov/pubmed/12591734">PubMed Abstract </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/1012699">F1000 Recommendation</a></span></li><li><a name=ref-207 class=n-a></a><span class=label>207. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/1020969"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d2476e6789 class=n-a></a>Oost TK, Sun C, Armstrong RC, <i> et al.</i>: Discovery of potent antagonists of the antiapoptotic protein XIAP for the treatment of cancer. <i>J Med Chem.</i> 2004; <b>47</b>(18): 4417–26. <a target=xrefwindow id=d2476e6800 href="http://www.ncbi.nlm.nih.gov/pubmed/15317454">PubMed Abstract </a> | <a target=xrefwindow id=d2476e6803 href="http://dx.doi.org/10.1021/jm040037k">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/1020969">F1000 Recommendation</a></span></li><li><a name=ref-208 class=n-a></a><span class=label>208. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/1021261"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d2476e6816 class=n-a></a>Li L, Thomas RM, Suzuki H, <i> et al.</i>: A small molecule Smac mimic potentiates TRAIL- and TNFalpha-mediated cell death. <i>Science.</i> 2004; <b>305</b>(5689): 1471–4. <a target=xrefwindow id=d2476e6827 href="http://www.ncbi.nlm.nih.gov/pubmed/15353805">PubMed Abstract </a> | <a target=xrefwindow id=d2476e6830 href="http://dx.doi.org/10.1126/science.1098231">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/1021261">F1000 Recommendation</a></span></li><li><a name=ref-209 class=n-a></a><span class=label>209. </span>&nbsp;<span class=citation><a name=d2476e6843 class=n-a></a>AstraZeneca: 2, 3-dihydro-1h-indene compounds and their use to treat cancer. <a target=xrefwindow id=d2476e6845 href="https://www.google.com/patents/WO2010142994A1?cl=es">Reference Source</a></span></li><li><a name=ref-210 class=n-a></a><span class=label>210. </span>&nbsp;<span class=citation><a name=d2476e6855 class=n-a></a>Bourguet CB, Boulay PL, Claing A, <i> et al.</i>: Design and synthesis of novel azapeptide activators of apoptosis mediated by caspase-9 in cancer cells. <i>Bioorg Med Chem Lett.</i> 2014; <b>24</b>(15): 3361–5. <a target=xrefwindow id=d2476e6866 href="http://www.ncbi.nlm.nih.gov/pubmed/24986663">PubMed Abstract </a> | <a target=xrefwindow id=d2476e6869 href="http://dx.doi.org/10.1016/j.bmcl.2014.05.095">Publisher Full Text </a></span></li><li><a name=ref-211 class=n-a></a><span class=label>211. </span>&nbsp;<span class=citation><a name=d2476e6878 class=n-a></a>Bristol-Myers Squibb, Ensemble Therapeutics: Macrocyclic compounds for inhibition of inhibitors of apoptosis. WO2014074665A1, 2014. <a target=xrefwindow id=d2476e6880 href="http://www.google.com/patents/WO2013071035A1?cl=3Den">Reference Source</a></span></li><li><a name=ref-212 class=n-a></a><span class=label>212. </span>&nbsp;<span class=citation><a name=d2476e6889 class=n-a></a>Genentech: Inhibitors of iap. WO2010017035A2, 2010. <a target=xrefwindow id=d2476e6891 href="https://www.google.com/patents/WO2010017035A2?cl=en10">Reference Source</a></span></li><li><a name=ref-213 class=n-a></a><span class=label>213. </span>&nbsp;<span class=citation><a name=d2476e6900 class=n-a></a>Genentech: Azaindole inhibitors of IAP. WO2010021934A2, 2010. <a target=xrefwindow id=d2476e6902 href="https://google.com/patents/WO2010021934A2?cl=zh">Reference Source</a></span></li><li><a name=ref-214 class=n-a></a><span class=label>214. </span>&nbsp;<span class=citation><a name=d2476e6911 class=n-a></a>Genentech: Inhibitors of IAP. US8835393B2, 2014. <a target=xrefwindow id=d2476e6913 href="https://www.google.ch/patents/US8835393">Reference Source</a></span></li><li><a name=ref-215 class=n-a></a><span class=label>215. </span>&nbsp;<span class=citation><a name=d2476e6922 class=n-a></a>Hennessy EJ, Adam A, Aquila BM, <i> et al.</i>: Discovery of a novel class of dimeric Smac mimetics as potent IAP antagonists resulting in a clinical candidate for the treatment of cancer (AZD5582). <i>J Med Chem.</i> 2013; <b>56</b>(24): 9897–919. <a target=xrefwindow id=d2476e6933 href="http://www.ncbi.nlm.nih.gov/pubmed/24320998">PubMed Abstract </a> | <a target=xrefwindow id=d2476e6936 href="http://dx.doi.org/10.1021/jm401075x">Publisher Full Text </a></span></li><li><a name=ref-216 class=n-a></a><span class=label>216. </span>&nbsp;<span class=citation><a name=d2476e6946 class=n-a></a>Hanmi Holdings: Imidazopyrazinone derivatives with apoptosis inducing activity on cells. WO2011090317A2, 2011. <a target=xrefwindow id=d2476e6948 href="http://www.google.com/patents/WO2011090317A2?cl=en">Reference Source</a></span></li><li><a name=ref-217 class=n-a></a><span class=label>217. </span>&nbsp;<span class=citation><a name=d2476e6957 class=n-a></a>Hanmi Holdings: Quinoline or quinazoline derivatives with apoptosis inducing activity on cells. WO2012030160A2, 2012. <a target=xrefwindow id=d2476e6959 href="http://www.google.com/patents/WO2012030160A2?cl=zh">Reference Source</a></span></li><li><a name=ref-218 class=n-a></a><span class=label>218. </span>&nbsp;<span class=citation><a name=d2476e6968 class=n-a></a>Boehringer Ingelheim International: 5-Alkynyl Pyridine. US20130225567A1, 2013. <a target=xrefwindow id=d2476e6970 href="http://www.google.com/patents/US20130225567">Reference Source</a></span></li><li><a name=ref-219 class=n-a></a><span class=label>219. </span>&nbsp;<span class=citation><a name=d2476e6979 class=n-a></a>Boehringer Ingelheim International: New 6-alkynyl pyridine. WO2015025019A1, 2015. <a target=xrefwindow id=d2476e6981 href="http://www.google.co.in/patents/WO2015025019A1?cl=ru">Reference Source</a></span></li><li><a name=ref-220 class=n-a></a><span class=label>220. </span>&nbsp;<span class=citation><a name=d2476e6990 class=n-a></a>Boehringer Ingelheim International: New bis-amido pyridines. WO2015025018A1, 2015. <a target=xrefwindow id=d2476e6992 href="https://google.com/patents/WO2015025018A1?cl=da">Reference Source</a></span></li><li><a name=ref-221 class=n-a></a><span class=label>221. </span>&nbsp;<span class=citation><a name=d2476e7001 class=n-a></a>Boehringer Ingelheim International: 6-alkynyl-pyridine derivatives. US20160039814A1, 2016. <a target=xrefwindow id=d2476e7003 href="http://www.google.com/patents/US20160039814">Reference Source</a></span></li><li><a name=ref-222 class=n-a></a><span class=label>222. </span>&nbsp;<span class=citation><a name=d2476e7013 class=n-a></a>Lee SH, Lee JY, Jung CL, <i> et al.</i>: A novel antagonist to the inhibitors of apoptosis (IAPs) potentiates cell death in EGFR-overexpressing non-small-cell lung cancer cells. <i>Cell Death Dis.</i> 2014; <b>5</b>: e1477. <a target=xrefwindow id=d2476e7024 href="http://www.ncbi.nlm.nih.gov/pubmed/25321484">PubMed Abstract </a> | <a target=xrefwindow id=d2476e7027 href="http://dx.doi.org/10.1038/cddis.2014.447">Publisher Full Text </a> | <a target=xrefwindow id=d2476e7031 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4649530">Free Full Text </a></span></li><li><a name=ref-223 class=n-a></a><span class=label>223. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/726544520"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d2476e7040 class=n-a></a>Li N, Feng L, Han HQ, <i> et al.</i>: A novel Smac mimetic APG-1387 demonstrates potent antitumor activity in nasopharyngeal carcinoma cells by inducing apoptosis. <i>Cancer Lett.</i> 2016; <b>381</b>(1): 14–22. <a target=xrefwindow id=d2476e7051 href="http://www.ncbi.nlm.nih.gov/pubmed/27424523">PubMed Abstract </a> | <a target=xrefwindow id=d2476e7054 href="http://dx.doi.org/10.1016/j.canlet.2016.07.008">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/726544520">F1000 Recommendation</a></span></li><li><a name=ref-224 class=n-a></a><span class=label>224. </span>&nbsp;<span class=citation><a name=d2476e7067 class=n-a></a>Manzoni L, Belvisi L, Bianchi A, <i> et al.</i>: Homo- and heterodimeric Smac mimetics/IAP inhibitors as <i>in vivo</i>-active pro-apoptotic agents. Part I: Synthesis. <i>Bioorg Med Chem.</i> 2012; <b>20</b>(22): 6687–708. <a target=xrefwindow id=d2476e7081 href="http://www.ncbi.nlm.nih.gov/pubmed/23036335">PubMed Abstract </a> | <a target=xrefwindow id=d2476e7085 href="http://dx.doi.org/10.1016/j.bmc.2012.09.020">Publisher Full Text </a></span></li><li><a name=ref-225 class=n-a></a><span class=label>225. </span>&nbsp;<span class=citation><a name=d2476e7094 class=n-a></a>Novartis: Dimeric iap inhibitors. WO2011104266A1, 2011. <a target=xrefwindow id=d2476e7096 href="https://google.com/patents/WO2011104266A1?cl=no">Reference Source</a></span></li><li><a name=ref-226 class=n-a></a><span class=label>226. </span>&nbsp;<span class=citation><a name=d2476e7105 class=n-a></a>Novartis: Dimeric iap inhibitors. WO2012080271A1, 2012. <a target=xrefwindow id=d2476e7107 href="http://www.google.co.in/patents/WO2012080271A1?cl=und">Reference Source</a></span></li><li><a name=ref-227 class=n-a></a><span class=label>227. </span>&nbsp;<span class=citation><a name=d2476e7116 class=n-a></a>Peng Y, Sun H, Nikolovska-Coleska Z, <i> et al.</i>: Potent, orally bioavailable diazabicyclic small-molecule mimetics of second mitochondria-derived activator of caspases. <i>J Med Chem.</i> 2008; <b>51</b>(24): 8158–62. <a target=xrefwindow id=d2476e7127 href="http://www.ncbi.nlm.nih.gov/pubmed/19049347">PubMed Abstract </a> | <a target=xrefwindow id=d2476e7130 href="http://dx.doi.org/10.1021/jm801254r">Publisher Full Text </a> | <a target=xrefwindow id=d2476e7134 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2679375">Free Full Text </a></span></li><li><a name=ref-228 class=n-a></a><span class=label>228. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/725621328"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d2476e7144 class=n-a></a>Perez HL, Chaudhry C, Emanuel SL, <i> et al.</i>: Discovery of potent heterodimeric antagonists of inhibitor of apoptosis proteins (IAPs) with sustained antitumor activity. <i>J Med Chem.</i> 2015; <b>58</b>(3): 1556–62. <a target=xrefwindow id=d2476e7155 href="http://www.ncbi.nlm.nih.gov/pubmed/25584393">PubMed Abstract </a> | <a target=xrefwindow id=d2476e7158 href="http://dx.doi.org/10.1021/jm501482t">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/725621328">F1000 Recommendation</a></span></li><li><a name=ref-229 class=n-a></a><span class=label>229. </span>&nbsp;<span class=citation><a name=d2476e7171 class=n-a></a>Allist Pharmaceuticals: Tetrapeptide analog, preparation method and application thereof. CN102050867A, 2011. <a target=xrefwindow id=d2476e7173 href="http://www.google.com/patents/CN102050867A?cl=en">Reference Source</a></span></li><li><a name=ref-230 class=n-a></a><span class=label>230. </span>&nbsp;<span class=citation><a name=d2476e7182 class=n-a></a>Joyant Pharmaceuticals: Dimeric smac mimetics. WO2011059763A2, 2011. <a target=xrefwindow id=d2476e7184 href="http://www.google.co.in/patents/WO2011059763A2?cl=ru">Reference Source</a></span></li><li><a name=ref-231 class=n-a></a><span class=label>231. </span>&nbsp;<span class=citation><a name=d2476e7193 class=n-a></a>Roche: Substituted hetero-azepinones. WO2014023708A1, 2014. <a target=xrefwindow id=d2476e7195 href="https://www.google.com/patents/WO2014023708A1?cl=en23">Reference Source</a></span></li><li><a name=ref-232 class=n-a></a><span class=label>232. </span>&nbsp;<span class=citation><a name=d2476e7204 class=n-a></a>Roche: Azaheterocycles as bir2 and/or bir3 inhibitors. WO2014026882A1, 2014. <a target=xrefwindow id=d2476e7206 href="https://www.google.com/patents/WO2014026882A1?cl=en22">Reference Source</a></span></li><li><a name=ref-233 class=n-a></a><span class=label>233. </span>&nbsp;<span class=citation><a name=d2476e7215 class=n-a></a>Roche: Azaindolines. WO2014056871A1, 2014. <a target=xrefwindow id=d2476e7217 href="https://www.google.co.in/patents/WO2014056871A1?cl=sk">Reference Source</a></span></li><li><a name=ref-234 class=n-a></a><span class=label>234. </span>&nbsp;<span class=citation><a name=d2476e7227 class=n-a></a>Roche: Dimeric compounds. WO2014090709A1, 2014. <a target=xrefwindow id=d2476e7229 href="http://www.google.com.na/patents/WO2014090709A1?cl=en">Reference Source</a></span></li><li><a name=ref-235 class=n-a></a><span class=label>235. </span>&nbsp;<span class=citation><a name=d2476e7238 class=n-a></a>Roche: Indolines. WO2014056755A1, 2014. <a target=xrefwindow id=d2476e7240 href="https://www.google.com/patents/WO2014056755A1?cl=en10">Reference Source</a></span></li><li><a name=ref-236 class=n-a></a><span class=label>236. </span>&nbsp;<span class=citation><a name=d2476e7249 class=n-a></a>Roche: Tetrahydro-benzodiazepinones. WO2015071393A1, 2015. <a target=xrefwindow id=d2476e7251 href="http://www.google.co.in/patents/WO2015071393A1?cl=und">Reference Source</a></span></li><li><a name=ref-237 class=n-a></a><span class=label>237. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/725479520"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d2476e7260 class=n-a></a>Seigal BA, Connors WH, Fraley A, <i> et al.</i>: The discovery of macrocyclic XIAP antagonists from a DNA-programmed chemistry library, and their optimization to give lead compounds with <i>in vivo</i> antitumor activity. <i>J Med Chem.</i> 2015; <b>58</b>(6): 2855–61. <a target=xrefwindow id=d2476e7274 href="http://www.ncbi.nlm.nih.gov/pubmed/25695766">PubMed Abstract </a> | <a target=xrefwindow id=d2476e7278 href="http://dx.doi.org/10.1021/jm501892g">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/725479520">F1000 Recommendation</a></span></li><li><a name=ref-238 class=n-a></a><span class=label>238. </span>&nbsp;<span class=citation><a name=d2476e7291 class=n-a></a>Seneci P, Bianchi A, Battaglia C, <i> et al.</i>: Rational design, synthesis and characterization of potent, non-peptidic Smac mimics/XIAP inhibitors as proapoptotic agents for cancer therapy. <i>Bioorg Med Chem.</i> 2009; <b>17</b>(16): 5834–56. <a target=xrefwindow id=d2476e7302 href="http://www.ncbi.nlm.nih.gov/pubmed/19620011">PubMed Abstract </a> | <a target=xrefwindow id=d2476e7305 href="http://dx.doi.org/10.1016/j.bmc.2009.07.009">Publisher Full Text </a></span></li><li><a name=ref-239 class=n-a></a><span class=label>239. </span>&nbsp;<span class=citation><a name=d2476e7314 class=n-a></a>Bristol-Myers Squibb: IAP antagonists. WO2014055461A1, 2014. <a target=xrefwindow id=d2476e7316 href="https://encrypted.google.com/patents/WO2014055461A1?cl=da">Reference Source</a></span></li><li><a name=ref-240 class=n-a></a><span class=label>240. </span>&nbsp;<span class=citation><a name=d2476e7326 class=n-a></a>Bristol-Myers Squibb: IAP antagonists. WO2015006524A1, 2015. <a target=xrefwindow id=d2476e7328 href="https://www.google.co.in/patents/WO2015006524A1?cl=ko">Reference Source</a></span></li><li><a name=ref-241 class=n-a></a><span class=label>241. </span>&nbsp;<span class=citation><a name=d2476e7337 class=n-a></a>Sun H, Nikolovska-Coleska Z, Lu J, <i> et al.</i>: Design, synthesis, and characterization of a potent, nonpeptide, cell-permeable, bivalent Smac mimetic that concurrently targets both the BIR2 and BIR3 domains in XIAP. <i>J Am Chem Soc.</i> 2007; <b>129</b>(49): 15279–94. <a target=xrefwindow id=d2476e7348 href="http://www.ncbi.nlm.nih.gov/pubmed/17999504">PubMed Abstract </a> | <a target=xrefwindow id=d2476e7351 href="http://dx.doi.org/10.1021/ja074725f">Publisher Full Text </a> | <a target=xrefwindow id=d2476e7355 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2553712">Free Full Text </a></span></li><li><a name=ref-242 class=n-a></a><span class=label>242. </span>&nbsp;<span class=citation><a name=d2476e7364 class=n-a></a>Takeda: Alanine derivatives as inhibitors of apoptosis proteins. WO2011016576A1, 2011. <a target=xrefwindow id=d2476e7366 href="http://www.google.co.in/patents/WO2011016576A1?cl=ko">Reference Source</a></span></li><li><a name=ref-243 class=n-a></a><span class=label>243. </span>&nbsp;<span class=citation><a name=d2476e7375 class=n-a></a>Takeda: Heterocyclic compound. JP2012176934A, 2012. </span></li><li><a name=ref-244 class=n-a></a><span class=label>244. </span>&nbsp;<span class=citation><a name=d2476e7384 class=n-a></a>Tetralogic: IAP inhibitors. WO2010033531A1, 2010. <a target=xrefwindow id=d2476e7386 href="http://www.google.co.in/patents/WO2010033531A1?cl=en">Reference Source</a></span></li><li><a name=ref-245 class=n-a></a><span class=label>245. </span>&nbsp;<span class=citation><a name=d2476e7395 class=n-a></a>Tetralogic: IAP inhibitors. WO2011068926A1, 2011. <a target=xrefwindow id=d2476e7397 href="https://www.google.com/patents/WO2011068926A1?cl=en17">Reference Source</a></span></li><li><a name=ref-246 class=n-a></a><span class=label>246. </span>&nbsp;<span class=citation><a name=d2476e7407 class=n-a></a>Aegera Therapeutics: Bir domain binding compounds. WO2007101347A1, 2007. <a target=xrefwindow id=d2476e7409 href="https://www.google.com/patents/WO2007101347A1?cl=enIt">Reference Source</a></span></li><li><a name=ref-247 class=n-a></a><span class=label>247. </span>&nbsp;<span class=citation><a name=d2476e7418 class=n-a></a>Aegera Therapeutics: IAP Bir domain binding compounds. WO2010031171A1, 2010. <a target=xrefwindow id=d2476e7420 href="https://www.google.com/patents/WO2010031171A1?cl=en&amp;dq=WO2010031171A1&amp;hl=en&amp;sa=X&amp;ved=0ahUKEwjMr772wrfTAhWHjZQKHdAjCD8Q6AEIIzAA">Reference Source</a></span></li><li><a name=ref-248 class=n-a></a><span class=label>248. </span>&nbsp;<span class=citation><a name=d2476e7429 class=n-a></a>Aegera Therapeutics: Functionalized pyrrolidines and use thereof as iap inhibitors. WO2010015090A1, 2010. <a target=xrefwindow id=d2476e7431 href="https://www.google.com/patents/WO2010015090A1?cl=un">Reference Source</a></span></li><li><a name=ref-249 class=n-a></a><span class=label>249. </span>&nbsp;<span class=citation><a name=d2476e7440 class=n-a></a>Avila Therapeutics: Ligand-directed covalent modification of protein. WO2011082285A1, 2011. <a target=xrefwindow id=d2476e7442 href="https://www.google.com/patents/WO2011082285A1?cl=es">Reference Source</a></span></li><li><a name=ref-250 class=n-a></a><span class=label>250. </span>&nbsp;<span class=citation><a name=d2476e7451 class=n-a></a>Aegera Therapeutics: IAP Bir domain binding compounds. US20120141496A1, 2012. <a target=xrefwindow id=d2476e7453 href="http://www.google.ch/patents/US20120141496">Reference Source</a></span></li><li><a name=ref-251 class=n-a></a><span class=label>251. </span>&nbsp;<span class=citation><a name=d2476e7462 class=n-a></a>Astex Therapeutics: Bicyclic heterocycle compounds and their uses in therapy. WO2014060767A1, 2014. <a target=xrefwindow id=d2476e7464 href="https://encrypted.google.com/patents/WO2014060767A1?cl=ja">Reference Source</a></span></li><li><a name=ref-252 class=n-a></a><span class=label>252. </span>&nbsp;<span class=citation><a name=d2476e7474 class=n-a></a>Astex Therapeutics: Bicyclic heterocycle compounds and their uses in therapy. WO2014060768A1, 2014. <a target=xrefwindow id=d2476e7476 href="https://www.google.com/patents/WO2014060768A1?cl=pt">Reference Source</a></span></li><li><a name=ref-253 class=n-a></a><span class=label>253. </span>&nbsp;<span class=citation><a name=d2476e7485 class=n-a></a>Astex Therapeutics: Bicyclic heterocycle compounds and their uses in therapy. WO2014060770A1, 2014. <a target=xrefwindow id=d2476e7487 href="https://www.google.com/patents/WO2014060770A1?cl=ar">Reference Source</a></span></li><li><a name=ref-254 class=n-a></a><span class=label>254. </span>&nbsp;<span class=citation><a name=d2476e7496 class=n-a></a>Rockefeller University: Mitochondrial targeted stimulators of apoptosis. US20130244325A1, 2013. <a target=xrefwindow id=d2476e7498 href="https://www.google.ch/patents/US20130244325">Reference Source</a></span></li><li><a name=ref-255 class=n-a></a><span class=label>255. </span>&nbsp;<span class=citation><a name=d2476e7507 class=n-a></a>Wong H, Gould SE, Budha N, <i> et al.</i>: Learning and confirming with preclinical studies: modeling and simulation in the discovery of GDC-0917, an inhibitor of apoptosis proteins antagonist. <i>Drug Metab Dispos.</i> 2013; <b>41</b>(12): 2104–13. <a target=xrefwindow id=d2476e7518 href="http://www.ncbi.nlm.nih.gov/pubmed/24041744">PubMed Abstract </a> | <a target=xrefwindow id=d2476e7521 href="http://dx.doi.org/10.1124/dmd.113.053926">Publisher Full Text </a></span></li><li><a name=ref-256 class=n-a></a><span class=label>256. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/725838291"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d2476e7530 class=n-a></a>Zhang Y, Seigal BA, Terrett NK, <i> et al.</i>: Dimeric Macrocyclic Antagonists of Inhibitor of Apoptosis Proteins for the Treatment of Cancer. <i>ACS Med Chem Lett.</i> 2015; <b>6</b>(7): 770–5. <a target=xrefwindow id=d2476e7541 href="http://www.ncbi.nlm.nih.gov/pubmed/26191364">PubMed Abstract </a> | <a target=xrefwindow id=d2476e7544 href="http://dx.doi.org/10.1021/acsmedchemlett.5b00091">Publisher Full Text </a> | <a target=xrefwindow id=d2476e7548 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4499820">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/725838291">F1000 Recommendation</a></span></li><li><a name=ref-257 class=n-a></a><span class=label>257. </span>&nbsp;<span class=citation><a name=d2476e7561 class=n-a></a>Flygare JA, Fairbrother WJ: Small-molecule pan-IAP antagonists: a patent review. <i>Expert Opin Ther Pat.</i> 2010; <b>20</b>(2): 251–67. <a target=xrefwindow id=d2476e7569 href="http://www.ncbi.nlm.nih.gov/pubmed/20100005">PubMed Abstract </a> | <a target=xrefwindow id=d2476e7572 href="http://dx.doi.org/10.1517/13543770903567077">Publisher Full Text </a></span></li><li><a name=ref-258 class=n-a></a><span class=label>258. </span>&nbsp;<span class=citation><a name=d2476e7582 class=n-a></a>Dubrez L, Berthelet J, Glorian V: IAP proteins as targets for drug development in oncology. <i>Onco Targets Ther.</i> 2013; <b>9</b>: 1285–304. <a target=xrefwindow id=d2476e7590 href="http://www.ncbi.nlm.nih.gov/pubmed/24092992">PubMed Abstract </a> | <a target=xrefwindow id=d2476e7593 href="http://dx.doi.org/10.2147/OTT.S33375">Publisher Full Text </a> | <a target=xrefwindow id=d2476e7596 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3787928">Free Full Text </a></span></li><li><a name=ref-259 class=n-a></a><span class=label>259. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/725295402"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d2476e7605 class=n-a></a>Silke J, Vaux DL: IAP gene deletion and conditional knockout models. <i>Semin Cell Dev Biol.</i> 2015; <b>39</b>: 97–105. <a target=xrefwindow id=d2476e7613 href="http://www.ncbi.nlm.nih.gov/pubmed/25545814">PubMed Abstract </a> | <a target=xrefwindow id=d2476e7616 href="http://dx.doi.org/10.1016/j.semcdb.2014.12.004">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/725295402">F1000 Recommendation</a></span></li><li><a name=ref-260 class=n-a></a><span class=label>260. </span>&nbsp;<span class=citation><a name=d2476e7629 class=n-a></a>Beug ST, LaCasse EC, Korneluk RG: Smac mimetics combined with innate immune stimuli create the perfect cytokine storm to kill tumor cells. <i>Oncoimmunology.</i> 2014; <b>3</b>: e28541. <a target=xrefwindow id=d2476e7637 href="http://www.ncbi.nlm.nih.gov/pubmed/25050221">PubMed Abstract </a> | <a target=xrefwindow id=d2476e7640 href="http://dx.doi.org/10.4161/onci.28541">Publisher Full Text </a> | <a target=xrefwindow id=d2476e7643 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4063156">Free Full Text </a></span></li><li><a name=ref-261 class=n-a></a><span class=label>261. </span>&nbsp;<span class=citation><a name=d2476e7652 class=n-a></a>Eckhardt I, Weigert A, Fulda S: Identification of IRF1 as critical dual regulator of Smac mimetic-induced apoptosis and inflammatory cytokine response. <i>Cell Death Dis.</i> 2014; <b>5</b>(12): e1562. <a target=xrefwindow id=d2476e7660 href="http://www.ncbi.nlm.nih.gov/pubmed/25501823">PubMed Abstract </a> | <a target=xrefwindow id=d2476e7663 href="http://dx.doi.org/10.1038/cddis.2014.498">Publisher Full Text </a> | <a target=xrefwindow id=d2476e7666 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4454156">Free Full Text </a></span></li><li><a name=ref-262 class=n-a></a><span class=label>262. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725693340"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d2476e7675 class=n-a></a>Janzen DM, Tiourin E, Salehi JA, <i> et al.</i>: An apoptosis-enhancing drug overcomes platinum resistance in a tumour-initiating subpopulation of ovarian cancer. <i>Nat Commun.</i> 2015; <b>6</b>: 7956. <a target=xrefwindow id=d2476e7686 href="http://www.ncbi.nlm.nih.gov/pubmed/26234182">PubMed Abstract </a> | <a target=xrefwindow id=d2476e7689 href="http://dx.doi.org/10.1038/ncomms8956">Publisher Full Text </a> | <a target=xrefwindow id=d2476e7693 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4532886">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725693340">F1000 Recommendation</a></span></li><li><a name=ref-263 class=n-a></a><span class=label>263. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726845620"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d2476e7706 class=n-a></a>Yang C, Wang H, Zhang B, <i> et al.</i>: LCL161 increases paclitaxel-induced apoptosis by degrading cIAP1 and cIAP2 in NSCLC. <i>J Exp Clin Cancer Res.</i> 2016; <b>35</b>(1): 158. <a target=xrefwindow id=d2476e7717 href="http://www.ncbi.nlm.nih.gov/pubmed/27737687">PubMed Abstract </a> | <a target=xrefwindow id=d2476e7720 href="http://dx.doi.org/10.1186/s13046-016-0435-7">Publisher Full Text </a> | <a target=xrefwindow id=d2476e7724 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5062899">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726845620">F1000 Recommendation</a></span></li><li><a name=ref-264 class=n-a></a><span class=label>264. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725580624"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d2476e7738 class=n-a></a>Matzinger O, Viertl D, Tsoutsou P, <i> et al.</i>: The radiosensitizing activity of the SMAC-mimetic, Debio 1143, is TNFα-mediated in head and neck squamous cell carcinoma. <i>Radiother Oncol.</i> 2015; <b>116</b>(3): 495–503. <a target=xrefwindow id=d2476e7749 href="http://www.ncbi.nlm.nih.gov/pubmed/26096848">PubMed Abstract </a> | <a target=xrefwindow id=d2476e7752 href="http://dx.doi.org/10.1016/j.radonc.2015.05.017">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725580624">F1000 Recommendation</a></span></li><li><a name=ref-265 class=n-a></a><span class=label>265. </span>&nbsp;<span class=citation><a name=d2476e7765 class=n-a></a>TetraLogic Pharmaceuticals: Study of Birinapant in Combination With Conatumumab in Subjects With Relapsed Ovarian Cancer. In ClinicalTrials.Gov. [cited Dec, 2016], 2016. <a target=xrefwindow id=d2476e7767 href="https://clinicaltrials.gov/ct2/show/NCT01940172">Reference Source</a></span></li><li><a name=ref-266 class=n-a></a><span class=label>266. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725767047"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d2476e7776 class=n-a></a>Amaravadi RK, Schilder RJ, Martin LP, <i> et al.</i>: A Phase I Study of the SMAC-Mimetic Birinapant in Adults with Refractory Solid Tumors or Lymphoma. <i>Mol Cancer Ther.</i> 2015; <b>14</b>(11): 2569–75. <a target=xrefwindow id=d2476e7787 href="http://www.ncbi.nlm.nih.gov/pubmed/26333381">PubMed Abstract </a> | <a target=xrefwindow id=d2476e7790 href="http://dx.doi.org/10.1158/1535-7163.MCT-15-0475">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725767047">F1000 Recommendation</a></span></li><li><a name=ref-267 class=n-a></a><span class=label>267. </span>&nbsp;<span class=citation><a name=d2476e7803 class=n-a></a>Noonan AM, Bunch KP, Chen J, <i> et al.</i>: Pharmacodynamic markers and clinical results from the phase 2 study of the SMAC mimetic birinapant in women with relapsed platinum-resistant or -refractory epithelial ovarian cancer. <i>Cancer.</i> 2016; <b>122</b>(4): 588–97. <a target=xrefwindow id=d2476e7814 href="http://www.ncbi.nlm.nih.gov/pubmed/26566079">PubMed Abstract </a> | <a target=xrefwindow id=d2476e7817 href="http://dx.doi.org/10.1002/cncr.29783">Publisher Full Text </a> | <a target=xrefwindow id=d2476e7821 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4742409">Free Full Text </a></span></li><li><a name=ref-268 class=n-a></a><span class=label>268. </span>&nbsp;<span class=citation><a name=d2476e7830 class=n-a></a>Senzer NN, LoRusso P, Martin LP, <i> et al.</i>: Phase II Clinical Activity and Tolerability of the SMAC-Mimetic Birinapant (TL32711) plus Irinotecan in Irinotecan-Relapsed/Refractory Metastatic Colorectal Cancer. In ASCO 2013, ASCO: Chicago, IL, 2013; <b>31</b>. : 3621. <a target=xrefwindow id=d2476e7838 href="http://meetinglibrary.asco.org/content/115753-132">Reference Source</a></span></li><li><a name=ref-269 class=n-a></a><span class=label>269. </span>&nbsp;<span class=citation><a name=d2476e7847 class=n-a></a>Grothey A, Van Cutsem E, Sobrero A, <i> et al.</i>: Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. <i>Lancet.</i> 2013; <b>381</b>(9863): 303–12. <a target=xrefwindow id=d2476e7858 href="http://www.ncbi.nlm.nih.gov/pubmed/23177514">PubMed Abstract </a> | <a target=xrefwindow id=d2476e7861 href="http://dx.doi.org/10.1016/S0140-6736(12)61900-X">Publisher Full Text </a></span></li><li><a name=ref-270 class=n-a></a><span class=label>270. </span>&nbsp;<span class=citation><a name=d2476e7871 class=n-a></a>BusinessWire: Medivir Strengthens Its Clinical Pipeline by Entering into Agreement to Acquire a Portfolio of Clinical Stage Oncology Programs. (accessed 12/21/2016). <a target=xrefwindow id=d2476e7873 href="http://www.businesswire.com/news/home/20161102006786/en/Medivir-Strengthens-Clinical-Pipeline-Entering-Agreement-Acquire">Reference Source</a></span></li><li><a name=ref-271 class=n-a></a><span class=label>271. </span>&nbsp;<span class=citation><a name=d2476e7882 class=n-a></a>Infante JR, Dees EC, Olszanski AJ, <i> et al.</i>: Phase I dose-escalation study of LCL161, an oral inhibitor of apoptosis proteins inhibitor, in patients with advanced solid tumors. <i>J Clin Oncol.</i> 2014; <b>32</b>(28): 3103–10. <a target=xrefwindow id=d2476e7893 href="http://www.ncbi.nlm.nih.gov/pubmed/25113756">PubMed Abstract </a> | <a target=xrefwindow id=d2476e7896 href="http://dx.doi.org/10.1200/JCO.2013.52.3993">Publisher Full Text </a></span></li><li><a name=ref-272 class=n-a></a><span class=label>272. </span>&nbsp;<span class=citation><a name=d2476e7905 class=n-a></a>West AC, Martin BP, Andrews DA, <i> et al.</i>: The SMAC mimetic, LCL-161, reduces survival in aggressive MYC-driven lymphoma while promoting susceptibility to endotoxic shock. <i>Oncogenesis.</i> 2016; <b>5</b>: e216. <a target=xrefwindow id=d2476e7916 href="http://www.ncbi.nlm.nih.gov/pubmed/27043662">PubMed Abstract </a> | <a target=xrefwindow id=d2476e7919 href="http://dx.doi.org/10.1038/oncsis.2016.26">Publisher Full Text </a> | <a target=xrefwindow id=d2476e7923 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4848837">Free Full Text </a></span></li><li><a name=ref-273 class=n-a></a><span class=label>273. </span>&nbsp;<span class=citation><a name=d2476e7932 class=n-a></a>Novartis Pharmaceuticals: A Randomized, Phase 2, Neoadjuvant Study of Weekly Paclitaxel With or Without LCL161 in Patients With Triple Negative Breast Cancer. In ClinicalTrials.Gov. [cited Dec, 2016], 2016. <a target=xrefwindow id=d2476e7934 href="https://clinicaltrials.gov/ct2/show/NCT01617668">Reference Source</a></span></li><li><a name=ref-274 class=n-a></a><span class=label>274. </span>&nbsp;<span class=citation><a name=d2476e7943 class=n-a></a>Parton M, Bardia A, Kummel S, <i> et al.</i>: A phase II, open-label, neoadjuvant, randomized study of LCL161 with paclitaxel in patients with triple-negative breast cancer (TNBC). In ASCO 2015, ASCO: Chicago, IL, 2015; <b>33</b>: 128. <a target=xrefwindow id=d2476e7951 href="http://meetinglibrary.asco.org/content/144033-156">Reference Source</a></span></li><li><a name=ref-275 class=n-a></a><span class=label>275. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/726972000"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d2476e7960 class=n-a></a>Chesi M, Mirza NN, Garbitt VM, <i> et al.</i>: IAP antagonists induce anti-tumor immunity in multiple myeloma. <i>Nat Med.</i> 2016; <b>22</b>(12): 1411–20. <a target=xrefwindow id=d2476e7971 href="http://www.ncbi.nlm.nih.gov/pubmed/27841872">PubMed Abstract </a> | <a target=xrefwindow id=d2476e7974 href="http://dx.doi.org/10.1038/nm.4229">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/726972000">F1000 Recommendation</a></span></li><li><a name=ref-276 class=n-a></a><span class=label>276. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/727307641"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d2476e7988 class=n-a></a>Beug ST, Beauregard CE, Healy C, <i> et al.</i>: Smac mimetics synergize with immune checkpoint inhibitors to promote tumour immunity against glioblastoma. <i>Nat Commun.</i> 2017; <b>8</b>: 14278. <a target=xrefwindow id=d2476e7999 href="http://www.ncbi.nlm.nih.gov/pubmed/28198370">PubMed Abstract </a> | <a target=xrefwindow id=d2476e8002 href="http://dx.doi.org/10.1038/ncomms14278">Publisher Full Text </a> | <a target=xrefwindow id=d2476e8006 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5330852">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/727307641">F1000 Recommendation</a></span></li><li><a name=ref-277 class=n-a></a><span class=label>277. </span>&nbsp;<span class=citation><a name=d2476e8019 class=n-a></a>Hurwitz H, Pitot HC, Smith DC, <i> et al.</i>: First-in-human, pharmacokinetic (PK), and pharmacodynamics (PD) phase I study of Debio1143 (AT-406) in patients with advanced cancer: Final results. In ASCO 2014, ASCO: Chicago, IL, 2014; <b>32</b>: 2532. <a target=xrefwindow id=d2476e8027 href="http://meetinglibrary.asco.org/content/126727-144">Reference Source</a></span></li><li><a name=ref-278 class=n-a></a><span class=label>278. </span>&nbsp;<span class=citation><a name=d2476e8036 class=n-a></a>Thompson N, Ahn M, Chessari G, <i> et al.</i>: Characterization of a Potent XIAP and cIAP1 Dual Antagonist in Models of Melanoma and Leukemia. In 24th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, AACR: Dublin, Ireland, 2012. </span></li><li><a name=ref-279 class=n-a></a><span class=label>279. </span>&nbsp;<span class=citation><a name=d2476e8048 class=n-a></a>Welsh K, Milutinovic S, Ardecky RJ, <i> et al.</i>: Characterization of Potent SMAC Mimetics that Sensitize Cancer Cells to TNF Family-Induced Apoptosis. <i>PLoS One.</i> 2016; <b>11</b>(9): e0161952. <a target=xrefwindow id=d2476e8059 href="http://www.ncbi.nlm.nih.gov/pubmed/27617834">PubMed Abstract </a> | <a target=xrefwindow id=d2476e8062 href="http://dx.doi.org/10.1371/journal.pone.0161952">Publisher Full Text </a> | <a target=xrefwindow id=d2476e8066 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5019375">Free Full Text </a></span></li><li><a name=ref-280 class=n-a></a><span class=label>280. </span>&nbsp;<span class=citation><a name=d2476e8075 class=n-a></a>González-López M, Welsh K, Finlay D, <i> et al.</i>: Design, synthesis and evaluation of monovalent Smac mimetics that bind to the BIR2 domain of the anti-apoptotic protein XIAP. <i>Bioorg Med Chem Lett.</i> 2011; <b>21</b>(14): 4332–6. <a target=xrefwindow id=d2476e8086 href="http://www.ncbi.nlm.nih.gov/pubmed/21680182">PubMed Abstract </a> | <a target=xrefwindow id=d2476e8089 href="http://dx.doi.org/10.1016/j.bmcl.2011.05.049">Publisher Full Text </a> | <a target=xrefwindow id=d2476e8093 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3440873">Free Full Text </a></span></li><li><a name=ref-281 class=n-a></a><span class=label>281. </span>&nbsp;<span class=citation><a name=d2476e8102 class=n-a></a>Lu J, McEachern D, Sun H, <i> et al.</i>: Therapeutic potential and molecular mechanism of a novel, potent, nonpeptide, Smac mimetic SM-164 in combination with TRAIL for cancer treatment. <i>Mol Cancer Ther.</i> 2011; <b>10</b>(5): 902–14. <a target=xrefwindow id=d2476e8113 href="http://www.ncbi.nlm.nih.gov/pubmed/21372226">PubMed Abstract </a> | <a target=xrefwindow id=d2476e8116 href="http://dx.doi.org/ 10.1158/1535-7163.MCT-10-0864">Publisher Full Text </a> | <a target=xrefwindow id=d2476e8120 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3091962">Free Full Text </a></span></li><li><a name=ref-282 class=n-a></a><span class=label>282. </span>&nbsp;<span class=citation><a name=d2476e8130 class=n-a></a>Metwalli AR, Khanbolooki S, Jinesh G, <i> et al.</i>: Smac mimetic reverses resistance to TRAIL and chemotherapy in human urothelial cancer cells. <i>Cancer Biol Ther.</i> 2010; <b>10</b>(9): 885–92. <a target=xrefwindow id=d2476e8141 href="http://www.ncbi.nlm.nih.gov/pubmed/20814238">PubMed Abstract </a> | <a target=xrefwindow id=d2476e8144 href="http://dx.doi.org/10.4161/cbt.10.9.13237">Publisher Full Text </a> | <a target=xrefwindow id=d2476e8148 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3230293">Free Full Text </a></span></li><li><a name=ref-283 class=n-a></a><span class=label>283. </span>&nbsp;<span class=citation><a name=d2476e8157 class=n-a></a>Lecis D, Drago C, Manzoni L, <i> et al.</i>: Novel SMAC-mimetics synergistically stimulate melanoma cell death in combination with TRAIL and Bortezomib. <i>Br J Cancer.</i> 2010; <b>102</b>(12): 1707–16. <a target=xrefwindow id=d2476e8168 href="http://www.ncbi.nlm.nih.gov/pubmed/20461078">PubMed Abstract </a> | <a target=xrefwindow id=d2476e8171 href="http://dx.doi.org/10.1038/sj.bjc.6605687">Publisher Full Text </a> | <a target=xrefwindow id=d2476e8175 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2883696">Free Full Text </a></span></li><li><a name=ref-284 class=n-a></a><span class=label>284. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725437503"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d2476e8184 class=n-a></a>Cristofanon S, Abhari BA, Krueger M, <i> et al.</i>: Identification of RIP1 as a critical mediator of Smac mimetic-mediated sensitization of glioblastoma cells for Drozitumab-induced apoptosis. <i>Cell Death Dis.</i> 2015; <b>6</b>(4): e1724. <a target=xrefwindow id=d2476e8195 href="http://www.ncbi.nlm.nih.gov/pubmed/25880091">PubMed Abstract </a> | <a target=xrefwindow id=d2476e8198 href="http://dx.doi.org/10.1038/cddis.2014.592">Publisher Full Text </a> | <a target=xrefwindow id=d2476e8202 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4650534">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725437503">F1000 Recommendation</a></span></li><li><a name=ref-285 class=n-a></a><span class=label>285. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/718442425"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d2476e8215 class=n-a></a>Tuthill MH, Montinaro A, Zinngrebe J, <i> et al.</i>: TRAIL-R2-specific antibodies and recombinant TRAIL can synergise to kill cancer cells. <i>Oncogene.</i> 2015; <b>34</b>(16): 2138–44. <a target=xrefwindow id=d2476e8226 href="http://www.ncbi.nlm.nih.gov/pubmed/24909167">PubMed Abstract </a> | <a target=xrefwindow id=d2476e8229 href="http://dx.doi.org/10.1038/onc.2014.156">Publisher Full Text </a> | <a target=xrefwindow id=d2476e8233 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4240732">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/718442425">F1000 Recommendation</a></span></li><li><a name=ref-286 class=n-a></a><span class=label>286. </span>&nbsp;<span class=citation><a name=d2476e8246 class=n-a></a>Basit F, Humphreys R, Fulda S: RIP1 protein-dependent assembly of a cytosolic cell death complex is required for inhibitor of apoptosis (IAP) inhibitor-mediated sensitization to lexatumumab-induced apoptosis. <i>J Biol Chem.</i> 2012; <b>287</b>(46): 38767–77. <a target=xrefwindow id=d2476e8254 href="http://www.ncbi.nlm.nih.gov/pubmed/22927431">PubMed Abstract </a> | <a target=xrefwindow id=d2476e8257 href="http://dx.doi.org/10.1074/jbc.M112.398966">Publisher Full Text </a> | <a target=xrefwindow id=d2476e8260 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3493919">Free Full Text </a></span></li><li><a name=ref-287 class=n-a></a><span class=label>287. </span>&nbsp;<span class=citation><a name=d2476e8269 class=n-a></a>Amm HM, Zhou T, Steg AD, <i> et al.</i>: Mechanisms of drug sensitization to TRA-8, an agonistic death receptor 5 antibody, involve modulation of the intrinsic apoptotic pathway in human breast cancer cells. <i>Mol Cancer Res.</i> 2011; <b>9</b>(4): 403–17. <a target=xrefwindow id=d2476e8280 href="http://www.ncbi.nlm.nih.gov/pubmed/21357440">PubMed Abstract </a> | <a target=xrefwindow id=d2476e8283 href="http://dx.doi.org/10.1158/1541-7786.MCR-10-0133">Publisher Full Text </a> | <a target=xrefwindow id=d2476e8287 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3086592">Free Full Text </a></span></li><li><a name=ref-288 class=n-a></a><span class=label>288. </span>&nbsp;<span class=citation><a name=d2476e8297 class=n-a></a>Varfolomeev E, Alicke B, Elliott JM, <i> et al.</i>: X chromosome-linked inhibitor of apoptosis regulates cell death induction by proapoptotic receptor agonists. <i>J Biol Chem.</i> 2009; <b>284</b>(50): 34553–60. <a target=xrefwindow id=d2476e8308 href="http://www.ncbi.nlm.nih.gov/pubmed/19854829">PubMed Abstract </a> | <a target=xrefwindow id=d2476e8311 href="http://dx.doi.org/10.1074/jbc.M109.040139">Publisher Full Text </a> | <a target=xrefwindow id=d2476e8315 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2787317">Free Full Text </a></span></li><li><a name=ref-289 class=n-a></a><span class=label>289. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/718252429"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d2476e8324 class=n-a></a>Beug ST, Tang VA, LaCasse EC, <i> et al.</i>: Smac mimetics and innate immune stimuli synergize to promote tumor death. <i>Nat Biotechnol.</i> 2014; <b>32</b>(2): 182–90. <a target=xrefwindow id=d2476e8335 href="http://www.ncbi.nlm.nih.gov/pubmed/24463573">PubMed Abstract </a> | <a target=xrefwindow id=d2476e8338 href="http://dx.doi.org/10.1038/nbt.2806">Publisher Full Text </a> | <a target=xrefwindow id=d2476e8342 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5030098">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/718252429">F1000 Recommendation</a></span></li><li><a name=ref-290 class=n-a></a><span class=label>290. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727107848"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d2476e8355 class=n-a></a>Dobson CC, Naing T, Beug ST, <i> et al.</i>: Oncolytic virus synergizes with Smac mimetic compounds to induce rhabdomyosarcoma cell death in a syngeneic murine model. <i>Oncotarget.</i> 2017; <b>8</b>(2): 3495–508. <a target=xrefwindow id=d2476e8366 href="http://www.ncbi.nlm.nih.gov/pubmed/27966453">PubMed Abstract </a> | <a target=xrefwindow id=d2476e8369 href="http://dx.doi.org/10.18632/oncotarget.13849">Publisher Full Text </a> | <a target=xrefwindow id=d2476e8373 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5356898">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727107848">F1000 Recommendation</a></span></li><li><a name=ref-291 class=n-a></a><span class=label>291. </span>&nbsp;<span class=citation><a name=d2476e8386 class=n-a></a>MacKenzie A, LaCasse E: Inhibition of IAP's protection by <i>Diablo/Smac</i>: new therapeutic opportunities? <i>Cell Death Differ.</i> 2000; <b>7</b>(10): 866–7. <a target=xrefwindow id=d2476e8397 href="http://www.ncbi.nlm.nih.gov/pubmed/11279531">PubMed Abstract </a> | <a target=xrefwindow id=d2476e8400 href="http://dx.doi.org/10.1038/sj.cdd.4400747">Publisher Full Text </a></span></li></ul></div></div></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 27 Apr 2017</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/6-587&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/6-587&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> <div class="f1r-article-mobile margin-bottom-30"> <div class=contracted-details> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> NCI-Designated Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, 10901 North Torrey Pines Road, La Jolla, CA, 92037, USA<br/> <p> </p> </div> </div> <div class=contracted-details> <a href="#" class=section-title>Article Versions (1)</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> <div> <a href="https://f1000research.com/articles/6-587/v1" title="Open version 1 of this article." class="" gahelper=1>version 1</a> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div> Published: 27 Apr 2017, 6:587 </div> <div class=""><a href="https://doi.org/10.12688/f1000research.10625.1">https://doi.org/10.12688/f1000research.10625.1</a></div> </div> </div> <div class=contracted-details> <a href="#" class=section-title> <span class="f1r-icon icon-100_open_access"></span> Copyright </a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> © 2017 Finlay D <em>et al</em>. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Data associated with the article are available under the terms of the <a href="http://creativecommons.org/publicdomain/zero/1.0/" target=_blank data-test-id=box-data-licence-link>Creative Commons Zero "No rights reserved" data waiver</a> (CC0 1.0 Public domain dedication). </div> </div> <div class="padding-top-30 research-layout"> <div class=article-toolbox-wrapper-mobile> <div class=article-tools-icon-mobile data-section=download> <span class="f1r-icon icon-76_download_file white"></span> </div> <div class="article-tools-icon-mobile mobile-metrics article-metrics-wrapper metrics-icon-wrapper" data-section=metrics data-version-id=11449 data-id=10625 data-downloads="" data-views="" data-scholar="10.12688/f1000research.10625.1" data-recommended="" data-f1r-ga-helper="Article Page Metrics (Mobile)"> <span class="f1r-icon icon-89_metrics white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=cite> <span class="f1r-icon icon-82_quote white"></span> </div> <div class="article-tools-icon-mobile " data-section=track> <span class="f1r-icon icon-90_track white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=share> <span class="f1r-icon icon-34_share white"></span> </div> <span class=article-toolbox-stretch></span> </div> <div class=article-toolbox-content-mobile> <div class="toolbox-section download"> <div class=toolbox-section-heading>Download</div> <div class=toolbox-section-content> <a href="https://f1000research.com/articles/6-587/v1/pdf?article_uuid=15b6d791-fba4-4317-b6a1-e57346a94ca1" title="Download PDF" class="no-decoration pdf-download-helper"> <span class="f1r-icon icon-102_download_pdf toolbox-section-icon"></span> </a> <div class=toolbox-section-option-divider>&nbsp;</div> <a id=mobile-download-xml class=no-decoration href="#" title="Download XML"> <span class="f1r-icon icon-103_download_xml toolbox-section-icon"></span> </a> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>Export To</div> <div class=toolbox-section-content> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=WORKSPACE>Sciwheel</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=BIBTEX>Bibtex</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=ENDNOTE>EndNote</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=PROCITE>ProCite</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=REF_MANAGER>Ref. Manager (RIS)</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=SENTE>Sente</button> </div> </div> <div class="toolbox-section metrics"> <div class="toolbox-section-heading no-top-border">metrics</div> <div class="toolbox-section-divider toolbox-section-divider--no-height"></div> <div class=article-metrics-pageinfo> <div class=c-article-metrics-table> <table class=c-article-metrics-table__table> <thead> <tr> <th></th> <th><span class=c-article-metrics-table__heading>Views</span></th> <th><span class=c-article-metrics-table__heading>Downloads</span></th> </tr> </thead> <tbody> <tr> <th class=c-article-metrics-table__row-heading><span class="c-article-metrics-table__platform u-platform--" data-test-id=metrics_platform_name_mob>F1000Research</span></th> <td class="c-article-metrics-table__value js-article-views-count" data-test-id=metrics_platform_views_mob>-</td> <td class="c-article-metrics-table__value js-article-downloads-count" data-test-id=metrics_platform_downloads_mob>-</td> </tr> <tr> <th class=c-article-metrics-table__row-heading> <span class="u-ib u-middle c-article-metrics-table__pmc" data-test-id=metrics_pmc_name_mob>PubMed Central</span> <div class="c-block-tip c-block-tip--centered c-article-metrics-table__tooltip c-block-tip--md-padding c-block-tip--small-arrow u-ib u-middle"> <button type=button class="u-black--medium u-black--high@hover u-ib u-middle c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content>Data from PMC are received and updated monthly.</div> </div> </th> <td class="c-article-metrics-table__value js-pmc-views-count" data-test-id=metrics_pmc_views_mob>-</td> <td class="c-article-metrics-table__value js-pmc-downloads-count" data-test-id=metrics_pmc_downloads_mob>-</td> </tr> </tbody> </table> </div> </div> <span class=metrics-citations-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-heading u-mb--1">Citations</div> <div> <div class=toolbox-section-colsplit> <div class=citations-scopus-logo> <a href="" target=_blank class="is-hidden metrics-citation-icon" title="View full citation details at www.scopus.com"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count scopus"> <a href='' class='scopus-citation-link is-hidden' target=_blank title='View full citation details at www.scopus.com'>0</a> </div> </div> <div class=toolbox-section-colsplit> <div class="citations-pubmed-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon f1000research" title="View full citation details"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count pubmed"> <a href='' class='pubmed-citation-link is-hidden' target=_blank title='View full citation details'>0</a> </div> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <div class="citations-scholar-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon google-scholar f1000research" title="View full citation details" data-scholar="10.12688/f1000research.10625.1"><i class="material-icons scopus-icon">open_in_new</i></a> </div> </div> </div> </span> <span class=metrics-details-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-content altmetric-section"> <div class=altmetrics-image></div> <div class=altmetrics-more-link> <a href="" target=_blank class=f1r-standard-link>SEE MORE DETAILS</a> </div> <div class=altmetric-mobile-column-counts></div> <div class=altmetric-mobile-column-readers></div> <div class=toolbox-section-divider></div> </div> </span> </div> <div class="toolbox-section cite"> <div class="toolbox-section-heading no-top-border">CITE</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>how to cite this article</div> <div id=citation-copy-mobile class="toolbox-section-content text-content heading9 small" data-test-id=mob_copy-citation_text> Finlay D, Teriete P, Vamos M <em>et al.</em> Inducing death in tumor cells: roles of the inhibitor of apoptosis proteins [version 1; peer review: 3 approved] <i>F1000Research</i> 2017, <b>6</b>(F1000 Faculty Rev):587 (<a href="https://doi.org/10.12688/f1000research.10625.1" target=_blank>https://doi.org/10.12688/f1000research.10625.1</a>) </div> <div class=toolbox-section-divider></div> <div class="toolbox-section-content text-content heading9 small"> NOTE: <em>it is important to ensure the information in <b>square brackets after the title</b> is included in all citations of this article.</em> </div> <div class=toolbox-section-content> <button class="primary orange extra-padding copy-cite-article-mobile js-clipboard" data-clipboard-target="#citation-copy-mobile" title="Copy the current citation details." data-test-id=mob_copy-citation_button-mob>COPY CITATION DETAILS</button> </div> </div> <div class="toolbox-section track"> <div class="toolbox-section-heading no-top-border">track</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>receive updates on this article</div> <div class="toolbox-section-content padding-left-20 padding-right-20 heading9 small"> Track an article to receive email alerts on any updates to this article. </div> <div class=toolbox-section-content> <a data-article-id=10625 id=mobile-track-article-signin-10625 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/10625?target=/articles/6-587"> <button class="primary orange extra-padding"> TRACK THIS ARTICLE </button> </a> </div> </div> <div class="toolbox-section share"> <div class="toolbox-section-heading no-top-border">Share</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <a target=_blank class="f1r-shares-icon-square f1r-shares-email" title="Email this article"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-twitter" title="Share on Twitter"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-facebook" title="Share on Facebook"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-linkedin" title="Share on LinkedIn"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-reddit" title="Share on Reddit"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-mendelay" title="Share on Mendeley"></a> <div class="email-article-wrapper email-article-version-container"> <div class=toolbox-section-divider></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form-mobile research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=11449 /> <input name=articleId type=hidden value=10625 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> </div> </div> </div> <a name=article-reports></a> <div id=article-reports class="u-mt--3 reports-comments no-divider"> <div class="current-referee-status current-referee-status--faculty "> <h2 class=main-title id=current-referee-status> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-85_peer_review size30"></span> </span> Open Peer Review <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> <a name=current-referee-status></a> <div class=current-referee-status__content name=add-new-report-comment id=add-new-report-comment> Current Reviewer Status: <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile"> <div class=mobile-ref-status-help> Key to Reviewer Statuses <span class=referee-status-pointer></span> <span class="view-control float-right">VIEW</span> <span class="view-control float-right is-hidden">HIDE</span> <div class=mobile-ref-status-help-content> <div class="cf margin-top"> <span class="f1r-icon icon-86_approved status-green smaller float-left margin-bottom-40 margin-right" title=Approved></span> <span class=title>Approved</span>The paper is scientifically sound in its current form and only minor, if any, improvements are suggested </div> <div class="cf margin-top"> <span class="f1r-icon icon-87_approved_reservations status-green smaller float-left margin-bottom-40 margin-right" title="Approved with Reservations"></span> <span class=title>Approved with reservations</span> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </div> <div class="cf margin-top"> <span class="f1r-icon icon-88_not_approved status-red small float-left margin-bottom-30 margin-right" title="Not Approved"></span> <span class=title>Not approved</span>Fundamental flaws in the paper seriously undermine the findings and conclusions </div> </div> </div> </span> <div class=editorial-note> <h5 class=editorial-note__title>Editorial Note on the Review Process</h5> <p class=editorial-note__text><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home">Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> </div> <div class=approved-referee> <h4 class=approved-referee__title>Reviewers who approved this article</h4> <ol class=approved-referee__list> <li class="approved-referee__list-item "> <span class=approved-referee__co-referee> <strong>Craig M Walsh</strong>, University of California, Irvine, USA </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> <li class="approved-referee__list-item margin-top-20"> <span class=approved-referee__co-referee> <strong>Domagoj Vucic</strong>, Department of Early Discovery Biochemistry, Genentech, South San Francisco, USA </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> <li class="approved-referee__list-item margin-top-20"> <span class=approved-referee__co-referee> <strong>Robert G Korneluk</strong>, Apoptosis Research Centre, Children’s Hospital of Eastern Ontario Research Institute, Canada </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> <span class=approved-referee__co-referee> <strong>Eric C LaCasse</strong>, Apoptosis Research Centre, Children’s Hospital of Eastern Ontario Research Institute, Canada </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> <span class=approved-referee__co-referee> <strong>Shawn T Beug</strong>, Apoptosis Research Centre, Children’s Hospital of Eastern Ontario Research Institute, Canada </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> </ol> </div> </div> </div> </div> <div class="f1r-article-mobile research-layout"> <div class="mobile-sections-divider before-comments"></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 27 Apr 2017</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/6-587&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/6-587&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> </div> </div> <div id=article_main-column class="p-article__sidebar o-layout__item u-1/3 not-expanded js-article-sidebar"> <div class="o-tab p-article__column-toggle-container"> <button class="c-tab c-tab--left js-column-toggle p-article__column-toggle not-expanded " type=button data-target-main=article_main-column data-target-secondary=article_secondary-column><i class="c-tab__icon material-icons u-hide@expanded">keyboard_arrow_left</i><i class="c-tab__icon material-icons u-show@expanded">keyboard_arrow_right</i></button> </div> <div class=p-article__sidebar-content> <div class="p-article__sidebar-scroller js-article-sidebar-scroller"> <section class="p-article__sidebar-view js-article-sidebar-view js-article-sidebar-main u-pt u-pb--8" data-view=peer-review> <div class="o-layout o-layout--flush"> <div class="o-layout__item u-pl"> <h3 class="u-mt--0 u-mb--2 t-h3 u-weight--md u-pl" data-test-id=article_sidebar_heading>Open Peer Review</h3> </div> <div class=o-layout__item> <section class=""> <div class="p-article__sidebar-highlight u-mb--2 u-pr--1"> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md u-mr--1/2">Reviewer Status</h4> <div class="c-referee-status__icons u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=22150-21918></i> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=22153-21919></i> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=22149-21917></i> </div> </div> <div class="o-actions__secondary _mdl-layout"> <div class="c-block-tip p-article__sidebar-tooltip c-block-tip--below c-block-tip--small-arrow c-block-tip--sm-padding"> <button type=button class="c-button c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content> <p class="t-body u-mt--0 u-mb--0"><em class=u-weight--md>Alongside their report, reviewers assign a status to the article:</em></p> <dl class=c-definitions> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved</span></dt> <dd class="c-definitions__description t-caption">The paper is scientifically sound in its current form and only minor, if any, improvements are suggested</dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--reservations" title="Approved with Reservations" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved with reservations</span></dt> <dd class="c-definitions__description t-caption"> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--not-approved " title="Not Approved" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Not approved</span></dt> <dd class="c-definitions__description t-caption">Fundamental flaws in the paper seriously undermine the findings and conclusions</dd> </dl> </div> </div> </div> </div> </div> <div class="o-layout__item u-mb--1"><h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md">Reviewer Reports</h4></div> <table class="c-report-timeline u-mb--2"> <thead class=c-report-timeline__headings> <tr> <th></th> <th class="u-pb--1/2" colspan=3><em class="t-body u-weight--rg">Invited Reviewers</em></th> </tr> <tr class=c-report-timeline__headings-row> <th></th> <th class="c-report-timeline__headings-version p-article__color--dark">1</th> <th class="c-report-timeline__headings-version p-article__color--dark">2</th> <th class="c-report-timeline__headings-version p-article__color--dark">3</th> </tr> </thead> <tbody> <tr class="c-report-timeline__row c-report-timeline__row--selected "> <th class=c-report-timeline__version> <a data-test-id=sidebar_timeline_v1_version href="https://f1000research.com/articles/6-587/v1">Version 1</a><br/> <span class=p-article__color--dark> <span data-test-id=sidebar_timeline_v1_date class=c-report-timeline__date>27 Apr 17</span> </span> </th> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> </tr> </tbody> </table> <div class=o-layout__item> <hr class="c-hr c-hr--low u-mb--2"> </div> </section> </div> <div class=o-layout__item> <div class="u-pl u-pr"> <p class="t-body u-mt--0 u-mb--2"><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home" target=_blank class=in-text-link>Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> <ol class="p-article__faculty-referee-list t-caption"> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Craig M Walsh</strong>, University of California, Irvine, USA </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Domagoj Vucic</strong>, Department of Early Discovery Biochemistry, Genentech, South San Francisco, USA </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Robert G Korneluk</strong>, Apoptosis Research Centre, Children’s Hospital of Eastern Ontario Research Institute, Canada </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> <p class=" u-mt--2 u-mb--1/2"><strong>Eric C LaCasse</strong>, Apoptosis Research Centre, Children’s Hospital of Eastern Ontario Research Institute, Canada </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> <p class=" u-mt--2 u-mb--1/2"><strong>Shawn T Beug</strong>, Apoptosis Research Centre, Children’s Hospital of Eastern Ontario Research Institute, Canada </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> </ol> </div> </div> <section class="o-layout__item u-pl"> <div class=u-pl> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--2">Comments on this article</h4> <div class=u-mb--4> <p class="u-mt--0 u-mb--1 t-h4"><a class=p-article__color--light href="#article-comments">All Comments</a><span class=" u-ib u-ml--1/2 p-article__color--light">(0)</span></p> <a class=t-h4 href="/login?originalPath=/articles/6-587&scrollTo=add-new-comment" data-test-id=add-comment>Add a comment</a> </div> <hr class="c-hr c-hr--low c-hr--md u-mb--4"> <div class="research-layout f1r-article-desk"> <div class="heading6 c-ribbon-wrapper c-ribbon-wrapper--etoc f1000research "> <div class=c-ribbon-wrapper__body>Sign up for content alerts</div> </div> </div> <div class="research-layout sidebar-sign-up-form f1r-article-desk u-mb--4 "> <form class=js-email-alert-signup action="#" method=POST data-email=tocAlertWeekly> <input type=hidden name=isUserLoggedIn class=js-email-alert-signup-logged-in value=N /> <input type=hidden name=userId class=js-email-alert-signup-user-id value=""/> <input type=hidden name=frequency class=js-email-alert-signup-frequency value=WEEKLY /> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <input type=email name=emailAddress class="form-input-field js-email-alert-signup-address u-1/1 u-bb" required=required placeholder=Email /> </div> <div class=o-actions__secondary> <div class="_mdl-layout u-ml--1/2"> <button class="mdl-button mdl-js-button mdl-button--colored mdl-button--small mdl-button--filled js-email-alert-signup-submit">Sign Up</button> </div> </div> </div> </form> <div id=sidebar-sign-up-message class="section-text js-email-alert-signup-msg is-hidden">You are now signed up to receive this alert</div> </div> <section class=js-terms-container> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--1">Browse by related subjects</h4> <div class="article-subcontainer article-subcontainer--sidebar"> <ul class=js-terms-list></ul> </div> </section> </div> </section> </div> </section> </div> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/read-more.js"></script> <script src="/js/article/article-router.js"></script> <script src="/js/article/article-sidebar.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/article/article-column-toggle.js"></script> </div> </div> </div> </main> <input type=hidden id=_articleVersionUrl value="https://f1000research.com/articles/6-587/v1/"> <div class=research-help id=about-referee-status> <div class="research-layout research-help-content about-referee-status"> <span class="close-research-help dark-cross" title=Close></span> Alongside their report, reviewers assign a status to the article: <div class="cf research-help-row"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> <span class=research-help-text>Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested</span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-87_approved_reservations status-green smaller" title="Approved with Reservations"></span> <span class=research-help-text>Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-88_not_approved status-red small" title="Not Approved"></span> <span class=research-help-text>Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions</span> </div> </div> </div> <div id=datasets-info class=is-hidden> </div> <div class=article-interactive-content-container style="display: none;"> <a name=f-template class=n-a></a> <div class="interactive-content-wrapper padding-20"> <img src="" class=interactive-content-image title="Open the interactive image display"> <div class=interactive-content-title></div> <div class=interactive-content-text></div> <div class="f1r-article-desk interactive-content-ribbon" data-interactive-content-type=R-Script> <div class=interactive-content-label>Adjust parameters to alter display</div> <div class=interactive-content-button></div> </div> <div class="f1r-article-mobile mobile-interactive-note"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div id=article-interactive-omero-container class=article-interactive-omero-container style="display: none;"> <div class=interactive-content-wrapper> <div class="interactive-omero-button omero-content" title="Open the interactive content window." data-interactive-content-type=Omero></div> <div class=has-interactive-content-image> <span class=box-arrow></span> <span class=box-middle>Includes Interactive Elements</span> <span class=box-end></span> </div> <div class="fig panel clearfix" style="margin: 0; padding-bottom: 20px;"> <a name=templatelink class=n-a></a> <a target=_blank href="" class=link-for-omero-image> <img src="" class=interactive-omero-image title="Open the image display window."> </a> <div class=caption> <div class=interactive-content-title></div> <div class=interactive-content-text></div> </div> <div class="is-hidden omero-image-list"></div> </div> <div class="f1r-article-mobile mobile-interactive-note omero"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div class="add-comment-container shadow-box is-hidden" id=save-comment-container> <span id=save-comment-text class=intro-text>Edit comment</span> <textarea id=new-comment name=new-comment class="global-textarea comment margin-bottom margin-top"></textarea> <p><strong>Competing Interests</strong></p> <textarea id=new-competing-interests name=competing-interests class="global-textarea competing-interests margin-bottom check-xss"></textarea> <div class=clearfix></div> <button id=cancelComment type=button class="general-white-orange-button float-right no-background-button margin-left"> Cancel </button> <button id=save-comment-button commentId="" type=button class="general-white-orange-button float-right"> Save </button> <div class=clearfix></div> <div class="green-message margin-top is-hidden comment-is-saved">The comment has been saved.</div> <div class="red-message margin-top is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class="red-message margin-top is-hidden comment-enter-text ucf">Your must enter a comment.</div> <div class="red-message margin-top is-hidden comment-references-error references">References error.</div> </div> <div class="modal-window-wrapper is-hidden"> <div id=conflicts-interests class="modal-window padding-20"> <div class=modal-window__content> <h2 class=h2-title>Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div class="f1r-article-mobile research-layout"> <span class=modal-window-close-button></span> </div> </div> </div> <div class="o-modal c-email-alert-popup js-email-alert-popup is-hidden"> <div class="o-modal__body js-modal-body c-email-alert-popup__inner"> <h3 class=c-email-alert-popup__title>Stay Updated</h3> <p class=c-email-alert-popup__sub>Sign up for content alerts and receive a weekly or monthly email with all newly published articles</p> <p><a href="/register?originalPath=" class="c-email-alert-popup__lnk c-email-alert-popup__button js-email-alert-popup-action">Register with F1000Research</a></p> <p>Already registered? <a href="/login?originalPath=" class="c-email-alert-popup__lnk js-email-alert-popup-action">Sign in</a></p> <p class=c-email-alert-popup__footer><a class="c-email-alert-popup__lnk js-email-alert-popup-cancel" href="#">Not now, thanks</a></p> </div> </div> <div id=addCommentModal role=dialog aria-labelledby=addCommentModal_title aria-describedby=addCommentModal_description> <div class="c-modal js-modal is-closed p-article__add-comment-modal c-modal--xlarge js-article-comment-modal c-modal--scroll "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-bg--2 c-modal--scroll-always "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <div id=addCommentModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div class="js-add-comment-container t-caption u-black--high"> <div class=u-weight--bd>PLEASE NOTE</div> <div class=u-mt--1> <span class="red u-weight--bd">If you are an AUTHOR of this article,</span> please check that you signed in with the account associated with this article otherwise we cannot automatically identify your role as an author and your comment will be labelled as a &ldquo;User Comment&rdquo;. </div> <div class=u-mt--1> <span class="red u-weight--bd">If you are a REVIEWER of this article,</span> please check that you have signed in with the account associated with this article and then go to your <a href="/my/referee">account</a> to submit your report, please do not post your review here. </div> <div class="u-mt--1 u-mb--1"> If you do not have access to your original account, please <a href="mailto:research@f1000.com">contact us</a>. </div> <p class=no-top-margin>All commenters must hold a formal affiliation as per our <a href="/about/policies#commentspolicy" target=_blank>Policies</a>. The information that you give us will be displayed next to your comment.</p> <p>User comments must be in English, comprehensible and relevant to the article under discussion. We reserve the right to remove any comments that we consider to be inappropriate, offensive or otherwise in breach of the <a href="/about/legal/usercommenttermsandconditions" target=_blank>User Comment Terms and Conditions</a>. Commenters must not use a comment for personal attacks. When criticisms of the article are based on unpublished data, the data should be made available.</p> <div class="comments-note margin-bottom" id=accept-user-comments> <input class=js-add-comment-accept-terms type=checkbox id=acceptedTermsAndConditions name=acceptedTermsAndConditions> I accept the <a href="/about/legal/usercommenttermsandconditions" target=_blank> User Comment Terms and Conditions</a> <span class=required>&nbsp;</span> </div> <div class="default-error margin-top is-hidden comment-accept-conditions utac">Please confirm that you accept the User Comment Terms and Conditions.</div> <div class="research-layout registration-form u-mb--2"> <div class="u-mb--1 u-mt--2"> <strong>Affiliation</strong> </div> <div class=form-field> <input type=text name=institution class="form-input-field check-xss js-add-comment-institution" placeholder="Organization *" autocomplete=off /> <div class="default-error margin-top is-hidden comment-enter-institution institution">Please enter your organisation.</div> </div> <div class=form-field> <input type=text name=place class="form-input-field check-xss js-add-comment-place" placeholder=Place> </div> <div class=form-field> <div class="form-input-wrapper hundred-percent-wide"> <div class="new-select-standard-wrapper half-width inline-display heading10"> <select name=countryId id=country class="form-select-menu smaller js-add-comment-country"> <option value=-1>Country*</option> <option value=840>USA</option> <option value=826>UK</option> <option value=124>Canada</option> <option value=156>China</option> <option value=250>France</option> <option value=276>Germany</option> <optgroup label=-----------------------------------------------></optgroup> <option value=4>Afghanistan</option> <option value=248>Aland Islands</option> <option value=8>Albania</option> <option value=12>Algeria</option> <option value=16>American Samoa</option> <option value=20>Andorra</option> <option value=24>Angola</option> <option value=660>Anguilla</option> <option value=10>Antarctica</option> <option value=28>Antigua and Barbuda</option> <option value=32>Argentina</option> <option value=51>Armenia</option> <option value=533>Aruba</option> <option value=36>Australia</option> <option value=40>Austria</option> <option value=31>Azerbaijan</option> <option value=44>Bahamas</option> <option value=48>Bahrain</option> <option value=50>Bangladesh</option> <option value=52>Barbados</option> <option value=112>Belarus</option> <option value=56>Belgium</option> <option value=84>Belize</option> <option value=204>Benin</option> <option value=60>Bermuda</option> <option value=64>Bhutan</option> <option value=68>Bolivia</option> <option value=70>Bosnia and Herzegovina</option> <option value=72>Botswana</option> <option value=74>Bouvet Island</option> <option value=76>Brazil</option> <option value=86>British Indian Ocean Territory</option> <option value=92>British Virgin Islands</option> <option value=96>Brunei</option> <option value=100>Bulgaria</option> <option value=854>Burkina Faso</option> <option value=108>Burundi</option> <option value=116>Cambodia</option> <option value=120>Cameroon</option> <option value=124>Canada</option> <option value=132>Cape Verde</option> <option value=136>Cayman Islands</option> <option value=140>Central African Republic</option> <option value=148>Chad</option> <option value=152>Chile</option> <option value=156>China</option> <option value=162>Christmas Island</option> <option value=166>Cocos (Keeling) Islands</option> <option value=170>Colombia</option> <option value=174>Comoros</option> <option value=178>Congo</option> <option value=184>Cook Islands</option> <option value=188>Costa Rica</option> <option value=384>Cote d'Ivoire</option> <option value=191>Croatia</option> <option value=192>Cuba</option> <option value=196>Cyprus</option> <option value=203>Czech Republic</option> <option value=180>Democratic Republic of the Congo</option> <option value=208>Denmark</option> <option value=262>Djibouti</option> <option value=212>Dominica</option> <option value=214>Dominican Republic</option> <option value=218>Ecuador</option> <option value=818>Egypt</option> <option value=222>El Salvador</option> <option value=226>Equatorial Guinea</option> <option value=232>Eritrea</option> <option value=233>Estonia</option> <option value=231>Ethiopia</option> <option value=238>Falkland Islands</option> <option value=234>Faroe Islands</option> <option value=583>Federated States of Micronesia</option> <option value=242>Fiji</option> <option value=246>Finland</option> <option value=250>France</option> <option value=254>French Guiana</option> <option value=258>French Polynesia</option> <option value=260>French Southern Territories</option> <option value=266>Gabon</option> <option value=268>Georgia</option> <option value=276>Germany</option> <option value=288>Ghana</option> <option value=292>Gibraltar</option> <option value=300>Greece</option> <option value=304>Greenland</option> <option value=308>Grenada</option> <option value=312>Guadeloupe</option> <option value=316>Guam</option> <option value=320>Guatemala</option> <option value=831>Guernsey</option> <option value=324>Guinea</option> <option value=624>Guinea-Bissau</option> <option value=328>Guyana</option> <option value=332>Haiti</option> <option value=334>Heard Island and Mcdonald Islands</option> <option value=336>Holy See (Vatican City State)</option> <option value=340>Honduras</option> <option value=344>Hong Kong</option> <option value=348>Hungary</option> <option value=352>Iceland</option> <option value=356>India</option> <option value=360>Indonesia</option> <option value=364>Iran</option> <option value=368>Iraq</option> <option value=372>Ireland</option> <option value=376>Israel</option> <option value=380>Italy</option> <option value=388>Jamaica</option> <option value=392>Japan</option> <option value=832>Jersey</option> <option value=400>Jordan</option> <option value=398>Kazakhstan</option> <option value=404>Kenya</option> <option value=296>Kiribati</option> <option value=901>Kosovo (Serbia and Montenegro)</option> <option value=414>Kuwait</option> <option value=417>Kyrgyzstan</option> <option value=418>Lao People's Democratic Republic</option> <option value=428>Latvia</option> <option value=422>Lebanon</option> <option value=426>Lesotho</option> <option value=430>Liberia</option> <option value=434>Libya</option> <option value=438>Liechtenstein</option> <option value=440>Lithuania</option> <option value=442>Luxembourg</option> <option value=446>Macao</option> <option value=807>Macedonia</option> <option value=450>Madagascar</option> <option value=454>Malawi</option> <option value=458>Malaysia</option> <option value=462>Maldives</option> <option value=466>Mali</option> <option value=470>Malta</option> <option value=584>Marshall Islands</option> <option value=474>Martinique</option> <option value=478>Mauritania</option> <option value=480>Mauritius</option> <option value=175>Mayotte</option> <option value=484>Mexico</option> <option value=581>Minor Outlying Islands of the United States</option> <option value=498>Moldova</option> <option value=492>Monaco</option> <option value=496>Mongolia</option> <option value=499>Montenegro</option> <option value=500>Montserrat</option> <option value=504>Morocco</option> <option value=508>Mozambique</option> <option value=104>Myanmar</option> <option value=516>Namibia</option> <option value=520>Nauru</option> <option value=524>Nepal</option> <option value=530>Netherlands Antilles</option> <option value=540>New Caledonia</option> <option value=554>New Zealand</option> <option value=558>Nicaragua</option> <option value=562>Niger</option> <option value=566>Nigeria</option> <option value=570>Niue</option> <option value=574>Norfolk Island</option> <option value=580>Northern Mariana Islands</option> <option value=408>North Korea</option> <option value=578>Norway</option> <option value=512>Oman</option> <option value=586>Pakistan</option> <option value=585>Palau</option> <option value=275>Palestinian Territory</option> <option value=591>Panama</option> <option value=598>Papua New Guinea</option> <option value=600>Paraguay</option> <option value=604>Peru</option> <option value=608>Philippines</option> <option value=612>Pitcairn</option> <option value=616>Poland</option> <option value=620>Portugal</option> <option value=630>Puerto Rico</option> <option value=634>Qatar</option> <option value=638>Reunion</option> <option value=642>Romania</option> <option value=643>Russian Federation</option> <option value=646>Rwanda</option> <option value=654>Saint Helena</option> <option value=659>Saint Kitts and Nevis</option> <option value=662>Saint Lucia</option> <option value=666>Saint Pierre and Miquelon</option> <option value=670>Saint Vincent and the Grenadines</option> <option value=882>Samoa</option> <option value=674>San Marino</option> <option value=678>Sao Tome and Principe</option> <option value=682>Saudi Arabia</option> <option value=686>Senegal</option> <option value=688>Serbia</option> <option value=690>Seychelles</option> <option value=694>Sierra Leone</option> <option value=702>Singapore</option> <option value=703>Slovakia</option> <option value=705>Slovenia</option> <option value=90>Solomon Islands</option> <option value=706>Somalia</option> <option value=710>South Africa</option> <option value=239>South Georgia and the South Sandwich Is</option> <option value=410>South Korea</option> <option value=724>Spain</option> <option value=144>Sri Lanka</option> <option value=736>Sudan</option> <option value=740>Suriname</option> <option value=744>Svalbard and Jan Mayen</option> <option value=748>Swaziland</option> <option value=752>Sweden</option> <option value=756>Switzerland</option> <option value=760>Syria</option> <option value=158>Taiwan</option> <option value=762>Tajikistan</option> <option value=834>Tanzania</option> <option value=764>Thailand</option> <option value=270>The Gambia</option> <option value=528>The Netherlands</option> <option value=626>Timor-Leste</option> <option value=768>Togo</option> <option value=772>Tokelau</option> <option value=776>Tonga</option> <option value=780>Trinidad and Tobago</option> <option value=788>Tunisia</option> <option value=792>Turkey</option> <option value=795>Turkmenistan</option> <option value=796>Turks and Caicos Islands</option> <option value=798>Tuvalu</option> <option value=800>Uganda</option> <option value=826>UK</option> <option value=804>Ukraine</option> <option value=784>United Arab Emirates</option> <option value=850>United States Virgin Islands</option> <option value=858>Uruguay</option> <option value=840>USA</option> <option value=860>Uzbekistan</option> <option value=548>Vanuatu</option> <option value=862>Venezuela</option> <option value=704>Vietnam</option> <option value=876>Wallis and Futuna</option> <option value=905>West Bank and Gaza Strip</option> <option value=732>Western Sahara</option> <option value=887>Yemen</option> <option value=894>Zambia</option> <option value=716>Zimbabwe</option> </select> </div> </div> <div class="default-error margin-top is-hidden comment-enter-country country">Please select your country.</div> </div> </div> <textarea data-test-id=article_add-comment_comment name=new-comment class="js-add-comment-comment comment margin-bottom margin-top"></textarea> <div class="default-error margin-top comment-enter-text comment-error is-hidden ">You must enter a comment.</div> <label class="comments-note u-mt--2 u-mb--2" for=competingInterests_1> <div class="u-mb--1 u-mt--2"><strong data-test-id=article_report-add-comment_competing-interests-title>Competing Interests</strong></div> <p class="u-mb--2 u-mt--0" data-test-id=article_report-add-comment_competing-interests-description>Please disclose any <a href="#article-competing-intersts-policy" class=js-modal-competing-intersts-toggle>competing interests</a> that might be construed to influence your judgment of the article's or peer review report's validity or importance.</p> </label> <div id=article-competing-intersts-policy class=js-article-competing-interests-policy style="display: none;"> <h2 class="h2-title u-mt--0 u-pt--0">Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div id=competingInterests_1 class="c-inline-editor js-inline-editor js-form_input u-bb--all u-mb--2 js-comment-competing-interests" data-name=competing-interests data-rows=3> <textarea id=competingInterests_1_input name=competing-interests placeholder="&nbsp;" required=false class="u-hide-visually js-inline-editor_input" tabindex=-1></textarea> <div class="c-inline-editor__editor js-inline-editor_editor o-box c-box o-box--tiny u-bg--11" data-target=competingInterests_1_input role=textbox required=false data-placeholder="&nbsp;" contenteditable=true></div> <span class="c-inline-editor__error js-inline-editor-message">Please state your competing interests</span> </div> <div data-test-id=article_add-comment_saved class="green-message comments is-hidden comment-is-saved">The comment has been saved.</div> <div data-test-id=article_add-comment_error class="default-error comments is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class=clearfix></div> <div class=js-hook></div> </div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" data-test-id=article_add-comment_cancel class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" data-test-id=article_add-comment_post class="c-button c-button--full js-modal__confirm c-button--primary">Post</a> </div> </aside> </div> </div> <style>
                .at-icon-wrapper {
        background-size: 100% !important;
    }
</style> <script src="/js/namespace.js"></script> <script src="/js/constants.js"></script> <script src="/js/utilities.js"></script> <script src="/js/article/alert-signup.js"></script> <script type='text/javascript'>
    var lTitle = "Inducing death in tumor cells: roles of the...".replace("'", '');
    var linkedInUrl = "http://www.linkedin.com/shareArticle?url=https://f1000research.com/articles/6-587/v1" + "&title=" + encodeURIComponent(lTitle) + "&summary=" + encodeURIComponent('Read the article by ');

    var deliciousUrl = "https://del.icio.us/post?url=https://f1000research.com/articles/6-587/v1&title=" + encodeURIComponent(lTitle);

    var redditUrl = "http://reddit.com/submit?url=https://f1000research.com/articles/6-587/v1" + "&title=" + encodeURIComponent(lTitle);

            linkedInUrl += encodeURIComponent('Finlay D et al.');
    
    var offsetTop = /chrome/i.test( navigator.userAgent ) ? 4 : -10; 
    var addthis_config = {
            ui_offset_top: offsetTop,
                                    services_compact : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_expanded : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_custom : [
                {
                    name: "LinkedIn",
                    url:  linkedInUrl,
                    icon:"/img/icon/at_linkedin.svg"
                },
                {
                    name: "Mendeley",
                    url:  "http://www.mendeley.com/import/?url=https://f1000research.com/articles/6-587/v1/mendeley",
                    icon:"/img/icon/at_mendeley.svg"
                },
                {
                    name: "Reddit",
                    url:  redditUrl,
                    icon:"/img/icon/at_reddit.svg"
                },
            ]
        };


    var addthis_share = {
            url: "https://f1000research.com/articles/6-587",
            templates : {
                twitter : "Inducing death in tumor cells: roles of the inhibitor of apoptosis.... Finlay D et al., published by " + 
               "@F1000Research"
       + ", https://f1000research.com/articles/6-587/v1"
            }
        };

    if (typeof(addthis) != "undefined"){
        addthis.addEventListener('addthis.ready', checkCount);
        addthis.addEventListener('addthis.menu.share', checkCount);
    }

        $(".f1r-shares-twitter").attr("href", "https://twitter.com/intent/tweet?text=" + addthis_share.templates.twitter);
    $(".f1r-shares-facebook").attr("href", "https://www.facebook.com/sharer/sharer.php?u=" + addthis_share.url);
    $(".f1r-shares-linkedin").attr("href", addthis_config.services_custom[0].url);
    $(".f1r-shares-reddit").attr("href", addthis_config.services_custom[2].url);
    $(".f1r-shares-mendelay").attr("href", addthis_config.services_custom[1].url);

    function checkCount(){
        setTimeout(function(){
            $(".addthis_button_expanded").each(function(){
                var count = $(this).text();
                if (count !== "" && count != "0")
                    $(this).removeClass("is-hidden");
                else
                    $(this).addClass("is-hidden");
            });
        }, 1000);
    }
</script> <div id=citeReportModal role=dialog aria-labelledby=citeReportModal_title aria-describedby=citeReportModal_description> <div class="c-modal js-modal is-closed c-modal--large js-cite-report-modal "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-black--high "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <h1 id=citeReportModal_title class="c-modal__title t-h3 u-mt--0 u-mb--2 u-weight--md">How to cite this report</h1> <div id=citeReportModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div id="" class=js-report-citation-container>{{reportCitation}}</div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" title="Copy the current citation details to the clipboard." data-clipboard-target="#referee-report-citation" data-test-id=report_copy-citation_button class="c-button c-button--full js-modal__confirm c-button--primary js-clipboard c-mini-tooltip--above">Copy Citation Details</a> </div> </aside> </div> </div> <script src="/js/referee/new/referee_validators.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/referee/new/referee_checkbox-input.js"></script> <script src="/js/referee/new/referee_inline-editor.js"></script> <script type="text/javascript">
    $(function(){
        var gaCat = "F1000Research";
        if (gaCat === "") {
            gaCat = $("body").hasClass("wellcome-brand") ? "Wellcome Open Research" : "F1000Research";
        }
        GAHelper.track({category: gaCat, action: "Article Page: Inducing death in tumor cells: roles of the inhibitor of apoptosis proteins", label: "pageviews"});
        GAHelper.track({category: gaCat, action: "Article Type: Review", label: "Article Page"});
        $(".f1r-article-desk .collection-image").each(function (idx, el) {
            var whatChannel = $(el).find("a").attr("href"),
                channelName = $.trim($(el).parent().find(".collection-detail a").text()),
                gaRef = "(ID: " + whatChannel.replace("/collections/", "") + ") " + channelName;
            GAHelper.track({category: 'ChannelStats', action: "Article Page: Inducing death in tumor cells: roles of the inhibitor of apoptosis proteins", label: gaRef});
        });
    });
</script> <script>
    $(function(){R.ui.buttonDropdowns('.dropdown-for-downloads');});
    $(function(){R.ui.toolbarDropdowns('.toolbar-dropdown-for-downloads');});
</script> <script src="/js/article/track_article.js" type="text/javascript"></script> <script type="text/javascript">
    $.get("/articles/acj/10625/11449")
</script> <script type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js"></script> <script type="text/javascript" src="/js/app/messenger.js"></script> <script type="text/javascript" src="/js/article/article_mobiles.js"></script> <script src="/js/vendor/clipboard.min.js"></script> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/clipboard.js"></script> <script src="/js/article/thesaurus-terms-display.js"></script> <script>
    new F1000.Clipboard();
    new F1000.ThesaurusTermsDisplay("faculty-reviews", "article", "11449");
</script> <script>
    $(document).ready(function() {
        $( "#frame1" ).on('load', function() {
            var mydiv = $(this).contents().find("div");
            var h     = mydiv.height();
            console.log(h)
        });

        
        var tooltipLivingFigure = jQuery(".interactive-living-figure-label .icon-more-info"),
            titleLivingFigure = tooltipLivingFigure.attr("title");
        tooltipLivingFigure.simpletip({
            fixed: true,
            position: ["-115", "30"],
            baseClass: 'small-tooltip',
            content:titleLivingFigure + "<div class='tooltip-arrow'></div>"
        });
        tooltipLivingFigure.removeAttr("title");

        $("body").on("click", ".cite-living-figure", function(e) {
            e.preventDefault();
            var ref = $(this).attr("data-ref");
            $(this).closest(".living-figure-list-container").find("#" + ref).fadeIn(200);
        });
        $("body").on("click", ".close-cite-living-figure", function(e) {
            e.preventDefault();
            $(this).closest(".popup-window-wrapper").fadeOut(200);
        });

                $(document).on("mouseup", function(e) {
            var metricsContainer = $(".article-metrics-popover-wrapper");
            if (!metricsContainer.is(e.target) && metricsContainer.has(e.target).length === 0) {
                $(".article-metrics-close-button").click();
            }
        });

        var articleId = $('#articleId').val();

        if($("#main-article-count-box").attachArticleMetrics) {
            $("#main-article-count-box").attachArticleMetrics(articleId, {
                articleMetricsView: true
            });
        }
    });

    var figshareWidget = $(".new_figshare_widget");
    if (figshareWidget.length > 0) {
        window.figshare.load("f1000", function(Widget) {
            // Select a tag/tags defined in your page. In this tag we will place the widget.
            _.map(figshareWidget, function(el){
                var widget = new Widget({
                    articleId: $(el).attr("figshare_articleId")
                    //height:300 // this is the height of the viewer part. [Default: 550]
                });
                widget.initialize(); // initialize the widget
                widget.mount(el); // mount it in a tag that's on your page
                // this will save the widget on the global scope for later use from
                // your JS scripts. This line is optional.
                //window.widget = widget;
            });
        });
    }
</script>

<script>
    $(document).ready(function () {

        
        var reportIds = {
                           "21917": 0,
                           "21918": 0,
                           "21919": 0,
                    };

        $(".referee-response-container,.js-referee-report").each(function(index, el) {
            var reportId = $(el).attr("data-reportid"),
                reportCount = reportIds[reportId] || 0;
            $(el).find(".comments-count-container,.js-referee-report-views").html(reportCount);
        });

        var uuidInput = $("#article_uuid"),
            oldUUId = uuidInput.val(),
            newUUId = "2f415b04-8b29-4fd3-a1d1-5e91d659a09a";
        uuidInput.val(newUUId);

        $("a[href*='article_uuid=']").each(function(index, el) {
            var newHref = $(el).attr("href").replace(oldUUId, newUUId);
            $(el).attr("href", newHref);
        });

    });
</script>              </div>
        </div>

        
            
            <div class="o-page__footer sticky-email-wrapper">
                
                

                


<footer class="c-footer t-inverted">

    <div class="o-wrapper">
        <div class="o-layout">


                        
            <div class="o-layout__item u-mb--3">
                <div class="c-branding c-branding--research">
                    <img src="/img/research/F1000Research_white.svg" alt="F1000Research">
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <p class="t-h3 u-mt--0 u-mb--0">An innovative open access publishing platform offering rapid publication and open peer review, whilst supporting data deposition and sharing.</p>

            </div>


                        
            <div class="o-layout__item u-2/3@md">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <div class="o-layout">
                    <nav class="c-footer__nav">

                            <div class="o-layout__item u-3/5@sm u-mb--3">


                                <div class="o-columns o-columns--2">

                                                                            <a href="/browse/articles" class="t-body c-footer__nav-item "      >Browse</a>
                                                                            <a href="/gateways" class="t-body c-footer__nav-item "      >Gateways</a>
                                                                            <a href="/collections" class="t-body c-footer__nav-item "      >Collections</a>
                                                                            <a href="/about" class="t-body c-footer__nav-item "      >How it Works</a>
                                                                            <a href="https://blog.f1000.com/blogs/f1000research/" class="t-body c-footer__nav-item "      >Blog</a>
                                                                            <a href="/contact" class="t-body c-footer__nav-item "      >Contact</a>
                                                                            <a href="/developers" class="t-body c-footer__nav-item u-hide u-show@navbar"      >For Developers</a>
                                                                            <a href="/published/rss" class="t-body c-footer__nav-item "   title="RSS feed of published articles"     >RSS</a>
                                    
                                </div>

                            </div>

                            <div class="o-layout__item u-2/5@sm u-center u-right@sm u-mb--3">

                                <div class="u-hide u-show@lg">
                                    <div class="_mdl-layout">
                                        <a class="mdl-button mdl-js-button mdl-button--inverted mdl-button--no-shadow mdl-js-ripple-effect mdl-button--outline" href="/for-authors/publish-your-research"   data-test-id="footer_submit_research"  >Submit Your Research</a>
                                    </div>
                                </div>

                            </div>

                    </nav>
                </div>

            </div>

            <div class="o-layout__item u-mb--2">
                <div class="c-footer__share">
                        <div class="c-footer__share">
        <span class="c-footer__share-icon" title="Open Access">
            <span class="f1r-icon icon-100_open_access license-icon"></span>
        </span>

        <a class="c-footer__share-icon" href="//creativecommons.org/licenses" target="_blank" title="Creative Commons License CC-BY">
            <span class="f1r-icon icon-116_cc license-icon license-icon-cc"></span>
            <span class="f1r-icon icon-117_ccby license-icon license-icon-cc"></span>
        </a>

        <a class="c-footer__share-icon" href="//creativecommons.org/about/cc0" target="_blank" title="Creative Commons License CC0">
            <span class="f1r-icon icon-118_cco license-icon"></span>
        </a>

    </div>
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="c-footer__social u-mt--0 u-mb--0 u-white--low-med">Follow us
                    <a href="https://www.facebook.com/F1000" target="_blank" class="c-footer__social-icon f1r-icon icon-55_footer_facebook"></a>
                    <a href="https://twitter.com/#!/F1000Research" target="_blank" class="c-footer__social-icon f1r-icon icon-56_footer_twitter"></a>
                    <a href="http://www.youtube.com/user/F1000research" target="_blank" class="c-footer__social-icon f1r-icon icon-57_footer_youtube"></a></p>

            </div>


                        
            <div class="o-layout__item u-2/3@md u-right@md">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="t-caption u-white--low-med">&copy; 2012-2020 F1000 Research Ltd. ISSN 2046-1402 | <a href="/about/legal" class="copyrightLegal">Legal</a> | Partner of <a target="_blank" href="http://www.who.int/hinari/en/">HINARI</a>  &bull; <a target="_blank" href="http://crossref.org/">CrossRef</a> &bull; <a target="_blank" href="http://about.orcid.org/">ORCID</a> &bull; <a target="_blank" href="http://www.fairsharing.org">FAIRSharing</a></p>

            </div>
        </div>
    </div>

</footer>            </div>
        
    </div>

            <div class="js-cookie-spacer"></div>
        <div class="cookie-warning">
            <div class="instruction">The F1000Research website uses cookies. By continuing to browse the site, you are agreeing to our use of cookies. <a class="js-scroll-to" href="/about/legal/privacypolicy#use-of-cookies" data-scroll-target="#use-of-cookies">Find out more &raquo;</a></div>
            <div class="close-button"></div>
        </div>
    
    <script>
                    R.templateTests.simpleTemplate = R.template('<p class="$variable.one">$text</p><p class="${variable.two}">$text</p><p class="$!variable.three">$text</p><p class="$!{variable.four}">$text</p><p class="${selector}.five">$text</p>');
            R.templateTests.runTests();
        
        var F1000platform = new F1000.Platform({
            name: "f1000research",
            displayName: "F1000Research",
            hostName: "f1000research.com",
            id: "1",
            editorialEmail: "research@f1000.com",
            infoEmail: "info@f1000.com",
            usePmcStats: true
        });

                    $(function(){R.ui.dropdowns('.dropdown-for-authors, .dropdown-for-about, .dropdown-for-myresearch');});
            // $(function(){R.ui.dropdowns('.dropdown-for-referees');});

            $(document).ready(function () {
                if ($(".cookie-warning").is(":visible")) {
                    $(".sticky").css("margin-bottom", "35px");
                    $(".devices").addClass("devices-and-cookie-warning");
                }
                $(".cookie-warning .close-button").click(function (e) {
                    $(".devices").removeClass("devices-and-cookie-warning");
                    $(".sticky").css("margin-bottom", "0");
                });

                $("#tweeter-feed .tweet-message").each(function (i, message) {
                    var self = $(message);
                    self.html(linkify(self.html()));
                });

                $(".partner").on("mouseenter mouseleave", function() {
                    $(this).find(".gray-scale, .colour").toggleClass("is-hidden");
                });
            });
        
    </script>

            
<div class="sign-in-popup">
	<!-- <a href="#" class="sign-in shadow">Sign in <span class="sign-in-image-active"></span></a> -->
	<a href="#" class="sign-in ${locale}">Sign In <span class="arrow-closed sign-in-arrow-padding arrow-opened"></span></a>
	<div class="sign-in-form">

            <form action="https://f1000research.com/j_spring_oauth_security_check" id="googleOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/6-587.html"/>
                            <input id="google-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-google" name="system" type="hidden" value="GOOGLE"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="facebookOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/6-587.html"/>
                            <input id="facebook-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-fb" name="system" type="hidden" value="FACEBOOK"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="orcidOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/6-587.html"/>
                            <input id="orcid-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-orcid" name="system" type="hidden" value="ORCID"/>
    </form>
		<form id="sign-in-form" class="login-container" action="https://f1000research.com/login" method="post" name="f">
           <div id="sign-in-form-gfb-popup"></div>

                                                            <input class="target-field" type="hidden" name="target" value="/articles/6-587.html"/>
                            			<input type="text" name="username" id="signin-email-box" class="sign-in-input" placeholder="Email address" autocomplete="email">
			<input type="password" name="password" id="signin-password-box" class="sign-in-input" placeholder="Password" autocomplete="current-password">
			<div class="sign-in-remember">
                <div class="checkbox-wrapper">
    				<input type="checkbox" id="remember-me" name="remember_me" class="checkbox is-hidden">
                </div>
                <span class="checkbox-label">Remember me</span>
			</div>
			<a href="#" class="sign-in-link" id="forgot-password-link">Forgotten your password?</a>
			<div class="sign-in-button-container margin-top margin-left-20 margin-bottom">
				<button type="submit" id="sign-in-button" class="sign-in-buttons general-white-orange-button">Sign In</button>
				<button type="button" id="sign-in-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
				<div class="clearfix"></div>
			</div>
			<div class="sign-in-error">Email or password not correct. Please try again</div>
			<div class="sign-in-loading">Please wait...</div>
		</form>
		<div class="forgot-password-container">
			
<script type="text/javascript">
	$(function(){
		// Note: All the setup needs to run against a name attribute and *not* the id due the clonish
		// nature of facebox...
		$("a[id=googleSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("GOOGLE");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=facebookSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("FACEBOOK");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=orcidSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("ORCID");
            $("form[id=oAuthForm]").submit();
        });
	});
</script>

<span class="text first">
	If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password.
    <p>The email address should be the one you originally registered with F1000.</p>
</span>
<input name="email" class="sign-in-input" id="email-forgot-password" type="text" placeholder="Email address">
<div class="forgot-password-email-error">
	Email address not valid, please try again
</div>
<div class="forgot-password-google-email-error">
    <p>You registered with F1000 via Google, so we cannot reset your password.</p>
	<p>To sign in, please click <a href="#" id="googleSignInButton">here</a>.</p>
    <p>If you still need help with your Google account password, please click <a href="https://www.google.com/accounts/recovery">here</a>.</p>
</div>
<div class="forgot-password-facebook-email-error">
    <p>You registered with F1000 via Facebook, so we cannot reset your password.</p>
    <p>To sign in, please click <a href="#" id="facebookSignInButton">here</a>.</p>
	<p>If you still need help with your Facebook account password, please click <a href="https://www.facebook.com/recover/initiate">here</a>.</p>
</div>
<div class="clearfix"></div>
<div class="forgot-password-captcha-error">
	Code not correct, please try again
</div>
<div class="clearfix"></div>
<div class="sign-in-button-container margin-left-20 margin-bottom">
	<button type="button" id="sign-in-reset-password" class="sign-in-buttons general-white-orange-button">Reset password</button>
	<button type="button" id="forgot-password-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
	<div class="clearfix"></div>
</div>
<span class="text last">
	<a href="mailto:">Email us</a> for further assistance.
</span>
<form action="https://f1000research.com/j_spring_oauth_security_check" id="oAuthForm" method="post" target="_top">
                        <input class="target-field" type="hidden" name="target" value="/articles/6-587.html"/>
                <input id="oAuthSystem" name="system" type="hidden"/>
</form>
			<div class="forgot-password-server-error">Server error, please try again.</div>
			<div class="sign-in-success">
                <p>We have sent an email to <span id="email-value"></span>, please follow the instructions to reset your password.</p>
                <p>If you don't receive this email, please check your spam filters and/or contact .</p>
            </div>
			<div class="sign-in-loading">Please wait...</div>
		</div>

		<div class="sign-in-form-register-section">
			<div class="sign-in-button-container margin-left-20 margin-bottom">
				<a href="/register" title="Register"><button type="button" id="sign-in-register-button" class="sign-in-buttons general-white-orange-button">Register</button></a>
				<div class="clearfix"></div>
			</div>
		</div>

	</div>
</div>

<script type="text/javascript">
$(document).ready(function () {

    signIn.createSignInAsRow($("#sign-in-form-gfb-popup"));

    $(".target-field").each(function () {
        var uris = $(this).val().split("/");
        if (uris.pop() === "login") {
        	$(this).val(uris.toString().replace(",","/"));
        }
    });
});
</script>
        <div id="templateOverlay" class="is-hidden" hidden="hidden">
  <div class="o-overlay js-overlay is-hidden" hidden="hidden"></div>
</div>

<div id="templateExternalMessages" class="is-hidden" hidden="hidden">
  <div class="o-modal o-modal--auto@md js-external-messages is-hidden" hidden="hidden">
    <div class="o-modal__body">
      <section class="c-console">
        <div class="_mdl-layout c-console__bdy js-external-messages-body"></div>
        <footer class="_mdl-layout c-console__ftr o-flex o-flex--reverse js-external-messages-footer">
          <button type="button" class="mdl-button mdl-js-button mdl-button--raised mdl-button--colored c-console__btn js-external-messages-close" data-action="maintenance-close">I Understand</button>
        </footer>
      </section>
    </div>
  </div>
</div>

<script src="https://cdnjs.cloudflare.com/ajax/libs/moment.js/2.22.1/moment.min.js"></script>

<script src="/js/namespace.js"></script>
<script src="/js/constants.js"></script>
<script src="/js/utilities.js"></script>

<script>
                  F1000.ExtenalMaintenanceItems = [
    {
      start: '2018-12-10T14:21:00Z',
      end: '2018-12-13T16:00:00Z',
      msg: 'This site will be down for a short time on XX December. It is advisable not to start any submissions on that day or you may lose your work unless you save regularly.',
      cookieName: 'outage23122018',
      editor: false,
    }
  ];
</script>

<script src="/js/shared_scripts/cookie-helper.js"></script>
<script src="/js/shared_scripts/mdl-helper.js"></script>

<script src="/js/app/external-maintenance.js"></script>

                <script type="text/javascript">
            (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
            (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
            m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
            })(window,document,'script','//www.google-analytics.com/analytics.js','ga');

            ga('create', 'UA-5646075-11', 'auto');
            ga('require', 'displayfeatures');
            ga('send', 'pageview');
        </script>
        
                <script type="text/javascript" src="/js/app/research.analytics.js"></script>

        <!-- Start of HubSpot Embed Code -->
        <script type="text/javascript" id="hs-script-loader" async defer src="//js.hs-scripts.com/4475190.js"></script>
        <!-- End of HubSpot Embed Code -->
    
            <script src="https://my.hellobar.com/4e0495c6f18cbd68731a1dc1978195a144e767ba.js" type="text/javascript" charset="utf-8" async="async"></script>
    </body>

</html>